Conditions: Agitation in Participants With Dementia of the Alzheimer's Type
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 522
Healthy volunteers: no

Brief summary:
Participants with agitation secondary to dementia of the Alzheimer's type. The diagnosis of probable Alzheimer's disease (AD) will be based on the "2011 Diagnostic Guidelines for Alzheimer's Disease" issued by the National Institute on Aging (NIA)-Alzheimer's Association (AA) workgroups.

Detailed description:
Eligible participants for this study must have a diagnosis of probable AD and must have clinically meaningful agitation secondary to AD.

This is a multicenter, randomized, placebo-controlled study, consisting of 12 weeks of treatment.

Approximately 470 participants will be enrolled at approximately 75 centers in North America.

Study medication will be administered orally twice-daily from Day 1 through Week 12 (Day 85). Screening will occur within approximately 4 weeks prior to randomization. Following screening procedures for assessment of inclusion and exclusion criteria, eligible participants will be randomized into the study.

Arms:
arm 1: Participants were administered AVP-786 matching placebo capsules, orally, twice daily (BID) for up to 12 weeks. arm 2: Participants were administered AVP-786-18 capsule, orally, once daily (QD) along with AVP-786 matching placebo capsule, orally, QD during Week 1 followed by AVP-786-18 capsules, orally, BID during Weeks 2, 3 and AVP-786-28 capsules, orally, BID during Weeks 4 to 12. arm 3: Participants were administered AVP-786-28 capsules, orally, QD along with AVP-786 matching placebo capsule, orally, QD during Week 1 followed by AVP-786-28 capsules, orally, BID during Weeks 2, 3, and AVP-786-42.63 capsules, orally, BID during Weeks 4 to 12.

Interventions: intervention 1: AVP-786-18 intervention 2: Placebo intervention 3: AVP-786-28 intervention 4: AVP-786-42.63
Intervention descriptions: intervention 1: 18 mg of Deudextromethorphan hydrobromide (d6-DM) and 4.9 mg of Quinidine sulfate (Q) intervention 2: Administered as capsules. intervention 3: 28 mg of d6-DM and 4.9 mg of Q intervention 4: 42.63 mg of d6-DM and 4.9 mg of Q

Protocol document:
Prot_000.pdf: 
Official Title: 
NCT Number: 
Document Date: 
A Phase 3, multicenter, randomized, double-blind, placebo-controlled study 
to assess the efficacy, safety, and tolerability of AVP-786 (deuterated [d6]-
dextromethorphan hydrobromide [d6- DM]/quinidine sulfate [Q]) for the 
treatment of agitation in patients with dementia of the Alzheimer’s type
NCT02442778 
Protocol Version 5.0: 28 February 2017 




 
AVANIR PHARMACEUTICALS, INC. 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
Page 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 




 
AVANIR PHARMACEUTICALS, INC. 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
Page 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 


 
AVANIR PHARMACEUTICALS, INC. 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
Page 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 


 
AVANIR PHARMACEUTICALS, INC. 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
Page 6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 


 
AVANIR PHARMACEUTICALS, INC. 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
Page 7 
 
Protocol Amendment 2 (Version 3.0) 
Summary of Changes 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
. 


 
AVANIR PHARMACEUTICALS, INC. 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
Page 8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


 
AVANIR PHARMACEUTICALS, INC. 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
Page 9 
 
 
 
 
 
  
 
 
  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 


 
AVANIR PHARMACEUTICALS, INC. 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
Page 10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


 
AVANIR PHARMACEUTICALS, INC. 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
Page 11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0 
Page 12 
TABLE OF CONTENTS 
Table of Contents .................................................................................................................................... 12 
List of Tables ......................................................................................................................................... 15 
List of Figures ........................................................................................................................................ 15 
List of Abbreviations ............................................................................................................................... 16 
Protocol Agreement ................................................................................................................................ 19 
Study Synopsis ........................................................................................................................................ 20 
1 
Background and Clinical Rationale .............................................................................................. 27 
1.1 
Rationale for Studying AVP-786 for Treatment of Agitation in Dementia .................... 27 
1.2 
Rationale for the Study Design ........................................................................................ 28 
1.3 
Rationale for AVP-786 Dose ........................................................................................... 29 
1.4 
Rationale for the Duration of Dosing .............................................................................. 29 
2 
Study Objectives ........................................................................................................................... 30 
3 
Study Design ................................................................................................................................. 31 
4 
Study Population ........................................................................................................................... 33 
4.1 
Inclusion Criteria ............................................................................................................. 33 
4.2 
Exclusion Criteria ............................................................................................................ 35 
4.3 
Patient Withdrawal From the Study ................................................................................ 36 
5 
Study Treatments .......................................................................................................................... 38 
5.1 
Treatments Administered ................................................................................................ 38 
5.1.1 Description of Study Medications ........................................................................ 38 
5.1.2 Composition of AVP-786 .................................................................................... 38 
5.1.3 Packaging ............................................................................................................. 39 
5.1.4 Labeling................................................................................................................ 39 
5.1.5 Storage of Clinical Supplies ................................................................................. 39 
5.1.6 Study Medication Administration ........................................................................ 40 
5.2 
Accountability of Study Supplies .................................................................................... 40 
5.2.1 Receipt of Supplies .............................................................................................. 40 
5.2.2 Record of Dispensing ........................................................................................... 40 
5.2.3 Unused Supplies ................................................................................................... 40 
5.3 
Methods of Assigning Patients to Treatment Groups ...................................................... 41 
5.3.1 Randomization ..................................................................................................... 41 
5.3.2 Blinding/Masking ................................................................................................. 41 


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
 
 
 
Page 13 
 
5.4 
Patient Compliance .......................................................................................................... 41 
5.5 
Concomitant Medications and Nondrug Therapies ......................................................... 41 
 
...................................................................... 42 
5.5.2 Rescue Medication for the Symptoms of Agitation ............................................. 43 
 
 ................................................................... 43 
5.5.4 Nondrug Therapies ............................................................................................... 43 
5.5.5 Nonpharmacological Interventions for the Treatment of Agitation ..................... 43 
6 
Study Assessments and Procedures .............................................................................................. 44 
6.1 
Efficacy ............................................................................................................................ 44 
6.1.1 Cohen-Mansfield Agitation Inventory (CMAI) ................................................... 44 
6.1.2 Neuropsychiatric Inventory (NPI)........................................................................ 44 
6.1.3 Clinical Global Impression of Severity of Illness-Agitation 
(CGIS-Agitation).................................................................................................. 45 
6.1.4 Alzheimer’s Disease Cooperative Study - Clinical Global 
Impression of Change Rating (ADCS-CGIC-Overall) ........................................ 45 
6.1.5 Modified Alzheimer’s Disease Cooperative Study - Clinical 
Global Impression of Change Rating (mADCS-CGIC-Agitation) ...................... 46 
6.1.6 Zarit Burden Interview (ZBI) ............................................................................... 46 
6.1.7 Patient Global Impression of Change (PGIC) ...................................................... 47 
6.1.8 Dementia Quality of Life (DEMQOL) ................................................................ 47 
6.1.9 Alzheimer’s Disease Assessment Scale-Cognitive Subscale 
(ADAS-cog) ......................................................................................................... 47 
6.1.10 Cornell Scale for Depression in Dementia (CSDD) ............................................ 47 
6.1.11 Resource Utilization in Dementia (RUD) ............................................................ 48 
6.1.12 General Medical Health Rating (GMHR) ............................................................ 48 
6.2 
Pharmacokinetics (PK) .................................................................................................... 48 
6.3 
Safety ............................................................................................................................... 49 
6.3.1 Adverse Events..................................................................................................... 49 
6.3.2 Physical and Neurological Examinations............................................................. 51 
6.3.3 Vital Signs ............................................................................................................ 52 
6.3.4 Clinical Laboratory Tests ..................................................................................... 52 
6.3.5 Pregnancy Tests ................................................................................................... 53 
6.3.6 Electrocardiograms .............................................................................................. 53 
6.3.7 Sheehan Suicidality Tracking Scale (S-STS) ....................................................... 53 


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
 
 
 
Page 14 
 
6.3.8 Mini Mental State Examination (MMSE) ............................................................ 53 
6.3.9 Timed Up and Go (TUG) Test ............................................................................. 54 
6.3.10 Epworth Sleepiness Scale (ESS) .......................................................................... 54 
6.4 
Schedule of Evaluations and Procedures ......................................................................... 54 
6.4.1 Description of Study Procedures .......................................................................... 54 
7 
Data Management ......................................................................................................................... 66 
7.1 
Data Collection ................................................................................................................ 66 
8 
Statistical Methods ....................................................................................................................... 67 
8.1 
Analysis Populations ....................................................................................................... 67 
8.2 
Demographic and Baseline Characteristics ..................................................................... 67 
8.3 
Efficacy Analysis ............................................................................................................. 67 
8.3.1 Study Endpoints ................................................................................................... 67 
8.3.2 Primary Efficacy Analysis ................................................................................... 68 
8.3.3 Secondary Efficacy Analyses ............................................................................... 68 
8.4 
PK/PD Analysis ............................................................................................................... 69 
8.6 
Safety Analysis ................................................................................................................ 69 
8.6.1 Adverse Events..................................................................................................... 69 
8.6.2 Vital Signs and ECGs........................................................................................... 69 
8.6.3 Clinical Laboratory Values .................................................................................. 69 
8.6.4 Data and Safety Monitoring Board ...................................................................... 70 
8.6.5 Interim Analysis ................................................................................................... 70 
8.7 
Sample Size Calculations ................................................................................................ 70 
9 
Administrative Procedures............................................................................................................ 71 
9.1 
Institutional Review Board/Ethics Committee Approval ................................................ 71 
9.2 
Informed Consent Form................................................................................................... 71 
9.3 
Patient’s Diary Card ........................................................................................................ 71 
9.4 
Electronic Case Report Forms ......................................................................................... 72 
9.5 
Quality Assurance............................................................................................................ 72 
9.5.1 Documentation ..................................................................................................... 72 
9.5.2 Monitoring............................................................................................................ 72 
9.6 
Record Retention ............................................................................................................. 73 
9.7 
Source Data...................................................................................................................... 73 


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
 
 
 
Page 15 
 
9.8 
Data Handling .................................................................................................................. 73 
9.9 
Laboratory Procedures ..................................................................................................... 73 
9.10 
Guidelines for Good Clinical Practice ............................................................................. 74 
9.11 
Conditions for Amending the Protocol ............................................................................ 74 
9.12 
Conditions for Terminating the Study ............................................................................. 74 
9.13 
Confidentiality of Study Documents and Patient Records .............................................. 74 
9.14 
Reports ............................................................................................................................. 74 
9.15 
Publications ..................................................................................................................... 75 
9.16 
Audits/Inspections ........................................................................................................... 75 
10 
References..................................................................................................................................... 76 
 
 
 
List of Tables 
Table 1 
 Schedule of Evaluations and Visits ........................................................................... 24 
Table 2 
Composition of Investigational Product ..................................................................... 38 
 
List of Figure s 
Figure 1 
Sample Configuration of Investigational Product Blister Card .................................. 39 
 


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
 
 
 
Page 16 
 
LIST OF ABBREVIATIONS 
Abbreviation 
Definition 
AA 
Alzheimer’s Association 
AE 
Adverse event 
AD 
Alzheimer’s Disease 
ADAS-cog 
Alzheimer’s Disease Assessment Scale - cognitive subscale 
ADCS 
Alzheimer’s Disease Cooperative Study 
ADCS-CGIC-Overall 
Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change for 
Overall Clinical Status 
ADWG 
Agitation Definition Work Group 
ALT/SGPT 
Alanine aminotransferase/serum glutamic-pyruvic transaminase 
AST/SGOT 
Aspartate aminotransferase/serum glutamic-oxaloacetic transaminase 
BID 
Twice daily 
BP 
Blood pressure 
BUN 
Blood urea nitrogen 
CD-ROM 
Compact disc read-only-memory 
CFR 
Code of Federal Regulations 
Cit AD 
Citalopram study for Agitation in Alzheimer’s disease 
CGIC 
Clinical Global Impression of Change 
CGIS-Agitation 
Clinical Global Impression of Severity of Illness scale for Agitation 
CK 
Creatine kinase 
CMAI 
Cohen-Mansfield Agitation Inventory 
CNS 
Central nervous system 
CRO 
Contract research organization 
CSDD 
Cornell Scale for Depression in Dementia  
CYP 
Cytochrome P450 
d6-DM 
Deuterated (d6)-dextromethorphan hydrobromide (or free base form) 
DEMQOL 
Dementia Quality of Life 
DM 
Dextromethorphan hydrobromide 
DMP 
Data management plan 
DSMB 
Data and Safety Monitoring Board 
DSM-IV-TR 
Diagnostic and Statistical Manual of Mental Disorders 
EC 
Ethics Committee 
ECDEU 
Early Clinical Drug Evaluation Unit 
ECG 
Electrocardiogram 
eCRF 
Electronic case report form 
EDC 
Electronic data capture 
EP 
European Pharmacopeia 
ESS 
Epworth Sleepiness Scale 


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
 
 
 
Page 17 
 
Abbreviation 
Definition 
FDA 
US Food and Drug Administration 
GCP 
Good Clinical Practice 
GGT 
Gamma-glutamyl transferase 
GMHR 
General Medical Health Rating 
GMP 
Good Manufacturing Practice 
HbA1c 
Glycosylated hemoglobin  
HR 
Heart rate 
ICF 
Informed consent form 
ICH 
International Conference on Harmonisation 
IP 
Investigational product 
IPA 
International Psychogeriatric Association 
IRB 
Institutional Review Board 
ITT 
Intent-to-Treat 
IWRS 
Interactive Web Response System 
LDH 
Lactate dehydrogenase 
LOCF 
last observation carried forward  
mADCS-CGIC-Agitation 
Modified Alzheimer’s Disease Cooperative Study-Clinical Global Impression of 
Change for Agitation 
MAOI 
Monoamine oxidase inhibitor 
MedDRA 
Medical Dictionary for Regulatory Activities 
mITT 
Modified Intent-to-Treat 
MM 
Medical Monitor 
MMRM 
Mixed effects model repeated measures 
MMSE 
Mini-Mental State Examination 
MS 
Multiple Sclerosis 
NF 
National Formulary 
NIA 
National Institute on Aging 
NPI 
Neuropsychiatric Inventory 
NPI-NH 
Neuropsychiatric Inventory - Nursing Home version 
OTC 
Over–the-counter 
PGIC 
Patient Global Impression of Change 
pH 
Potential hydrogen 
PK 
Pharmacokinetics 
PR 
The P-R interval from an ECG tracing 
PVC 
Premature ventricular contraction 
Q 
Quinidine sulfate (or free base form) 
QRS 
The Q-R-S complex from an ECG tracing 
QT 
QT interval from an ECG tracing 
QTc 
QT interval corrected for heart rate 
QTcF 
QT interval corrected for heart rate using the Fridericia’s formula 


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
 
 
 
Page 18 
 
Abbreviation 
Definition 
RBC 
Red blood cell 
RUD 
Resource Utilization in Dementia 
SAE 
Serious adverse event 
SAP 
Statistical analysis plan 
SNRI 
Serotonin-norepinephrine reuptake inhibitor 
SOC 
System organ class 
SPCD 
Sequential Parallel Comparison Design 
SSRI 
Selective serotonin reuptake inhibitor 
S-STS 
Sheehan Suicidality Tracking Scale 
T3 
Triiodothyronine 
T4 
Thyroxine 
TCA 
Tricyclic antidepressant 
TEAE 
Treatment-emergent adverse event 
TSH 
Thyroid-stimulating hormone 
TUG 
Timed Up and Go 
USP 
United States Pharmacopoeia 
WBC 
White blood cell 
ZBI 
Zarit Burden Interview 


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
 
 
 
Page 19 
 
PROTOCOL AGREEMENT 
Protocol Title: 
A Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, 
and tolerability of AVP-786 (deuterated [d6]-dextromethorphan hydrobromide [d6-DM]/quinidine sulfate 
[Q]) for the treatment of agitation in patients with dementia of the Alzheimer’s type. 
Protocol Number: 15-AVP-786-302 (Amendment 4, 28 February 2017) 
This document is a confidential communication of Avanir Pharmaceuticals.  The recipient agrees that no 
unpublished information contained within this document or protocol will be disclosed or published 
without prior consent and written approval from Avanir.  An exception to this agreement may be made for 
the purposes of ethical or regulatory review, in which case this document may be disclosed to an Ethics 
Review Board or any authorized representative of a national authority as required by regulation. 
The signatures of the principal investigator and representative of the sponsor below constitute their 
approval of this protocol and further provide the necessary assurances that: 
1. This study will be conducted according to Good Clinical Practice (GCP) and to all stipulations, as 
specified in both clinical and administrative sections of the protocol including the Declaration of 
Helsinki. 
2. The conduct and results of this study will be kept confidential, and the electronic case report forms 
(eCRFs) and other pertinent data will become the property of Avanir Pharmaceuticals. 
3. The protocol contains all necessary information required to conduct the study, as outlined in the 
protocol, and that the study will not be initiated without the approval of an appropriate Institutional 
Review Board/Ethics Committee (IRB/EC). 
4. All participants in this study will provide written informed consent in accordance with the 
requirements specified in the Code of Federal Regulations (21 CFR Parts 50, 56, 312) and/or the 
Declaration of Helsinki.  All participants will also be informed that their medical records will be kept 
confidential except for review by Avanir or its representatives, the U.S. Food and Drug 
Administration (FDA), or other regulatory agencies if applicable. 
 
 
 
 
Principal Investigator Signature 
 
Date 
Principal Investigator Name: _____________________________ 
 
 
 
 
 
 
Avanir Representative Signature 
 
Date 
Avanir Representative Name:
, MD 
 
 


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
 
 
 
Page 20 
 
STUDY SYNOPSIS 
Title: A Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, 
safety, and tolerability of AVP-786 (deuterated [d6]-dextromethorphan hydrobromide [d6-DM]/quinidine 
sulfate [Q]) for the treatment of agitation in patients with dementia of the Alzheimer’s type. 
Study Objectives 
The objectives of the study are to evaluate the efficacy, safety, and tolerability of AVP-786 compared to 
placebo, for the treatment of agitation in patients with dementia of the Alzheimer’s type.   
Study Population 
Number of Patients:  Approximately 470 patients will be enrolled at approximately 75 centers in North 
America. 
Condition/Disease:  Patients with agitation secondary to dementia of the Alzheimer’s type.  The diagnosis 
of probable Alzheimer’s disease will be based on the ‘2011 Diagnostic Guidelines for Alzheimer’s 
Disease’ issued by the National Institute on Aging (NIA)-Alzheimer’s Association (AA) workgroups.1  
Diagnosis of agitation will be based on the provisional consensus definition of agitation in patients with 
cognitive disorders developed by the International Psychogeriatric Association (IPA) Agitation Definition 
Work Group.2  
Key Inclusion Criteria:  Patients with clinically significant, moderate/severe agitation at the time of 
screening and for at least 2 weeks prior to randomization, that interferes with daily routine and for which 
a prescription medication is indicated in the opinion of the investigator.  A Clinical Global Impression of 
Severity of Illness scale for Agitation (CGIS-Agitation) score of ≥ 4 (moderately ill) at screening and 
baseline is required for study participation.  Eligible patients must have a reliable caregiver who is able 
and willing to comply with study procedures, including not administering any prohibited medications 
during the course of the study.   
Key Exclusion Criteria:  Patients with dementia predominantly of the non-Alzheimer’s type (e.g., 
vascular dementia, frontotemporal dementia, Parkinson’s disease, substance-induced dementia) and 
patients with symptoms of agitation that are not secondary to Alzheimer’s disease (e.g., secondary to 
pain, other psychiatric disorder or delirium) are not eligible. 
A complete list of inclusion/exclusion criteria is presented in Section 4 of the study protocol. 
Study Design 
Structure: This is a phase 3, multicenter, randomized, double-blind, placebo-controlled study.   
Duration: Patients will be enrolled in the study for approximately 16 weeks; with up to 4-week screening 
period and 12-week treatment period.   
Study Treatment:  The investigational product is AVP-786 (deuterated [d6]-dextromethorphan 
hydrobromide [d6-DM; INN:deudextromethorphan]/quinidine sulfate [Q]).  Three doses of AVP-786 will 


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
 
 
 
Page 21 
 
be used in the study, d6-DM 18 mg/Q 4.9 mg, d6-DM 28 mg/Q 4.9 mg and d6-DM 42.63 mg/Q 4.9 mg, 
hereafter referred to as AVP-786-18/4.9, AVP-786-28/4.9, and AVP-786-42.63/4.9, respectively.  
Control:  Placebo capsules of identical appearance to study medication will be used as control. 
Randomization/Stratification:  Eligible patients will be randomized into the study to either AVP-786-
28/4.9, AVP-786-42.63/4.9, or placebo group.  The randomization will be stratified by the 
Neuropsychiatric Inventory (NPI) Agitation/Aggression domain score (≤ 6 vs. > 6), risk assessment for 
falls (normal/mild vs. moderate/severe), and concomitant use of antipsychotic medications (yes vs. no).    
Dose Regimen: Eligible patients will be randomly assigned at the Baseline visit to receive AVP-786 or 
matching placebo capsules.  Study medication will be administered orally twice daily (BID, 1 capsule in 
the morning and 1 capsule in the evening approximately 12 hours apart) throughout the study.  
Patients randomized to the AVP-786-28/4.9 group will start with AVP-786-18/4.9 once a day in the 
morning and placebo in the evening for the first 7 days of the study.  From Day 8, patients will receive 
AVP-786-18/4.9 BID for 14 days.  From Day 22, patients will receive AVP-786-28/4.9 BID for the 
remaining 9 weeks of the study.  If deemed necessary by the investigator, a one-time downward dose 
adjustment to AVP-786-18/4.9 will be allowed after Visit 3 up to and including Visit 4 (ie, Day 23 to Day 
43), and the patient will remain on the lower dose of study medication for the remaining study duration.  
Patients requiring a dose-adjustment between study visits will need to have an unscheduled visit to 
perform safety assessments.   
Patients randomized to the AVP-786-42.63/4.9 group will start with AVP-786-28/4.9 once a day in the 
morning and placebo in the evening for the first 7 days of the study.  From Day 8, patients will receive 
AVP-786-28/4.9 BID for 14 days.  From Day 22, patients will receive AVP-786-42.63/4.9 BID for the 
remaining 9 weeks of the study.  If deemed necessary by the investigator, a one-time downward dose 
adjustment to AVP-786-28/4.9 will be allowed after Visit 3 up to and including Visit 4 (ie, Day 23 to Day 
43), and the patient will remain on the lower dose of study medication for the remaining study duration.  
Patients requiring a dose-adjustment between study visits will need to have an unscheduled visit to 
perform safety assessments. 
Patients will have at least a 
 chance of receiving AVP-786 at some point during the study. 
Assessments and Visits  
Patients will attend clinic visits at Screening, Baseline (Day 1), and on Days 8 (Week 1), 15 (Week 2), 
22 (Week 3), 43 (Week 6), 64 (Week 9), and 85 (Week 12).  Patients who terminate early will receive 
daily phone calls for 5 consecutive days following the early termination (ET) visit to query on their 
overall well-being and will be asked to return for an in-clinic Follow-up visit 30 days after last dose of 
study medication for selected safety and efficacy assessments.  Safety follow-up phone calls will be made 
on Days 29 (Week 4) and 71 (Week 10).  Study procedures will be performed at each visit as outlined in 
the Schedule of Evaluations and Visits (Table 1).  


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
 
 
 
Page 22 
 
Response Measures 
Efficacy  
Primary measure: Primary efficacy will be assessed using the Cohen-Mansfield Agitation Inventory 
(CMAI).  
Secondary measures:  Secondary efficacy measures include: Agitation/Aggression domain of the NPI, 
modified Alzheimer’s Disease Cooperative Study Clinical Global Impression of Change (mADCS-CGIC-
Agitation), NPI-Agitation/Aggression domain Caregiver Distress score, NPI-Aberrant Motor Behavior 
domain, Zarit Burden Interview (ZBI), NPI-Irritability/Lability domain, Patient Global Impression of 
Change (PGIC-rated by caregiver), Dementia Quality of Life (DEMQOL), Cornell Scale for Depression 
in Dementia (CSDD), Resource Utilization in Dementia (RUD), total NPI, ADCS-CGIC-Overall, CGIS 
Agitation, Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-cog), and General Medical 
Health Rating (GMHR). 
For consistency of rating, assessments should be performed, whenever possible, by the same rater 
throughout the study.  The following scales MUST be administered by the same rater at each visit:  
CMAI, NPI, mADCS-CGIC-Agitation, and CGIS-Agitation. 
Pharmacokinetics 
Plasma concentrations of d6-DM, its metabolites, and Q will be measured. 
Safety and Tolerability  
Safety and tolerability of AVP-786 will be assessed by reported adverse events (AEs), physical and 
neurological examinations, vital signs, clinical laboratory assessments, resting 12-lead electrocardiograms 
(ECGs), Sheehan Suicidality Tracking Scale (S-STS), Mini Mental State Examination (MMSE), Timed 
Up and Go (TUG) test, and the Epworth Sleepiness Scale (ESS).  
Pregnancy tests will be conducted for females of childbearing potential.  
General Statistical Methods and Types of Analyses 
Analysis Populations 
Three analysis populations will be used; modified intent-to-treat (mITT), intent-to-treat (ITT), and safety.  
The mITT population includes all patients randomized in the study who had at least one post-baseline 
efficacy assessment, and will be used for all analyses of efficacy.  Patients in the mITT population will be 
included in the treatment group to which they were randomized regardless of treatment received.  The 
ITT population includes all randomized patients in the study, and will be used for exploratory efficacy 
analyses.  The safety population includes all patients who received study treatment, and will be used for 
all analyses of safety.  Patients will be included in the treatment group based on the actual treatment 
received. 


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
 
 
 
Page 23 
 
Efficacy Analyses  
The primary efficacy endpoint is the change from Baseline to Week 12 (Day 85) in the composite CMAI 
scores.  The primary treatment comparisons (AVP-786-42.63/4.9 vs. placebo and AVP-786-28/4.9 vs. 
placebo) will be performed by using a linear mixed effects model repeated measures (MMRM) with 
comparisons being made between the patients treated with AVP-786 and patients treated with concurrent 
placebo.  The model will include fixed effects for treatment, visit, treatment-by-visit interaction, baseline-
by-visit interaction, and baseline covariates which include baseline value and other factors as appropriate.  
An unstructured covariance model will be used.   
A gate-keeping procedure will be used to control the overall type I error at 2-sided α = 0.05 for the 2 
primary treatment comparisons (AVP-786-42.63/4.9 vs. placebo and AVP-786-28/4.9 vs. placebo). 
Specifically, the comparison between AVP-786-42.63/4.9 vs. placebo will be performed first at the 
significance level of 0.05.  If the comparison is statistically significant, the comparison between 
AVP-786-28/4.9 vs. placebo will be performed at the same significance level. 
Secondary efficacy endpoints include change from Baseline to Week 12 (Day 85) for the following 
efficacy measures: mADCS-CGIC-Agitation, NPI-Agitation/Aggression domain score and Caregiver 
Distress score, NPI-Aberrant Motor Behavior domain, ZBI, NPI-Irritability/Lability domain, PGIC, 
DEMQOL, CSDD, RUD, total NPI, ADCS-CGIC-Overall, CGIS-Agitation, ADAS-cog, and GMHR.   
Safety Analyses 
Safety measures will be summarized by treatment group.   
Sample Size Calculation 
Power calculation was performed assuming a normal distribution for the primary efficacy endpoint.  
 
 
 
  
 
  
The study protocol is amended to include another dose arm (AVP-786-42.63/4.9) with 140 patients in the 
treatment arm, when approximately 100 patients have already been enrolled (50 AVP-786 28/4.9 and 50 
placebo) in the study.  To maintain an approximate 
chance for an incoming patient to receive active 
drug, the sample size for the placebo treatment group is amended to 190.  Overall, the total sample size of 
470 patients will include 140 patients for AVP-786 28/4.9 and AVP-786 42.63/4.9 groups each and 190 
patients in the placebo group.  This sample size will provide approximately 
 power to detect a 
treatment effect size of 
between AVP-786 42.63/4.9 and concurrent placebo treatment group.   
  










 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
Page 28 
 
study of AVP-923 (dextromethorphan/quinidine combination) for the treatment of agitation in AD 
(Study 12-AVR-131). 
d6-DM binds to receptors responsible for modulation of glutamate, monoamine, sigma-1, and nicotinic 
cholinergic pathways that may be key to CNS therapeutics.  Pharmacology studies conducted by Avanir 
with d6-DM have demonstrated that deuteration does not alter the basic pharmacology of DM.  
Pharmacokinetic (PK) and drug metabolism studies indicate that d6-DM is metabolized by the same 
metabolic pathways as DM, but that deuteration results in a decreased rate of metabolism by CYP2D6.   
The recently completed Phase 2 Study 12-AVR-131 met the primary efficacy endpoint and showed clear 
improvement of agitation in patients receiving AVP-923 compared with placebo.  Study 12-AVR-131 
was a 10-week, randomized, double-blind, placebo-controlled, 2-stage, sequential parallel comparison 
design (SPCD) study to assess the efficacy, safety, and tolerability of AVP-923 for the treatment of 
symptoms of agitation in 220 patients with AD.  Patients who received AVP-923 had significantly 
reduced agitation compared to patients who received placebo (p<0.001) as measured by the 
Agitation/Aggression domain of the Neuropsychiatric Inventory (NPI).  The majority of the secondary 
endpoints studied (e.g., NPI-total, NPI-Agitation/Aggression domain Caregiver Distress, Clinical Global 
Impression of Change [CGIC]-Agitation, Clinical Global Impression of Severity [CGIS]-Agitation and 
Patient Global Impression of Change [PGIC]) were also statistically significant.  Both clinician and 
patient/caregiver impressions of change corroborated the clinical meaningfulness of improvements 
observed in agitation.  Numerically favorable response in cognition as measured by the Mini Mental State 
Examination (MMSE) and the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) 
were observed but neither achieved statistical significance.   
Studies conducted by Avanir have shown that d6-deuterium modification of DM reduced the rate of 
CYP2D6 metabolism such that combination with a significantly lower dose of quinidine (< 50% of the 
amount of Q contained in AVP-923) was sufficient for bioequivalence of d6-DM to DM in AVP-786 and 
AVP-923, respectively (Studies 12-AVR-132, 13-AVR-134, 14-AVP-786-101, and 14-AVP-786-102).  
The lower amount of Q in AVP-786 may reduce interactions with other CYP2D6 substrates, limit Q 
levels even in the presence of CYP3A4 inhibitors, and reduce the effects on cardiac repolarization and 
QTc interval.  
The receptor pharmacology of d6-DM and the robust clinical effect observed in Study 12-AVR-131 
suggest AVP-786 may have a benefit in agitation, while the significantly lower dose of Q in AVP-786 
may lead to improvement in the safety profile compared with AVP-923.  Combined, the potential efficacy 
and safety of AVP-786 warrant further clinical investigation.  The current study (Study 15-AVP-302) is 
designed to evaluate the efficacy, safety, and tolerability of AVP-786 for the treatment of agitation in 
patients with dementia of the Alzheimer’s type. 
1.2 
Rationale for the Study Design 
The randomized, placebo-controlled, double-blind design reduces sources of bias that are inherent in less 
well-controlled designs.  The safety assessments used are standard in clinical research and are generally 


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
Page 29 
 
recognized as reliable, accurate, and relevant.  The rating scales used to assess efficacy are well-
established instruments that are widely used in clinical studies of AD. 
1.3 
Rationale for AVP-786 Dose 
The planned doses of AVP-786 for this study initially were d6-DM 28 mg/Q 4.9 mg and d6-DM 
18 mg/Q 4.9 mg, hereafter referred to as AVP-786-28/4.9 and AVP-786-18/4.9, respectively.  The 
AVP-786-28/4.9 dose is achieved by gradual titration schedule starting with AVP-786-18/4.9.  The study 
protocol is amended to include an additional treatment arm with a dose of d6-DM 42.63 mg/Q 4.9 mg 
(AVP-786-42.63/4.9) achieved by gradual titration with AVP-786-28/4.9 using the same titration 
regimen. 
 
 
 
 
 
 
 
 
  
 
 
 
1.4 
Rationale for the Duration of Dosing 
A drug being developed for treatment of a chronic condition needs to show maintenance of effect.  A 
12-week treatment duration is generally considered by experts and regulators as a reasonable time frame 
to assess acute and chronic effects and safety of a compound for chronic use.  To ensure tolerability, 
patients allocated to the study treatment (AVP-786) will gradually be exposed to the assigned dose; 
beginning with once-daily dosing of a dose lower than the assigned dose for one week, followed by twice-
daily dosing of the same dose for 2 weeks, and then twice-daily dosing of the assigned dose (AVP-786-
28/4.9) for the remaining study duration.  
 
  
Thus, patients assigned to AVP-786-28/4.9 will receive AVP-786-18/4.9 once daily for one week, 
followed by AVP-786-18/4.9 twice daily for 2 weeks and then AVP-786-28/4.9 for the remaining study 
duration, with a provision for a one-time down titration to AVP-786-18/4.9, whereas patients assigned to 
AVP-786-42.63/4.9 will receive AVP-786-28/4.9 once daily for one week, followed by AVP-786-28/4.9 
twice daily for 2 weeks and then AVP-786-42.63/4.9 for the remaining study duration, with a provision 
for a one-time down titration to AVP-786-28/4.9 during the study. 
 


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
Page 30 
 
2 
STUDY OBJECTIVES 
The objectives of the study are to evaluate the efficacy, safety, and tolerability of AVP-786 compared to 
placebo, for the treatment of agitation in patients with dementia of the Alzheimer’s type.   


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
Page 31 
 
3 
STUDY DESIGN 
This is a phase 3, multicenter, randomized, double-blind, placebo-controlled study of 12-week treatment 
duration.   
Approximately 470 patients will be enrolled at approximately 75 centers in North America.  There will be 
8 scheduled clinic visits including a screening visit, and 2 safety follow-up phone calls in this study.  
Patients will attend clinic visits at Screening, Baseline (Day 1), and on Days 8 (Visit 2/Week 1), 
15 (Visit 2.1/Week 2), 22 (Visit 3/Week 3), 43 (Visit 4/Week 6), 64 (Visit 5/Week 9), and 85 (Visit 
6/Week 12).  Patients who terminate early will receive daily phone calls for 5 consecutive days following 
the ET visit to query on their overall well-being and will be asked to return for an in-clinic Follow-up 
visit 30 days after last dose of study medication for selected safety and efficacy assessments. Patients who 
do not roll over to the extension study (Study 15-AVP-786-303) will receive a safety follow-up phone 
call 30 days after the last dose of study medication.  Safety follow-up phone calls will be made on Days 
29 (Week 4) and 71 (Week 10).  Study procedures will be performed at each visit as outlined in the 
Schedule of Evaluations and Visits (Table 1). 
Eligible patients will be randomly assigned at the Baseline visit to receive AVP-786 or matching placebo.  
Study medication will be administered orally twice daily from Day 1 through Day 85.  Patients (or 
caregivers) will self-administer study medication on all study days except on applicable clinic-visit days 
when patients will be administered their morning dose of study medication at the clinic in the presence of 
site personnel, regardless of the time of day.  Screening will occur within 4 weeks prior to randomization.   
Following screening procedures for assessment of inclusion and exclusion criteria, eligible patients will 
be randomized into the study to either the AVP-786-28/4.9, AVP-786-42.63/4.9, or placebo group.  The 
randomization will be stratified by the NPI Agitation/Aggression domain score (≤ 6 vs. > 6), risk 
assessment for falls (normal/mild vs. moderate/severe), and concomitant use of antipsychotic medications 
(yes vs. no).  Study medication (active or placebo) will be administered orally BID (1 capsule in the 
morning and 1 capsule in the evening approximately 12 hours apart) throughout the treatment period. 
Patients randomized to the AVP-786-28/4/9 group will start with AVP-786-18/4.9 once a day in the 
morning and placebo in the evening for the first 7 days of the study.  From Day 8, patients will receive 
AVP-786-18/4.9 BID for 14 days.  From Day 22, patients will receive AVP-786-28/4.9 BID for the 
remaining 9 weeks of the study.  If deemed necessary by the investigator, a one-time downward dose 
adjustment to AVP-786-18/4.9 will be allowed after Visit 3 up to and including Visit 4 (ie, Day 23 to Day 
43), and the patient will remain on the lower dose of study medication for the remaining study duration.  
Patients requiring a dose-adjustment between study visits will need to have an unscheduled visit to 
perform safety assessments.   
Patients randomized to the AVP-786-42.63/4.9 group will start with AVP-786-28/4.9 once a day in the 
morning and placebo in the evening for the first 7 days of the study.  From Day 8, patients will receive 
AVP-786-28/4.9 BID for 14 days.  From Day 22, patients will receive AVP-786-42.63/4.9 BID for the 
remaining 9 weeks of the study.  If deemed necessary by the investigator, a one-time downward dose 
adjustment to AVP-786-28/4.9 will be allowed after Visit 3 up to and including Visit 4 (ie, Day 23 to Day 


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
Page 32 
 
43), and the patient will remain on the lower dose of study medication for the remaining study duration.  
Patients requiring a dose-adjustment between study visits will need to have an unscheduled visit to 
perform safety assessments.   
Patients will have at least a 
chance of receiving AVP-786 at some point during the study. 


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
Page 33 
 
4 
STUDY POPULATION 
Patients enrolled in this study must have a diagnosis of probable AD and must present with clinically 
meaningful, moderate/severe agitation secondary to AD.  
The diagnosis of probable AD will be based on the ‘2011 Diagnostic Guidelines for Alzheimer’s Disease’ 
issued by the National Institute on Aging (NIA)-Alzheimer’s Association (AA) workgroups.1  These new 
criteria were developed based on the review of the NINCDS–ADRDA criteria.18  Neither AD nor 
agitation should be explainable by delirium, substance use and/or major psychiatric disorders.  
The provisional consensus definition of agitation in patients with cognitive disorders developed by the 
Agitation Definition Work Group (ADWG) from the International Psychogeriatric Association (IPA),2  
will be used for selecting study patients.  This proposed definition is limited to patients with cognitive 
impairment and requires:  (a) evidence of emotional distress; (b) one of 3 observable types of behaviors-
excessive motor activity, verbal aggression, or physical aggression; (c) that the behavior causes excess 
disability; and (d) that the behaviors cannot be solely attributable to a suboptimal care environment or 
other disorder such as a psychiatric illness, a medical illness, or effects of a substance.  
Eligible patients must have agitation (persistent or frequently recurrent) at the time of study screening and 
for at least 2 weeks prior to randomization and the agitation symptoms must be severe enough such that 
they interfere with daily routine and cause distress to the patient and caregiver for which a prescription 
medication is deemed indicated, in the opinion of the treating physician. 
Agitation will further be assessed using the CGIS-Agitation scale (0-7).  A score of ≥ 4 (moderately ill) at 
screening and baseline are required for study participation. 
Eligible patients are to have otherwise acceptable and stable general health as required by the study 
protocol, and documented by medical history, physical examination, electrocardiogram (ECG), and 
clinical laboratory examinations. 
Eligible patients must have a caregiver who is able and willing to comply with all required study 
procedures, ensuring that the patient attends all study visits and takes the study medication as instructed.  
Caregivers will also be instructed to keep a study diary, to report any changes in patient’s status, 
including adverse events, standard of care setting (e.g., becoming a resident in an assisted living facility), 
and to provide their impression and assessment regarding the investigational treatment.  In order to 
qualify as a reliable informant (i.e., caregiver) capable of assessing changes in the patient’s condition 
during this study, the individual must spend a minimum of 2 hours per day for 4 days per week with the 
study patient. 
4.1 
Inclusion Criteria 
1. 
Males and females 50 to 90 years of age inclusive, at the time of informed consent. 
2. 
Diagnosis of probable AD according to the 2011 NIA-AA working groups criteria.  Either out-
patients or residents of an assisted-living facility or a skilled nursing home. 


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
Page 34 
 
3. 
The patient has clinically significant, moderate/severe agitation at the time of screening and for 
at least 2 weeks prior to randomization, that interferes with daily routine and for which a 
prescription medication is indicated, in the opinion of the investigator.   
4. 
The diagnosis of agitation must meet the IPA provisional definition of agitation. 
5. 
CGIS-Agitation score is ≥ 4 (moderately ill) at Screening and Baseline. 
6. 
MMSE score between 6 and 26 (inclusive) at Screening and Baseline. 
7. 
. 
8. 
 
 
9. 
 
 
 
 
 
 
 
 
 
 
. 
10. 
 
 
 
11. 
 
 
 
 
  
 
  
12. 
 
 
 
 
 
13. 
 
 
 
 
14. 
 
. 


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
Page 35 
 
15. 
 
 
 
 
16. 
Caregiver must be willing and able to comply with study procedures, including not 
administering any prohibited medications during the course of the study. 
17. 
 
  
 
 
 
4.2 
Exclusion Criteria 
1. 
Caregiver is unwilling or unable, in the opinion of the investigator, to comply with study 
instructions.  
2. 
Patient has dementia predominantly of non-Alzheimer’s type (e.g., vascular dementia, 
frontotemporal dementia, Parkinson’s disease, substance-induced dementia). 
3. 
 
 
4. 
Patients with myasthenia gravis 
 
5. 
 
 
 
 
 
 
 
 
6. 
. 
7. 
 
 
 
8. 
 
9. 
 
10. 
 


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
Page 36 
 
11. 
Patients with co-existent clinically significant or unstable systemic diseases that could 
confound the interpretation of the safety results of the study (e.g., malignancy [except skin 
basal-cell carcinoma or untreated prostate cancer], poorly controlled diabetes, poorly controlled 
hypertension, unstable pulmonary, renal or hepatic disease, unstable ischemic cardiac disease, 
dilated cardiomyopathy, or unstable valvular heart disease).  
 
  
 
 
12. 
 
 
13. 
 
 
14. 
. 
15. 
 
 
16. 
 
 
 
. 
4.3 
Patient Withdrawal From the Study 
Patients and caregivers will be advised verbally and in the written ICF that they have the right to 
withdraw from the study at any time without prejudice or loss of benefits to which they are otherwise 
entitled.  The investigator or sponsor may discontinue a patient from the study in the event of an 
intercurrent illness, adverse event, other reasons concerning the health or well-being of the patient, or in 
the case of lack of cooperation, non-compliance, protocol violation, or other administrative reasons.  If a 
patient does not return for a scheduled visit, every effort should be made to contact the patient.  
Regardless of the circumstance, every effort should be made to document patient outcome, if possible.  
The investigator should inquire about the reason for withdrawal, request the caregiver return all unused 
investigational product (IP), and follow-up with the patient regarding any unresolved adverse events.  
 
 
 
Patients who terminate early will be asked to return to the clinic to complete the Visit 6 assessments and 
an in-clinic Follow-up visit, 30 days after last dose of study medication for selected safety and efficacy 
assessments.  In addition, daily phone calls for 5 consecutive days following ET visit will be made for 
these patients to assess their overall well-being.   


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
Page 37 
 
If the patient withdraws from the study, and consent is withdrawn by the caregiver and/or patient’s 
representative for disclosure of future information, no further evaluations should be performed, and no 
additional data should be collected.  The sponsor may retain and continue to use any data collected before 
such withdrawal of consent.  Patients who withdraw from the study will not be replaced. 


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
Page 38 
 
5 
STUDY TREATMENTS 
5.1 
Treatments Administered 
5.1.1 
Description of Study Medications 
Clinical study medication will be provided as hard, printed, 
, gelatin capsules (
  Each 
capsule of the study medication contains 1 of the following: 
• 
42.63 mg of d6-DM and 4.9 mg of Q (USP, EP):  AVP-786-42.63/4.9 
• 
28 mg of d6-DM and 4.9 mg of Q (USP, EP):  AVP-786-28/4.9 
• 
18 mg of d6-DM and 4.9 mg of Q (USP, EP):  AVP-786-18/4.9 
• 
AVP-786 placebo 
Drug supplies will be provided to the site in double-blind, individual, pre-labeled blister cards.    
All medication used in this study will be prepared, packaged, and labeled in accordance with Good 
Manufacturing Practice (GMP) guidelines, International Conference on Harmonisation (ICH) Good 
Clinical Practice (GCP) guidelines, and applicable laws and regulations. 
5.1.2 
Composition of AVP-786 
The qualitative and quantitative compositions of the 3 doses of the IP and the placebo are listed in 
Table 2. 
Table 2 
Composition of Investigational Product 
Ingredient (amounts in mg) 
AVP-786-
42.63/4.9 
AVP-786-
28/4.9 
AVP-786-
18/4.9 
AVP-786 
Placebo 
Deudextromethorphan hydrobromide  
42.63 (33) 
28.00 (21.67) 
18.00 (13.93) 
0 
Quinidine sulfate USP, EP 
4.9 (4.26) 
4.90 (4.26) 
4.90 (4.26) 
0 
Croscarmellose sodium NF 
X 
X 
X 
X 
Microcrystalline cellulose NF 
X 
X 
X 
X 
Colloidal silicone dioxide NF 
X 
X 
X 
X 
Magnesium stearate NF 
X 
X 
X 
X 
 capsules  
X 
X 
X 
X 
EP = European Pharmacopoeia; USP = United States Pharmacopoeia; NF = National Formulary 
*  Free base equivalent indicated in parenthesis 
 


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
Page 39 
 
5.1.3 
Packaging 
The investigators will be supplied with pre-labeled, individually pre-packaged and tamper-proof sealed 
blister cards.  Each panel of the blister card (1 week of study medication) consists of 2 rows of blister 
strips, one row for the morning dose and one row for the evening dose (Figure 1).  Each blister card will 
contain 3 panels, providing sufficient study medication for 3 weeks of treatment and an additional 3 days 
of supply (total of 48 capsules).   
Figure 1 
Sample Configuration of Investigational Product Blister Card 
 
 
5.1.4 
Labeling 
All labels will contain protocol number, product name, blister card number, an investigational drug 
warning, and dosage instructions to take 1 capsule in the morning and 1 capsule in the evening, storage 
conditions, and company name.  The blister card label will consist of 2 panels, with 1 detachable panel 
that will be removed and affixed to the study medication Dispensing Log page at the time of dispensing.  
Space is provided on both panels of the card label to record Patient Number, the Visit Week, and 
Dispensing Date.  All investigational product labels comply with all applicable federal and local 
regulations.  
5.1.5 
Storage of Clinical Supplies 
Clinical supplies must be stored in compliance with label requirements in a secure place and kept at room 
temperature; 25°C (77°F) with excursions permitted to 15°C to 30°C (59°F-86°F). 


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
Page 40 
 
5.1.6 
Study Medication Administration 
All patients will receive study medication according to the blister card numbers assigned by an interactive 
web response system (IWRS) randomization scheme.  Designated staff at each site will dispense study 
medication.  Study medication should be administered to the patient by the caregiver, family member, 
nursing home staff, or self-administered with supervision, except on applicable clinic visit days when 
patients will be administered their dose of study medication at the clinic in the presence of site personnel, 
regardless of the time of day.  Patients and caregivers will be instructed that the patient should take the 
study medication orally with water approximately every 12 hours ± 4 hours (morning and evening).  The 
time the patient takes each dose of medication should be recorded in the diary card.  For Visits 2 (Day 8) 
and 2.1 (Day 15), caregivers should be advised that the patient should take the morning dose of study 
medication within 2 hours of the clinic appointment.  Patient’s missed doses will be noted in the 
electronic case report form (eCRF).  All study medication will be supplied and administered in a double-
blind manner throughout the entire duration of the study. 
5.2 
Accountability of Study Supplies 
5.2.1 
Receipt of Supplies 
The investigator is responsible for maintaining an inventory of each shipment of IP received and 
comparing it with the accompanying Drug Accountability Report/Material Shipping Form.  The 
investigator will verify the accuracy of the information on the form, sign and date it, and return the form 
to the sponsor or its representative.  All IP supplied is for use only in this study and should not be used for 
any other purpose.  All blister card material ID numbers will also be recorded and tracked at the site using 
the Drug Accountability Log. 
5.2.2 
Record of Dispensing 
Accurate recording of all IP dispensing for individual patients will be made in the appropriate section of 
the patient’s eCRF.  This eCRF will contain the following information: (i) the initials and patient number 
to whom the drug was dispensed; (ii) the date(s) and quantity of the drug dispensed to the patient; and 
(iii) the blister card material ID number assigned to the patient via IWRS.  
Additionally, the detachable panel of the two-panel label on each blister card will be removed and affixed 
to the study medication Dispensing Log page at the time of dispensing.  Space is provided on both panels 
of the blister card label to record patient number, the visit week and dispensing date.   
5.2.3 
Unused Supplies 
At the end of the study, all unused investigational supplies must be inventoried on the Drug 
Accountability Log and returned to the sponsor or its representative, along with a completed and signed 
Drug Accountability Report/Material Shipping Form.  If any study medication is lost or damaged, it 
should be indicated on the form.  


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
Page 41 
 
5.3 
Methods of Assigning Patients to Treatment Groups 
5.3.1 
Randomization 
Upon entry into the study (after ICF is signed at screening), all patients will be assigned a 
patient 
number.  
  
 
This 
 number is the main identifier for patients. 
Eligible patients will be randomized to receive either AVP-786-28/4.9, AVP-786-42.63/4.9, or placebo on 
Day 1 (Baseline) according to a randomization scheme devised by Avanir or its representative and 
managed within an IWRS.  The randomization will be stratified by the NPI Agitation/Aggression domain 
score (≤ 6 vs. > 6), risk assessment for falls (normal/mild vs. moderate/severe), and concomitant use of 
antipsychotic medications (yes vs. no).  Blocked randomization is used to ensure treatment balance in 
each stratum.  Patients will have at least a 
chance of receiving AVP 786 at some point during the 
study. 
5.3.2 
Blinding/Masking 
Blinding will be maintained by providing capsules of AVP-786 and placebo that are identical in 
appearance.  The sponsor, patients, caregivers, investigators, or other study personnel will not be aware of 
a patient’s treatment assignment.  In the event that it becomes medically necessary to identify which 
treatment a patient has received, the blind can be broken.  In that event, the investigator is to contact 
Avanir’s medical monitor or representative to request the unmasking of a patient.  The IWRS manager is 
not required to be blinded and he or she will have access to the study medication list and the 
randomization code. 
5.4 
Patient Compliance 
Patients and caregivers will be instructed to bring any unused study medication and empty containers to 
the clinic on Days 8, 15, 22, 43, 64, and 85 (Visits 2 – 6).  For this study, compliance will be defined as 
when a patient takes at least 80% of their scheduled doses (compliance range 80-120%).  Caregivers will 
be provided with diary cards and will be instructed to record daily the number of capsules taken and the 
time of administration.  Diary cards will be reviewed for compliance and collected on Days 22, 43, 64, 
and 85 (Visits 3 – 6), or at the time of early study discontinuation.  Patients should bring their Diary Card 
on Day 8 (Visit 2) and Day 15 (Visit 2.1) for compliance review; the Diary Card will be returned to the 
patient and collected at the next visit.  
5.5 
Concomitant Medications and Nondrug Therapies 
Patients may not take any of the disallowed medications listed in Appendix 1 during the study 
 
prior to the start of dosing on Day 1.  At each visit, caregivers will be 
queried as to whether or not the patient has taken any concomitant medications and, if so, the investigator 


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
Page 42 
 
will record the medications taken and the reasons for their use.  Caregivers will be instructed to record 
concomitant use of rescue medication 
 in the diary.  
  
 
 
  
 
 
 
 
 
 
. 
For patients who terminate early, the conditions of use for allowed concomitant medications and nondrug 
therapies or prohibited medications do not apply between the ET visit and the Follow-up visit.  Any use 
of medications during this period will be at the discretion of the investigator.  Patients should allow at 
least 14 days after stopping study medication before starting an MAOI. 
5.5.1 
 
 
 
 
 
 
 
  
 
 
 
  
 
 
 
 
 
 
   
 
 
 


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
Page 43 
 
 
 
 
 
   
5.5.2 
Rescue Medication for the Symptoms of Agitation 
Patients will be allowed to receive oral lorazepam as rescue medication for the short-term treatment of 
symptoms of agitation if deemed necessary by the investigator.  Lorazepam will be administered in a dose 
up to 1.5 mg/day and not to exceed 3 days in a 7-day period.  Caregivers must record concomitant use of 
lorazepam in the diary and must be reminded of the potential increase in the risk of falling by 
benzodiazepines. 
5.5.3 
 
  
 
 
5.5.4 
Nondrug Therapies 
Information on any prior and concomitant nondrug therapies will be recorded. 
5.5.5 
Nonpharmacological Interventions for the Treatment of Agitation 
Information on any nonpharmacological interventions for the treatment of agitation that were used prior 
to enrollment or used concomitantly during the study will be recorded. 
 


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
Page 44 
 
6 
STUDY ASSESSMENTS AND PROCEDURES 
6.1 
Efficacy 
Samples of all the scales and questionnaires to be used during the study are attached as Appendices.  
Whenever possible, each patient and caregiver should have the rating scales administered by the same 
raters throughout the study, for consistency of ratings.  The following scales MUST be administered by 
the same rater at each visit:  CMAI, NPI, mADCS-CGIC-Agitation, and CGIS-Agitation. 
6.1.1 
Cohen-Mansfield Agitation Inventory (CMAI) 
The CMAI will be used as the primary efficacy measure in this study.  The CMAI 
 is used to 
assess the frequency of manifestations of agitated behaviors in elderly persons.  
 
 
 
  
 
  
 
 
  Each of 
the 
 items is rated on a 7-point scale of frequency (1 = never, 2 = less than once a week but still 
occurring, 3 = once or twice a week, 4 = several times a week, 5 = once or twice a day, 6 = several times a 
day, 7 = several times an hour).  The ratings are based on the 2 weeks preceding assessment of CMAI.  
The CMAI (long-form version, 
 will be assessed at Screening (Day -28 to Day -1), Baseline 
(Day 1), Day 8 (Visit 2), Day 15 (Visit 2.1), Day 22 (Visit 3), Day 43 (Visit 4), Day 64 (Visit 5), and 
Day 85 (Visit 6), and Follow-up visit (for ET patients).  The CMAI must be administered by the same 
rater at each visit. 
6.1.2 
Neuropsychiatric Inventory (NPI) 
The NPI 
 is a validated clinical instrument for evaluating psychopathology in a variety of 
disease settings, including dementia.  The NPI is a retrospective caregiver-informant interview covering 
12 
neuropsychiatric 
symptom 
domains: 
delusions, 
hallucinations, 
agitation/aggression, 
depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, 
aberrant motor behavior, sleep and nighttime behavioral disorders, and appetite/eating disorders.  The 
scripted NPI interview includes a compound screening question for each symptom domain, followed by a 
list of interrogatives about domain-specific behaviors that is administered when a positive response to a 
screening question is elicited.  Neuropsychiatric manifestations within a domain are collectively rated by 
the caregiver in terms of both frequency (1 to 4) and severity (1 to 3), yielding a composite symptom 
domain score (frequency x severity).  Frequency and severity rating scales have defined anchor points to 
enhance the reliability of caregiver responses.  Caregiver distress is rated for each positive 
neuropsychiatric symptom domain on a scale anchored by scores of 0 (not distressing at all) to 
5 (extremely distressing).  The NPI will be administered to the patient’s caregiver at Baseline (Day 1), 
Day 22 (Visit 3), Day 43 (Visit 4), Day 64 (Visit 5), and Day 85 (Visit 6).  The Agitation/Aggression 


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
Page 45 
 
domain of the NPI will be administered to the patient’s caregiver at Screening (Day -28 to Day -1), Day 8 
(Visit 2), and Day 15 (Visit 2.1).  The NPI must be administered by the same rater at each visit. 
The NPI domains are generally evaluated for behaviors within the preceding 4 weeks but can be modified 
according to the needs of the study.  In this study, the recall period will be 2 weeks for all the visits.  
The NPI nursing-home version (NPI-NH) will be used for patients from in-patient or assisted living 
facilities.  The questions in the NPI-NH were rephrased for professional caregivers who may not know 
the patients prior to the onset of illness; however, the overall instrument domains and scoring is identical 
to the NPI except for the caregiver distress section which is replaced with occupational disruptiveness in 
the NPI-NH version.   
The Agitation/Aggression domain in the NPI will be assessed as part of the total NPI as described above 
and the composite score obtained for this category will be recorded separately at Baseline (Day 1), 
Day 22 (Visit 3), Day 43 (Visit 4), Day 64 (Visit 5), and Day 85 (Visit 6). 
6.1.3 
Clinical Global Impression of Severity of Illness-Agitation (CGIS-
Agitation) 
The CGIS 
 is an observer-rated scale that measures illness severity and is one of the most 
widely used brief assessment tools in psychiatry research.   
The Early Clinical Drug Evaluation Unit (ECDEU) version of the CGIS is the most widely used format of 
this validated tool, and asks that the clinician rate the patient relative to their past experience with other 
patients with the same diagnosis, with or without collateral information.  The CGIS has proved to be a 
robust measure of efficacy in many clinical drug trials22–26 and is easy and quick to administer, provided 
that the clinician knows the patient well.27  
Reliability and validity of CGI have been tested in multiple studies, including patients with dementia, 
schizophrenia and affective disorders.  Overall, CGI showed high correlation (r: ~90%) with other 
assessment instruments and it has also shown positive significant relationships and concurrent validity 
with other clinician’s rating.  In addition, the scale has good sensitivity to change over time.28–30  
The CGIS is a 7-point (1-7) scale (1 = normal, not at all ill; 7 = among the most extremely ill patients) 
and assesses severity of agitation in this study.  The CGIS-Agitation will be assessed at Screening (Day -
28 to Day -1), Baseline (Day 1), Day 43 (Visit 4), and Day 85 (Visit 6).  The CGIS-Agitation must be 
administered by the same rater at each visit. 
6.1.4 
Alzheimer’s Disease Cooperative Study - Clinical Global 
Impression of Change Rating (ADCS-CGIC-Overall) 
The intent of the ADCS version of the CGIC 
 (herein referred to as ADCS-CGIC-Overall), 
is to provide a means to reliably assess change from a baseline level of global function within the 
timeframe of a clinical trial.  Unlike a targeted symptom scale, the ADCS-CGIC-Overall takes into 
account a patient's overall function in the cognitive, behavioral and functional activity domains.  Relying 


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
Page 46 
 
on information gathered through a semi-structured interview of the patient and caregiver, the 
ADCS-CGIC-Overall focuses on clinician’s observations of change in the patient's cognitive, functional, 
and behavioral performance since the beginning of a trial.  Once the baseline level of severity is 
established, the change score at the follow-up visits is based on information gathered from the patient and 
caregiver interviews.  The ADCS-CGIC-Overall is rated as: marked improvement, moderate 
improvement, minimal improvement, no change, minimal worsening, moderate worsening, or marked 
worsening.   
The baseline ADCS-CGIC-Overall evaluation will be conducted at the Baseline (Day 1) visit.  The 
ADCS-CGIC-Overall will be assessed at Day 43 (Visit 4) and Day 85 (Visit 6) for change in Overall 
Clinical Status.  At Day 43 (Visit 4), change from the Baseline visit (Day 1) will be assessed.  At Day 85 
(Visit 6), change from Day 43 (Visit 4) and change from the Baseline visit (Day 1) will be assessed.  
6.1.5 
Modified Alzheimer’s Disease Cooperative Study - Clinical Global 
Impression of Change Rating (mADCS-CGIC-Agitation) 
The standard ADCS-CGIC instrument was modified to better assess aspects relevant to studying agitation 
in AD (mADCS-CGIC-Agitation).  The mADCS-CGIC-Agitation 
 contains questions 
related to agitation and an assessment of the Clinician’s Impression of Change focused specifically on 
agitation.  It was originally designed for the Citalopram study for Agitation in Alzheimer’s disease 
(CitAD)31,32 and utilizes a semi-structured interview of both patient and caregiver to determine a baseline 
level of severity for agitation.  Subsequent evaluations assess for change from baseline and also utilize the 
semi-structured agitation interview of both patient and caregiver.   
The baseline mADCS-CGIC-Agitation evaluation will be conducted at the Baseline (Day 1) visit.  The 
mADCS-CGIC-Agitation will be assessed at Day 43 (Visit 4), Day 85 (Visit 6) and Follow-up visit (for 
ET patients) for change in agitation syndrome.  At Day 43 (Visit 4), change from the Baseline visit (Day 
1) will be assessed.  At Day 85 (Visit 6), change from Day 43 (Visit 4) and change from the Baseline visit 
(Day 1) will be assessed.  At the Follow-up visit (for ET patients), change from Day 85 (Visit 6) will be 
assessed.  The mADCS-CGIC-Agitation must be administered by the same rater at each visit. 
6.1.6 
Zarit Burden Interview (ZBI) 
The ZBI 
 is a 22-item scale used to assess the impact of patient’s disabilities on the 
caregiver’s life.  It is designed to reflect the burden experienced by caregivers of dementia patients and 
can either be completed by the caregiver or administered as an interview.33 It is the most commonly used 
scale for measuring burden in caregivers’ of patients with dementia and also other illnesses.34  The ZBI 
has been shown to have high internal-reliability with an estimated Cronbach’s alpha at 0.88 and 0.91, and 
test-retest reliability at 0.71.  Validity has been estimated by correlating the total score with a single 
global rating of burden (r = 0.71).35  For each item of the scale, the caregiver has to indicate how often 
they felt that way (never, rarely, sometimes, quite frequently, or nearly always).  The score ranges from 
0 to 88 and is determined by adding the numbered responses of the individual items.  Higher scores 
indicate greater caregiver distress. 


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
Page 47 
 
The ZBI will be assessed at Baseline (Day 1), Day 43 (Visit 4), and Day 85 (Visit 6). 
6.1.7 
Patient Global Impression of Change (PGIC) 
The PGIC 
 is a 7-point (1-7) scale used to assess treatment response, and it is rated as: very 
much improved, much improved, minimally improved, no change, minimally worse, much worse, or very 
much worse.27  
The PGIC will be assessed and rated by the patient’s caregiver at Day 43 (Visit 4), and Day 85 (Visit 6), 
and will focus on the patient’s agitation.  
6.1.8 
Dementia Quality of Life (DEMQOL) 
The DEMQOL 
 is a scale used to evaluate health related quality of life in patients with 
dementia and their caregivers.36 There are 2 versions of the DEMQOL, a 28-item version (rated by 
patient) and a 31-item version (DEMQOL-proxy, rated by caregiver).  Both the 28-item and 31-item 
version are recommended to be used for evaluating patients (and their caregivers) with mild to moderate 
dementia (MMSE ≥10).  For patients with severe dementia, only the DEMQOL-proxy (administered to 
caregiver) is used.    
The DEMQOL-proxy (and DEMQOL for patients with MMSE ≥10 at the Baseline visit) will be assessed 
at Baseline (Day 1), Day 43 (Visit 4), and Day 85 (Visit 6). 
6.1.9 
Alzheimer’s 
Disease 
Assessment 
Scale-Cognitive 
Subscale 
(ADAS-cog) 
The ADAS 
 was designed to evaluate the cognitive and non-cognitive behavioral 
dysfunction characteristics of patients with AD.37  The cognitive sub-scale (ADAS-cog) consists of 
11 subsets related to memory, praxis, and language.  The ADAS-cog takes about 30 to 45 minutes to 
complete.     
The ADAS-cog will be assessed at Baseline (Day 1), Day 43 (Visit 4), and Day 85 (Visit 6) for patients 
with an MMSE score of ≥ 10 at the Baseline visit. 
6.1.10 
Cornell Scale for Depression in Dementia (CSDD) 
The CSDD 
 was specifically developed to assess signs and symptoms of major depression 
in patients with dementia.38  Because some of these patients may give unreliable reports, the CSDD uses a 
comprehensive interviewing approach that derives information from the patient and the caregiver.  
Information is elicited through two semi-structured interviews; an interview with a caregiver and an 
interview with the patient.  The interviews focus on depressive symptoms and signs occurring during the 
week preceding the assessment.  The CSDD takes approximately 20 minutes to administer.  
Each item is rated for severity on a scale of 0-2 (0 = absent, 1 = mild or intermittent, 2 = severe).  The 
item scores are added.  Scores above 10 indicate a probable major depression, scores above 18 indicate a 


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
Page 48 
 
definite major depression and scores below 6 as a rule are associated with absence of significant 
depressive symptoms. 
The CSDD will be assessed at Screening (Day -28 to Day -1), Day 43 (Visit 4), and Day 85 (Visit 6). 
6.1.11 
Resource Utilization in Dementia (RUD) 
The RUD 
 is used to calculate healthcare costs associated with dementia.39 It evaluates 
dementia patients’ utilization of formal and informal healthcare resources, including hospitalizations and 
doctor visits, living assistance, and time spent by nonprofessional caregivers.  Within the context of 
clinical trials, the RUD is often used to determine the cost effectiveness of new pharmaceutical 
treatments.40  
The RUD is administered as a semi-structured interview with the patient’s primary caregiver, and 
contains 2 sections; one focusing on caregiver impact (loss of work and leisure time incurred by 
caregiver) and the other focusing on the patient’s use of healthcare resources.  The total healthcare costs 
associated with the patient’s dementia can be estimated by multiplying the number of units used (e.g., 
hours of caregiver time, visits to doctors, nights in accommodation) by the corresponding unit price 
vector. 
The RUD will be assessed at Baseline (Day 1), Day 43 (Visit 4), and Day 85 (Visit 6). 
6.1.12 
General Medical Health Rating (GMHR) 
The GMHR 
 is a global clinical rating for medical health, designed to quantify in a single 
number (1 to 4) the severity of general co-morbidity in a patient with dementia.41  A rating of 1 = poor, 
2 = fair, 3 = good and 4 = excellent to very good.    
The GMHR will be assessed at Screening (Day -28 to Day -1) and Day 85 (Visit 6) 
6.2 
Pharmacokinetics (PK) 
At Day 43 (Visit 4) and Day 85 (Visit 6), patients will have a blood sample collected between 0 to 
3 hours after the morning dose of study medication for analysis of plasma levels of d6-DM, d6-DM 
metabolites and Q.  The time when the patient was administered the dose of study medication and the 
time of the blood draw will be recorded on the eCRF.  Plasma samples will be separated by centrifugation 
and then frozen at -20° C until assayed at the analytical unit.  


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
Page 49 
 
6.3 
Safety 
6.3.1 
Adverse Events 
6.3.1.1 
Definitions 
An AE is any untoward medical occurrence or unintended change (including physical, psychological, or 
behavioral) from the time ICF is signed, including inter-current illness, which occurs during the course of 
a clinical trial after treatment has started, whether considered related to treatment or not.  An AE can 
therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for 
example), symptom, or disease temporally associated with the use of a medicinal product, whether or not 
considered related to the medicinal product.  Changes associated with normal growth and development 
that do not vary in frequency or magnitude from that ordinarily anticipated clinically are not AEs (e.g., 
onset of menstruation occurring at a physiologically appropriate time). 
Clinical AEs should be described by diagnosis and not by symptoms when possible (e.g., cold, seasonal 
allergies, instead of “runny nose”). 
An overdose is a deliberate or inadvertent administration of a treatment at a dose higher than specified in 
the protocol and higher than known therapeutic doses.  It must be reported irrespective of outcome even if 
toxic effects were not observed. 
AEs will be graded on a 3-point scale and reported in detail as indicated on the eCRF: 
 
Mild:  
easily tolerated, causing minimal discomfort and not interfering with  
normal everyday activities 
 
Moderate:  
sufficiently discomforting to interfere with normal everyday activities 
 
Severe:  
incapacitating and/or preventing normal everyday activities 
The relationship of each AE to study medication should be determined by the investigator using the 
following explanations: 
 
Not related:  
the event is clearly related to other factors such as the patient’s clinical state, 
therapeutic interventions, or concomitant medications administered to the patient 
 
Unlikely related:  
the event is most likely produced by other factors such as the patient’s clinical 
state, therapeutic interventions, or concomitant medications administered to the 
patient; and does not follow a known response pattern to the study medication 
 
Possibly related:  
the event follows a reasonable temporal sequence from the time of drug 
administration; and/or follows a known response pattern to the study medication; 
but could have been produced by other factors such as the patient’s clinical state, 
therapeutic interventions, or concomitant medications administered to the patient 
 
Related:  
 the event follows a reasonable temporal sequence from the time of drug 
administration; and follows a known response pattern to the study medication; 


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
Page 50 
 
and cannot be reasonably explained by other factors such as the patient’s clinical 
state, therapeutic interventions, or concomitant medications administered to the 
patient 
6.3.1.2 
Serious Adverse Events 
A Serious Adverse Event (SAE) is any AE occurring at any dose that results in any of the following 
outcomes: 
1. Death 
2. Life-threatening experience (one that places the patient, in the view of the initial reporter, at 
immediate risk of death from the AE as it occurred, i.e., it does not include an AE that, had it 
occurred in a more severe form, might have caused death) 
3. Persistent or significant disability/incapacity (disability is a substantial disruption of a person’s 
ability to conduct normal life functions) 
4. In-patient hospitalization or prolongation of hospitalization 
5. Congenital anomaly/birth defect 
Important medical events that may not result in death, or be life-threatening, or require hospitalization 
may be considered an SAE when, based upon appropriate medical judgment, they may jeopardize the 
patient or require medical or surgical intervention to prevent one of the outcomes listed in the definition. 
The terms “cancer” and “overdose” are not considered to be SAEs, but if a patient experiences cancer or 
overdose, they are still reportable as AEs. 
Pregnancy is not considered to be an AE or an SAE, unless a complication occurs that meets the 
requirements for an AE or SAE, but must be reported on a pregnancy report form.  Women who are 
pregnant or likely to become pregnant are excluded from this study.  In the event a patient becomes 
pregnant during the study, study medication must be discontinued, a pregnancy report form must be 
completed to capture potential drug exposure during pregnancy, and the pregnancy must be reported 
within 24 hours of notice.  Any pregnant patient must be followed until the outcome of her pregnancy is 
known (i.e., normal delivery, abnormal delivery, spontaneous/voluntary/therapeutic abortion).  The 
pregnancy (i.e., the mother and the fetus) must be followed up through delivery with regard to outcome.  
A pregnancy report form must also be completed in the event that a female partner of a male patient 
becomes pregnant within 30 days after his last dose of study medication or study completion, whichever 
is greater.  
The term ‘severe’ is a measure of intensity; thus a severe AE is not necessarily serious.  For example, 
nausea of several hours duration may be rated as severe, but may not be clinically serious. 


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
Page 51 
 
6.3.1.3 
Reporting 
Caregivers will be queried regarding AEs at each clinic visit after the screening visit (Baseline [Day 1], 
Days 8, 15, 22, 43, 64, 85 [Visit 2-6], Follow-up visit [for ET patients]), and at safety follow-up phone 
calls at Days 29 and 71.  The investigator will assess and record all reported AEs.  Any AE newly 
reported after receiving the last dose of study medication and up until 30 days after receiving the last dose 
of study medication will be followed. 
A death occurring during the study, or which comes to the attention of the investigator within 30 days 
after stopping the treatment whether considered treatment-related or not, must be reported to the sponsor. 
For all SAEs, including an abnormal laboratory test value, the investigator should consult with Avanir’s 
MM or designated representative as needed and report any SAE by fax/email form no later than 24 hours 
after becoming aware of the event.  Subsequently, the SAE must be assessed for the following details: 
seriousness of event, start date, stop date, intensity, frequency, relationship to test drug, action taken 
regarding test drug, treatment required, and outcome to date.  These details must be recorded on the 
clinical study AE form that is provided.  This form should be transmitted by fax and the details given by 
telephone to the contact numbers below. 
SAE reporting by FAX or e-mail correspondence  
FAX:  
 or 
 
E-mail
 
SAE hotline (24-hour/7 days a week) 
Phone: 
 or 
 
Such preliminary reports will be followed by detailed descriptions later, which may include copies of 
hospital case reports, autopsy reports, and other related documents when requested. 
The Institutional Review Board/Ethics Committee (IRB/EC) will be notified of such an event in writing 
as soon as is practical in compliance with federal and local regulations. 
6.3.1.4 
Procedures to be Followed in the Event of Abnormal Test Values 
Any patients with clinically significant abnormal laboratory test results may be required by the MM to 
have a repeat test 1 week later or earlier, if medically indicated.  Clinically significant laboratory 
abnormalities may be a basis for exclusion from study entry. 
6.3.2 
Physical and Neurological Examinations 
Physical and neurological examinations will be performed at Screening (Day -28 to Day -1), Day 43 
(Visit 4), and Day 85 (Visit 6).  The physical examination will include assessments of head, eyes, ears, 
nose, throat, lymph nodes, skin, extremities, respiratory, gastrointestinal, musculoskeletal, cardiovascular, 
and nervous systems.  The neurological examination will include assessments of mental status, cranial 
nerves, motor system, reflexes, coordination, gait and station, and sensory system.  The physical and 
neurological examinations should be performed by the same person each time, whenever possible.  


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
Page 52 
 
Physical and neurological examination abnormalities determined by the investigator to be clinically 
significant at Screening should be recorded as medical history.  
Any clinically significant changes in physical and neurological examination findings from the screening 
examination should be recorded as AEs. 
6.3.3 
Vital Signs 
Orthostatic blood pressure (BP) and heart rate (HR) measurements will be performed at all clinic visits.  
Supine BP and HR will be measured after a patient has rested for at least 5 minutes in the supine position.  
Each measurement will be taken twice in the same position and recorded.  After the measurement of 
supine BP and HR, the patient will stand still for up to 3 minutes and a single measurement of standing 
BP and HR will be recorded within these 3 minutes of standing.  
Respiratory rate (breaths/minute) and body temperature (ºF) will be assessed at all clinic visits.  Weight 
will be recorded at Baseline (Day 1) and Day 85 (Visit 6).  
6.3.4 
Clinical Laboratory Tests 
The following clinical laboratory assessments are to be performed at Screening (Day -28 to Day -1), 
Day 22 (Visit 3), Day 43 (Visit 4), Day 64 (Visit 5), and Day 85 (Visit 6): 
• 
Blood chemistry (calcium, magnesium, phosphorus, glucose, sodium, potassium, chloride, 
carbon dioxide, blood urea nitrogen [BUN], serum creatinine, uric acid, albumin, total bilirubin, 
alkaline phosphatase, lactate dehydrogenase [LDH], aspartate aminotransferase/serum glutamic 
oxaloacetic transaminase [AST/SGOT], alanine aminotransferase/serum glutamic pyruvic 
transaminase [ALT/SGPT], creatine kinase [CK], gamma-glutamyl transferase [GGT], 
triglycerides, total protein, and total cholesterol) 
• 
Hematology (red blood cell [RBC] count, hemoglobin, hematocrit, white blood cell [WBC] 
count, neutrophils, bands, lymphocytes, monocytes, eosinophils, basophils, platelet count, and 
morphology) 
• 
Urinalysis (pH, specific gravity, protein, glucose, ketones, blood, leucocyte esterase, nitrates, 
and microscopic appearance) 
• 
Thyroid function tests (TSH, and reflex T3 and T4 if TSH is abnormal) at Screening visit only 
• 
Glycosylated hemoglobin (HbA1c) test at the Screening visit and Visit 6 only 
Any patients with clinically significant abnormal laboratory test results may be required by the MM to 
have a repeat test 1 week later or earlier, if medically indicated.  Clinically significant laboratory 
abnormalities may be a basis for exclusion from study entry. 


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
Page 53 
 
6.3.5 
Pregnancy Tests 
Urine pregnancy tests are to be performed for females of childbearing potential at Screening (Day -28 to 
Day -1), Baseline (Day 1), Day 43 (Visit 4), and Day 85 (Visit 6). 
All female patients of childbearing potential should be instructed to use appropriate birth control methods 
for up to 4 weeks following the last dose of study medication.  
6.3.6 
Electrocardiograms 
A resting 12-lead ECG will be performed at all clinic visits except on Day 8 (Visit 2).  At Screening, ECG 
will be performed in triplicate.  At Baseline (Day 1), two ECGs will be performed; one prior to study 
medication dosing and one 2-3 hours after dosing.  ECG equipment will be provided by the central reader.  
ECG data will be recorded at the study center and will include general findings, heart rate (beats/minute) 
QRS complex and PR and QTc intervals (milliseconds).  Results will be provided by the central reader to 
the investigators within 24 hours.  ECG data will be transferred automatically from the central reader into 
the eCRF monthly.  ECG abnormalities present at Screening will be recorded as medical history.  Any 
changes from the ECG status at Screening Visit that are deemed to be clinically significant by the 
investigator should be captured as AEs.  Any clinically significant abnormal ECG should be discussed 
with the study MM and, if necessary be repeated within a 1-week period. 
6.3.7 
Sheehan Suicidality Tracking Scale (S-STS) 
The S-STS 
 is a prospective scale that assesses treatment-emergent suicidal thoughts and 
behaviors.42  Each item of the S-STS is scored on a 5-point Likert scale (0 = not at all; 1 = a little; 
2 = moderate; 3 = very; and 4 = extremely).  The Sheehan-STS can be analyzed as individual item scores, 
suicidal ideation subscale score, suicidal behavior subscale score, or total score.  For the screening visit, 
the timeframe for the items on the scale will be ‘in the past 6 months’ and for all other visits it will be 
‘since last visit’.      
The S-STS will be assessed at Screening (Day -28 to Day -1), Baseline (Day 1), Day 8 (Visit 2), Day 15 
(Visit 2.1), Day 22 (Visit 3), Day 43 (Visit 4), Day 64 (Visit 5), Day 85 (Visit 6), and Follow-up visit (for 
ET patients).  Any change in the S-STS score indicating the presence of suicidality should be evaluated 
by the investigator and reported to the MM. 
6.3.8 
Mini Mental State Examination (MMSE) 
The MMSE 
 is a brief 30-point questionnaire test that is used to screen for cognitive 
impairment.  It is commonly used in medicine to screen for dementia.  It is also used to estimate the 
severity of cognitive impairment at a specific time and to follow the course of cognitive changes in an 
individual over time, thus making it an effective way to document an individual’s response to treatment.  
The MMSE scale comprises 11 questions or simple tasks concerning orientation, memory, attention, and 
language to evaluate the patient’s cognitive state.43  It requires only 5 to 10 minutes for a trained rater to 
administer it. 


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
Page 54 
 
The MMSE will be assessed at Screening (Day -28 to Day -1), Baseline (Day 1), Day 43 (Visit 4), and 
Day 85 (Visit 6). 
6.3.9 
Timed Up and Go (TUG) Test 
The TUG test 
 measures the time (in seconds) taken for an individual to stand up from a 
standard armchair, walk 3 meters, turn, walk back to the chair and sit down.  It is a commonly used scale 
for measuring functional mobility and risk of falls.44,45  
The TUG test will be performed at Screening (Day -28 to Day -1), Day 43 (Visit 4), and Day 85 (Visit 6).  
6.3.10 
Epworth Sleepiness Scale (ESS) 
The ESS 
 is an 8-item questionnaire that is used to measure sleepiness by rating the 
probability of falling asleep on 8 different situations that most people engage in during the day.46  The 
questions are rated on a 4 point scale (0 to 3) where 0 = would never doze, 1 = slight chance of dozing, 
2 = moderate chance of dozing, and 3 = high chance of dozing.  A total score of 0 to 9 is considered to be 
normal.    
The ESS will be assessed at Baseline (Day 1), Day 43 (Visit 4), and Day 85 (Visit 6) for patients with an 
MMSE score of ≥ 10 at the Baseline visit. 
6.4 
Schedule of Evaluations and Procedures 
A schedule of evaluations and procedures is provided in Table 1. 
6.4.1 
Description of Study Procedures 
At each visit throughout the study, site staff will be required to enter information into the IWRS regarding 
patient data and pre-defined study assessment results.  Further instructions will be provided in the IWRS 
Site Manual. 
6.4.1.1 
Screening Visit (Days -28 to -1, + 3-day window) 
The following procedures will be performed at Screening (within 28 days prior to Day 1).  The screening 
period may be extended after discussion with and approval by the MM.  In the event that a patient is 
rescreened for enrollment, new informed consent and/or assent documents must be signed, new patient 
number assigned and all screening procedures repeated. 
1. The investigator will provide the patients, authorized representatives and/or their caregivers with 
informed consent and/or assent documents and will explain the rationale for the study, providing 
ample time for participants, authorized representatives, and/or caregivers to ask questions. 


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
Page 55 
 
2. Medical history, including patient demographics, any prior and concomitant medications (including 
OTC, vitamins, and supplements), nondrug therapies, and any nonpharmacological interventions for 
the treatment of agitation will be reviewed and recorded. 
3. Review inclusion/exclusion criteria (eligibility form). 
4. Vital signs will be measured and recorded.  
5. Physical and neurological examination will be performed.  
6. Risk assessment for falls will be performed (worksheet and TUG test). 
7. A resting 12-lead ECG will be performed in triplicate. 
8. A blood and urine specimen will be collected for safety laboratory assessments.  
9. A urine pregnancy test will be performed for females of childbearing potential only. 
10. The following assessments will be completed: 
• 
MMSE; a score between 6 and 26 (inclusive) is required for study entry 
• 
CMAI 
• 
NPI Agitation/Aggression domain 
• 
CGIS-Agitation; a score of ≥ 4 is required for study entry 
• 
S-STS 
• 
CSDD; a score of <10 is required for study entry 
• 
GMHR 
Following screening procedures for assessment of inclusion and exclusion criteria, the site will complete 
a protocol eligibility form and submit to the MM for approval.  Patients deemed eligible by the PI and the 
MM will be randomized into the study.  Patients who have ECG or laboratory test results outside of the 
reference normal range that the investigator considers to be clinically significant, and may put the patient 
at a higher risk for study participation, will not be enrolled. 
6.4.1.2 
Baseline Visit (Day 1) 
The Baseline visit (Day 1) should occur in the morning.  The following procedures will be performed.  
Before Dosing: 
1. Inclusion/exclusion criteria will be reviewed. 
2. Caregivers will be queried regarding AEs, concomitant medication use (including OTC, vitamins, 
and supplements), nondrug therapies, and concomitant nonpharmacological interventions for the 
treatment of agitation. 
3. Vital signs and weight will be measured and recorded.  


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
Page 56 
 
4. A resting 12-lead ECG will be performed (twice this visit - pre and 2-3 hours post dose). 
6. A urine pregnancy test will be performed for females of childbearing potential only. 
7. The following assessments will be completed: 
• 
MMSE 
• 
CMAI  
• 
NPI 
• 
CGIS-Agitation 
• 
Baseline mADCS-CGIC-Agitation 
• 
ADAS-cog (only for patients with an MMSE score of ≥ 10 at baseline) 
• 
DEMQOL-proxy (and DEMQOL for patients with an MMSE score of ≥ 10 at baseline) 
• 
S-STS 
• 
ZBI 
• 
RUD 
• 
Baseline ADCS-CGIC-Overall 
• 
ESS (only for patients with an MMSE score of ≥ 10 at baseline) 
Patients will be randomized once it is determined that they satisfy all of the inclusion and none of the 
exclusion criteria (on the basis of the screening and baseline assessments described above) and will be 
assigned with a study medication kit number via IWRS. 
Study Medication Dosing: 
The first dose of study medication will be administered from the AM strip of blister card at the clinic 
regardless of the time of day.   
After Dosing: 
1. A resting 12-lead ECG will be performed between 2 and 3 hours (± 15 minutes) after taking the 
morning dose of study medication. 
2. The caregiver will be queried regarding AEs. 
3. Patient Diary Card and sufficient study medication for a 3-week treatment period will be 
dispensed. 


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
Page 57 
 
Patient/Caregiver Instruction 
Caregivers will be instructed to administer to the patient the study medication twice-daily (1 capsule of 
study medication from the top row [AM] of blister card in the morning and 1 capsule of study medication 
from the bottom row [PM] of the blister card in the evening, approximately every 12 hours ± 4 hours) for 
7 days. 
The investigator and/or study coordinator will give patients and caregivers detailed instructions regarding 
study procedures including how to complete the patient’s Diary Card.  They will also be instructed to 
consult with the study site prior to taking any non-study medications.  These requirements will be 
reviewed in person.  Caregivers will also be instructed to bring to the clinic any unused study medication 
and patient’s Diary Card at each study visit.  For the next scheduled visit (Visit 2), caregivers will be 
advised to administer the morning dose of study medication to the patient within 2 hours of the clinic 
appointment and note the time of dosing. 
Caregivers will be queried at the end of each visit to be certain they understand what is required of them. 
6.4.1.3 
Visit 2 (Day 8 + 3-day window) 
Visit 2 (Day 8) should occur in the morning within 2 hours of taking the AM dose.  The morning dose of 
study medication can be administered at home if the visit will occur within 2 hours of dosing; the time of 
dosing should be noted by the patient/caregiver.   
The following procedures will be performed: 
1. The caregiver will be queried regarding AEs, concomitant medication use (including OTC, vitamins, 
and supplements), nondrug therapies, and concomitant nonpharmacological interventions for the 
treatment of agitation. 
2. Vital signs will be measured and recorded. 
3. The following assessments will be completed: 
• 
CMAI 
• 
NPI Agitation/Aggression domain 
• 
S-STS 
4. Unused study medication will be accounted for compliance and the blister card returned to the 
patient. 
5. Patient’s Diary Card will be reviewed for compliance and returned to the patient. 
Patient/Caregiver Instruction 
Caregivers will be instructed to administer to the patient the study medication twice-daily (1 capsule of 
study medication from the top row [AM] of blister card in the morning and 1 capsule of study medication 


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
Page 58 
 
from the bottom row [PM] of the blister card in the evening, approximately every 12 hours ± 4 hours) for 
7 days. 
The investigator and/or study coordinator will give patients and caregivers detailed instructions regarding 
study procedures including how to complete the patient’s Diary Card.  They will also be instructed to 
consult with the study site prior to taking any non-study medications.  These requirements will be 
reviewed in person.  Caregivers will also be instructed to bring to the clinic any unused study medication 
and patient’s Diary Card at each study visit.  For the next scheduled visit (Visit 2.1), caregivers will be 
advised to administer the morning dose of study medication to the patient within 2 hours of the clinic 
appointment and note the time of dosing. 
Caregivers will be queried at the end of each visit to be certain they understand what is required of them. 
6.4.1.4 
Visit 2.1 (Day 15 ± 3-day window) 
Visit 2.1 (Day 15) should occur in the morning within 2 hours of taking the AM dose.  The morning dose 
of study medication can be administered at home if the visit will occur within 2 hours of dosing; the time 
of dosing should be noted by the patient/caregiver.   
The following procedures will be performed: 
1. 
A resting 12-lead ECG will be performed between 2 and 3 hours (± 15 minutes) after taking the 
morning dose of study medication. 
2. 
The caregiver will be queried regarding AEs, concomitant medication use (including OTC, 
vitamins, and supplements) nondrug therapies, and concomitant nonpharmacological interventions 
for the treatment of agitation. 
3. 
Vital signs will be measured and recorded. 
4. 
The following assessments will be completed: 
• 
CMAI 
• 
NPI Agitation/Aggression domain 
• 
S-STS 
5. 
Unused study medication will be accounted for compliance and the blister card returned to the 
patient. 
6. 
Patient’s Diary Card will be reviewed for compliance and returned to the patient. 
Patient/Caregiver Instruction 
Caregivers will be instructed to administer to the patient the study medication twice-daily (1 capsule of 
study medication from the top row [AM] of blister card in the morning and 1 capsule of study medication 


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
Page 59 
 
from the bottom row [PM] of the blister card in the evening, approximately every 12 hours ± 4 hours) for 
7 days. 
The investigator and/or study coordinator will give patients and caregivers detailed instructions regarding 
study procedures including how to complete the patient’s Diary Card.  They will also be instructed to 
consult with the study site prior to taking any non-study medications.  These requirements will be 
reviewed in person.  Caregivers will also be instructed to bring to the clinic any unused study medication 
and patient’s Diary Card at each study visit.  Caregivers will be queried at the end of each visit to be 
certain they understand what is required of them. 
6.4.1.5 
Visit 3 (Day 22 ± 3-day window) 
Visit 3 (Day 22) should occur in the morning.  The following procedures will be performed.  
Before Dosing: 
1. The caregiver will be queried regarding AEs, concomitant medication use (including OTC, vitamins, 
and supplements), nondrug therapies, and concomitant nonpharmacological interventions for the 
treatment of agitation. 
2. Vital signs will be measured and recorded. 
3. Returned, unused study medication will be accounted for compliance. 
4. Patient’s Diary Card will be collected and reviewed for compliance. 
5. The following assessments will be completed: 
• 
CMAI 
• 
NPI 
• 
S-STS 
Study Medication Dosing: 
Study medication will be administered from the AM strip of the newly dispensed blister card at the clinic 
regardless of the time of day.   
After Dosing: 
1. A blood and urine specimen will be collected within 3 hours for safety laboratory assessments. 
2. A resting 12-lead ECG will be performed between 2 and 3 hours (± 15 minutes) after taking the 
morning dose of study medication. 
3. Patient Diary Card and sufficient study medication for a 3-week treatment period will be dispensed. 


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
Page 60 
 
Patient/Caregiver Instruction 
Caregivers will be instructed to administer to the patient the study medication twice-daily (1 capsule of 
study medication from the top row [AM] of blister card in the morning and 1 capsule of study medication 
from the bottom row [PM] of the blister card in the evening, approximately every 12 hours ± 4 hours) for 
21 days. 
The investigator and/or study coordinator will give patients and caregivers detailed instructions regarding 
study procedures including how to complete the patient’s Diary Card.  They will also be instructed to 
consult with the study site prior to taking any non-study medications.  These requirements will be 
reviewed in person.  Caregivers will also be instructed to bring to the clinic any unused study medication 
at each study visit.  Caregivers will be queried at the end of each visit to be certain that they understand 
what is required of them. 
6.4.1.6 
Visit 4 (Day 43 ± 3-day window) 
Visit 4 (Day 43) should occur in the morning.  The following procedures will be performed. 
Before Dosing: 
1. Caregivers will be queried regarding AEs, concomitant medication use (including OTC, vitamins, 
and supplements), nondrug therapies, and concomitant nonpharmacological interventions for the 
treatment of agitation. 
2. Vital signs will be measured and recorded. 
3. Physical and neurological examination will be performed. 
4. Patient’s Diary Card will be collected and reviewed for compliance. 
5. Returned, unused study medication will be accounted for compliance. 
6. The following assessments will be completed: 
• 
CMAI 
• 
NPI 
• 
CGIS-Agitation 
• 
mADCS-CGIC-Agitation 
• 
ADCS-CGIC-Overall 
Study Medication Dosing: 
Study medication will be administered from the AM strip of the newly dispensed blister card at the clinic 
regardless of the time of day.   
After Dosing: 
1. A blood specimen will be collected within 3 hours after the morning dose of study medication for 
PK analysis and for safety laboratory assessments.   


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
Page 61 
 
2. A urine sample will be collected for urinalysis. 
3. A urine pregnancy test will be performed for females of childbearing potential only. 
4. The following assessments will be completed: 
• 
MMSE 
• 
ADAS-cog (only for patients with an MMSE score of ≥ 10 at baseline) 
• 
CSDD 
• 
DEMQOL-proxy (and DEMQOL for patients with an MMSE score of ≥ 10 at baseline) 
• 
S-STS 
• 
TUG 
• 
ZBI 
• 
RUD 
• 
PGIC 
• 
ESS (only for patients with an MMSE score of ≥ 10 at baseline) 
5. A resting 12-lead ECG will be performed between 2 and 3 hours (± 15 minutes) after taking the 
morning dose of study medication. 
6. Patient Diary Card and sufficient study medication for a 3-week treatment period will be dispensed. 
Patient/Caregiver Instruction 
Caregivers will be instructed to administer to the patient the study medication twice-daily (1 capsule of 
study medication from the top row [AM] of blister card in the morning and 1 capsule of study medication 
from the bottom row [PM] of the blister card in the evening, approximately every 12 hours ± 4 hours) for 
21 days. 
The investigator and/or study coordinator will give patients and caregivers detailed instructions regarding 
study procedures including how to complete the patient’s Diary Card.  They will also be instructed to 
consult with the study site prior to taking any non-study medications.  These requirements will be 
reviewed in person.  Caregivers will also be instructed to bring to the clinic any unused study medication 
at each study visit.  Caregivers will be queried at the end of each visit to be certain that they understand 
what is required of them. 


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
Page 62 
 
6.4.1.7 
Visit 5 (Day 64 ± 3-day window) 
Visit 5 (Day 64) should occur in the morning.  The following procedures will be performed. 
Before Dosing: 
1. The caregiver will be queried regarding AEs, concomitant medication use (including OTC, vitamins, 
and supplements), nondrug therapies, and concomitant nonpharmacological interventions for the 
treatment of agitation. 
2. Vital signs will be measured and recorded. 
3. Returned, unused study medication will be accounted for compliance. 
4. Patient’s Diary Card will be collected and reviewed for compliance. 
5. The following assessments will be completed: 
• 
CMAI 
• 
NPI 
• 
S-STS  
Study Medication Dosing: 
Study medication will be administered from the AM strip of the newly dispensed blister card at the clinic 
regardless of the time of day.   
After Dosing: 
1. A blood and urine specimen will be collected within 3 hours for safety laboratory assessments 
2. A resting 12-lead ECG will be performed between 2 and 3 hours (± 15 minutes) after taking the 
morning dose of study medication. 
3. Patient Diary Card and sufficient study medication for a 3-week treatment period will be dispensed. 
Patient/Caregiver Instruction 
Caregivers will be instructed to administer to the patient the study medication twice-daily (1 capsule of 
study medication from the top row [AM] of blister card in the morning and 1 capsule of study medication 
from the bottom row [PM] of the blister card in the evening, approximately every 12 hours ± 4 hours) for 
21 days.   
The investigator and/or study coordinator will give patients and caregivers detailed instructions regarding 
study procedures including how to complete the patient’s Diary Card.  They will also be instructed to 
consult with the study site prior to taking any non-study medications.  These requirements will be 
reviewed in person.  Caregivers will also be instructed to bring to the clinic any unused study medication 


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
Page 63 
 
at each study visit.  Caregivers will be queried at the end of each visit to be certain that they understand 
what is required of them. 
6.4.1.8 
Visit 6 (Day 85 ± 3-day window) / Early Termination 
Visit 6 (Day 85) should occur in the morning.  Patients who withdraw prior to study completion are 
required to complete study procedures as listed in Visit 6 within 48 hours of the last dose of study 
medication.  There is no specific time frame for the 12-lead ECG, and sample blood/urine specimen 
collection (safety labs and PK samples) for patients who terminate early. 
The last dose of study medication will be administered to the patient at the clinic regardless of the time of 
day, from the blister card brought in by the patient. 
The following procedures will be performed after dosing:  
1. The caregiver will be queried regarding AEs, concomitant medication use (including OTC, vitamins, 
and supplements), nondrug therapies, and concomitant nonpharmacological interventions for the 
treatment of agitation. 
2. Returned, unused study medication will be accounted for compliance. 
3. Patient’s Diary Card will be collected and reviewed. 
4. Vital signs and weight will be measured and recorded. 
5. Physical and neurological examination will be performed 
6. The following assessments will be completed: 
• 
MMSE 
• 
CMAI 
• 
NPI 
• 
CGIS-Agitation 
• 
mADCS-CGIC-Agitation  
• 
ADAS-cog (only for patients with an MMSE score of ≥ 10 at baseline) 
• 
CSDD 
• 
DEMQOL-proxy (and DEMQOL for patients with an MMSE score of ≥ 10 at baseline) 
• 
S-STS 
• 
TUG 
• 
GMHR 
• 
ZBI 
• 
RUD 


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
Page 64 
 
• 
ADCS-CGIC-Overall 
• 
PGIC 
• 
ESS (only for patients with an MMSE score of ≥ 10 at baseline) 
7. A resting 12-lead ECG will be performed between 2 and 3 hours (± 15 minutes) after taking the 
morning dose of study medication.  
8. A blood specimen will be collected within 3 hours after the morning dose of study medication for 
PK analysis and for safety laboratory assessments.   
9. A urine sample will be collected for urinalysis. 
10. Urinary pregnancy test will be performed in women of childbearing potential. 
Any previously reported and not yet resolved AE and any newly reported AE at the time of this visit, will 
be followed-up for up to 30 days after the last dose of study medication. 
6.4.1.9 
Follow-up Phone Call (Days 29 and 71, + 3-day window) 
Patient’s caregiver will receive a safety follow-up phone call on Days 29 and 71.  Caregiver will be 
queried on adverse events, concomitant medication use, nondrug therapies, and nonpharmacological 
interventions for agitation, since the last visit.  
Patients who do not roll over to the extension study (Study 15-AVP-786-303) will receive a safety 
follow-up phone call 30 days after the last dose of study medication.  The caregiver will be queried on the 
overall well-being of the patient.   
6.4.1.10 
Follow-up Visit and Phone Calls for ET Patients 
The Follow-up visit is for patients who terminate early and should occur 30 days after last dose of study 
medication (± 3-day window).  
The following procedures will be performed at the visit:  
1. The caregiver will be queried regarding AEs, concomitant medication use (including OTC, vitamins, 
and supplements), nondrug therapies, and concomitant nonpharmacological interventions for the 
treatment of agitation. 
2. The following assessments will be completed: 
• 
CMAI 
• 
mADCS-CGIC-Agitation  
• 
S-STS 
The follow-up phone calls for patients who terminate early should be made for 5 consecutive days 
following the ET visit.  The caregiver will be queried on the overall well-being of the patient. 


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
Page 65 
 
6.4.1.11 
Unscheduled Visit 
Patients may be required to return to the clinic for an unscheduled visit between Visit 3 (Day 22) and 
Visit 5 (Day 64) for safety assessments, if the investigator determines that dose adjustment is necessary.  
A one-time downward dose adjustment will be allowed after Visit 3 up to and including Visit 4 (ie, 
Day 23 to Day 43), at the discretion of the investigator.  
The safety assessments to be performed at the unscheduled visit will be based on the clinical judgment of 
the investigator. 
 
 


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
Page 66 
 
7 
DATA MANAGEMENT 
7.1 
Data Collection 
The sponsor or designated representative (e.g., CRO) will perform the data management activities in 
accordance with the data management plan (DMP).  The DMP will outline the systems and procedures to 
be used in the study. 
Clinical study data will be reported (captured) by study site personnel on eCRFs.  An eCRF must be 
completed for every patient enrolled in the study.  The eCRF data will be entered by trained study-site 
personnel and then reviewed for completeness and accuracy and electronically signed by the investigator 
or authorized designee.  All study-site personnel must use a password-protected user account to enter, 
review, or correct study data.  Electronic signature procedures shall comply with the CFR Title 21 
Part 11.  Passwords will be strictly confidential. 
All eCRF data will be exported from the electronic data capture (EDC) system and transferred to the 
sponsor or representative.  The sponsor or representative will also receive electronic transfers of non-
eCRF data such as laboratory data from the central laboratory, ECG data from the central ECG reader, as 
well as other data from third-party vendors as appropriate.  The electronic data format of all transfers will 
be agreed upon with the sponsor or representative and documented in the DMP or vendor data transfer 
requirements document as appropriate. 
The clinical monitoring staff will perform source data verification (SDV) of the data recorded in the EDC 
system with source documents at the clinical study sites according to the data management plan and 
clinical monitoring plan.  The data will be subjected to consistency and validation checks within the EDC 
system with supplemental data reviews performed outside of the EDC system.   
Medical history and adverse events will be coded using a current version of Medical Dictionary for 
Regulatory Activities (MedDRA), and concomitant medications using a current version of the WHO Drug 
Dictionary.  The sponsor or representative will perform a medical safety review of the coding. 
Completed eCRF images with a date- and time-stamped electronic audit trail indicating the user, the data 
entered, and any reason for change (if applicable) will be archived at the investigator’s site and at the 
sponsor’s site. 
 


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
Page 67 
 
8 
STATISTICAL METHODS 
8.1 
Analysis Populations 
Three analysis populations will be used; modified intent-to-treat (mITT), intent-to-treat (ITT), and safety. 
• 
mITT:  The mITT population includes all patients randomized in the study who had at least one 
post-baseline efficacy assessment.  The mITT population will be used for all analyses of efficacy.  
Patients will be included in the treatment group to which they were randomized regardless of 
treatment received.  
• 
ITT:  The ITT population includes all randomized patients in the study.  The ITT population will 
be used for exploratory efficacy analyses. 
• 
Safety:  The safety population includes all patients who received study treatment.  The safety 
population will be used for all analyses of safety.  Patients will be included in the treatment group 
based on the actual treatment received. 
8.2 
Demographic and Baseline Characteristics 
Demographic and baseline characteristics will be summarized by treatment group for the ITT and mITT 
populations using descriptive statistics.  
8.3 
Efficacy Analysis 
8.3.1 
Study Endpoints 
Primary efficacy endpoint: 
The primary efficacy endpoint is the change from Baseline to Week 12 (Day 85) in the composite CMAI 
scores.  
Secondary efficacy endpoints: 
The secondary efficacy endpoints are the change from Baseline to Week 12 (Day 85) in the following 
measures:   
• mADCS-CGIC-Agitation  
• NPI-Agitation/Aggression domain score and Caregiver Distress score 
• NPI-Aberrant Motor Behavior domain 
• ZBI 
• NPI-Irritability/Lability domain 
• Total NPI 


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
Page 68 
 
• CGIS-Agitation  
• ADCS-CGIC-Overall 
• PGIC  
• DEMQOL  
• CSDD  
• GMHR  
• ADAS-cog   
• RUD  
8.3.2 
Primary Efficacy Analysis 
The primary efficacy endpoint is the change from baseline to Day 85 (Week 12) in the composite CMAI 
scores.     
For the primary efficacy analysis, the null hypothesis is that there is no treatment effect between AVP-
786-42.63/4.9 and placebo during the study and it will be tested against the alternative that there is a 
treatment effect. Similar hypotheses apply to the comparison of the AVP-786-28/4.9 vs. placebo. The 
treatment effect will be estimated by using a linear mixed effects model repeated measures (MMRM) 
with comparisons being made between the patients treated with AVP-786 and the patients treated with 
concurrent placebo.  The model will include fixed effects for treatment, visit, treatment-by-visit 
interaction, baseline-by-visit interaction, and baseline covariates which include baseline value and other 
factors as appropriate.  An unstructured covariance model will be used.   
Analyses with missing values imputed by last observation carried forward (LOCF) and Multiple 
Imputation (MI) may be performed as sensitivity analyses.   
A gate-keeping procedure will be used to control the overall type I error at 2-sided α = 0.05 for the 2 
primary treatment comparisons (AVP-786-42.63/4.9 vs. placebo and AVP-786-28/4.9 vs. placebo). 
Specifically, the comparison between AVP-786-42.63/4.9 vs. placebo will be performed first at the 
significance level of 0.05.  If the comparison is statistically significant, the comparison between 
AVP-786-28/4.9 vs. placebo will be performed at the same significance level. 
8.3.3 
Secondary Efficacy Analyses 
Secondary efficacy endpoints include change from Baseline to Week 12 (Day 85) for the following 
efficacy measures: mADCS-CGIC-Agitation, NPI-Agitation/Aggression domain score and Caregiver 
Distress score, NPI-Aberrant Motor Behavior domain score, ZBI, NPI- Irritability/Lability domain score, 
PGIC, DEMQOL, CSDD, RUD, total NPI, CGIS-Agitation, ADCS-CGIC-Overall, ADAS-cog, and 
GMHR.   


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
Page 69 
 
Treatment comparison tests using similar MMRM method as the primary efficacy analysis will be 
performed when appropriate.  A proper multiple comparison procedure, e.g, gate keeping procedure, will 
be used to control overall type I error at 2-sided α = 0.05 for the secondary endpoints tested.  The testing 
procedure will be pre-specified in the statistical analysis plan (SAP) before un-blinding the study.   
8.4 
PK/PD Analysis 
Plasma concentrations of d6-DM, its metabolites, and Q will be measured and results will be summarized 
descriptively 
.  Plasma 
concentration results will be used to assess the PK properties of d6-DM and its metabolites.  Additional 
PK/PD correlations may also be performed.  Additional details will be described in the SAP. 
8.6 
Safety Analysis 
Safety will be assessed by the following measurements:  AEs, physical and neurological examination, 
vital signs, urine pregnancy test, clinical laboratory assessments, resting 12-lead ECG, S-STS, MMSE, 
TUG test, and ESS.   
Safety analyses will consist of data summaries for biological parameters and AEs.  Safety analyses will be 
tabulated by treatment.   
8.6.1 
Adverse Events 
AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA).  The percentages 
of patients experiencing 1 or more AEs will be summarized by treatment, system organ class (SOC), 
deaths, non-fatal SAEs, AEs, AEs resulting in study discontinuation, and treatment-emergent AEs 
(TEAE).  TEAEs are those AEs that occur after the first dose of study medication up until 30 days after 
last dose.   
8.6.2 
Vital Signs and ECGs  
Summary statistics of absolute values and percentage change from baseline for BP (diastolic and 
systolic), heart rate, respiratory rate, and ECG parameters will be provided.  All values outside a pre-
defined normal range will be highlighted in the individual patient data listings. 
8.6.3 
Clinical Laboratory Values 
Laboratory parameters will be summarized via descriptive statistics and via shifts in results in respect to 
normal ranges between Screening and end of treatment as increased, decreased, or no change.  


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
Page 70 
 
8.6.4 
Data and Safety Monitoring Board 
The sponsor will appoint a Data and Safety Monitoring Board (DSMB) for the periodic review of 
available study data. 
The DSMB is an independent group of experts that advises the sponsor and the study investigators.  The 
members of the DSMB serve in an individual capacity and provide their expertise and recommendations.  
The primary responsibilities of the DSMB are to (1) periodically review and evaluate the accumulated 
study data for participant safety, study conduct and progress, and (2) make recommendations to the 
sponsor concerning the continuation, modification, or termination of the study.  
The DSMB considers study-specific data as well as relevant background knowledge about the disease, 
test agent, or patient population under study.  
The DSMB is responsible for defining its deliberative processes, including event triggers that would call 
for an unscheduled review, stopping guidelines, unmasking, and voting procedures prior to initiating any 
data review.  The DSMB is also responsible for maintaining the confidentiality of its internal discussions 
and activities as well as the contents of reports provided to it. 
8.6.5 
Interim Analysis 
Interim analysis may be performed and will be prespecified in the SAP. 
8.7 
Sample Size Calculations  
Power calculation was performed assuming a normal distribution for the primary efficacy endpoint.  
 
 
 
  
 
  
The study protocol is amended to include another dose arm (AVP-786-42.63/4.9) with 140 patients in the 
treatment arm, when approximately 100 patients have already been enrolled (50 AVP-786 28/4.9 and 50 
placebo) in the study.  To maintain an approximate 
 chance for an incoming patient to receive active 
drug, the sample size for the placebo treatment group is amended to 190.  Overall, the total sample size of 
470 patients will include 140 patients for AVP-786 28/4.9 and AVP-786 42.63/4.9 groups each and 190 
patients in the placebo group.  This sample size will provide approximately 
 power to detect a 
treatment effect size of 
between AVP-786 42.63/4.9 and concurrent placebo treatment group.   


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0 
Page 71 
9 
ADMINISTRATIVE PROCEDURES 
9.1 
Institutional Review Board/Ethics Committee Approval 
Institutional Review Boards/Ethics Committees (IRBs/ECs) must meet the guidelines set out by the FDA 
and conform to local laws and customs where appropriate.  Written IRB/EC approval for the protocol and 
the signed ICF must be obtained and transmitted to Avanir Pharmaceuticals or representative before the 
study can be initiated.  The IRB/EC must be informed of and approve all protocol amendments.  The 
investigator will ensure that this study is conducted in full conformance with local laws and according to 
National and State/Provincial laws (see, Appendix 18, Investigator Responsibilities).  The complete text 
of the World Medical Association Declaration of Helsinki is given in Appendix 19. 
9.2 
Informed Consent Form 
The ICF will follow the principles outlined in the current version of the Declaration of Helsinki.  For each 
patient found to be eligible for the study, informed consent will be obtained from the patient (if the patient 
is capable in the judgment of the investigator to provide informed consent) or the authorized 
representative.  For patients that are not capable of providing informed consent, but are capable of 
providing assent, the patient will be asked to provide assent.  If the patient is not capable of providing 
assent, the investigator will document the reasons why and maintain that documentation with the other 
informed consent documents.  The patient’s caregiver will also be asked to provide informed consent as 
they will be providing data on themselves and the patient, as well as, being responsible for ensuring 
compliance from the patient between study visits. 
The patients and/or patient’s authorized representative and the caregiver will be properly informed of the 
purpose of the study.  The patients and/or patient’s authorized representative and the caregiver will be 
alerted to any anticipated AE that may be encountered with the study medication.  A signed ICF will be 
obtained from all patients and/or patient’s authorized representative and the caregiver prior to patient 
entry into this study.  Patients and/or patient’s authorized representative and the caregiver will be 
provided with a copy of their signed and dated ICF. 
9.3 
Patient’s Diary Card 
The Patient’s Diary Card will be reviewed by clinical study personnel at all study treatment visits for 
confirmation of medication dosage and any rescue medication received.  The study personnel are 
responsible for (i) ensuring that patients and/or caregivers are properly collecting data and recording it 
into the diaries; and (ii) transcribing the diary recordings into the eCRF.  The diary will be collected at all 
study visits after baseline except Visit 2 (Day 8) and Visit 2.1 (Day 15), wherein the diary will be 
reviewed and returned to the patient.  The originals of all diaries will be maintained at the site as source 
documents.  


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
Page 72 
 
9.4 
Electronic Case Report Forms 
For each patient enrolled who has given informed consent, an eCRF must be completed and electronically 
signed by the investigator to certify that the data within each eCRF are complete and correct.  This also 
applies to those patients who fail to complete the study.  If a patient is withdrawn from the study because 
of a treatment-limiting AE, thorough efforts should be made to document the outcome.  
Any site personnel delegated responsibility for data entry, query resolution, or eCRF approval must 
complete training prior to accessing the eCRF.  The electronic data capture (EDC) vendor will provide 
user-specific access to the live (production) eCRF once training completion has been confirmed and the 
account has been approved by the sponsor.  Changes to the data once it has been initially saved will be 
tracked via audit trail and will require a reason for the change.  The audit trail will also include who made 
the change and a date/time stamp. 
The eCRFs will be reviewed by the study monitor at the study site.  Errors detected by subsequent in-
house data review may necessitate clarification or correction of errors.  All changes will be documented 
and approved by the investigator. 
All investigators will be provided with copies of the eCRFs for their site on a CD-ROM at the end of the 
study. 
9.5 
Quality Assurance 
9.5.1 
Documentation 
For each process, evaluation, or test that generates study data but is not described in the protocol or eCRF, 
a written description of the data generation procedures shall be retained in the quality assurance section of 
the study files.  In the case of routine clinical diagnostic procedures, only a copy of the relevant 
certification document is required. 
9.5.2 
Monitoring 
Throughout the course of the study, the study monitor will make frequent contacts with the investigator.  
This will include telephone calls and on-site visits.  The study will be routinely monitored to ensure 
compliance with the study protocol and the overall quality of data collected.  During the on-site visits, the 
eCRFs will be reviewed for completeness and adherence to the protocol.  As part of the data audit, source 
documents will be made available for review by the study monitor.  The study monitor may periodically 
request review of the investigator study file to assure the completeness of documentation in all respects of 
clinical study conduct. 
The study monitor will verify that each patient has proper consent documentation from the patient and/or 
patient’s authorized representative and the caregiver for study procedures and for the release of medical 
records to the sponsor, FDA, other regulatory authorities, and the IRB/EC.  The study monitor will also 
verify that assent was obtained for patients not capable of providing informed consent or that 


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
Page 73 
 
documentation is provided by the investigator explaining why the patient was unable to provide assent.  
The investigator or appointed delegate will receive the study monitor during these on-site visits and will 
cooperate in providing the documents for inspection and respond to inquiries.  In addition, the 
investigator will permit inspection of the study files by authorized representatives of the regulatory 
agencies. 
On completion of the study, the study monitor will arrange for a final review of the study files after which 
the files should be secured for the appropriate time period. 
9.6 
Record Retention 
To enable evaluations and/or audits from regulatory authorities or Avanir, the investigator agrees to keep 
records, including the identity of all participating patients (sufficient information to link records, e.g., 
CRFs and hospital records), all original signed ICFs, copies of all eCRFs, SAE forms, source documents, 
and detailed records of treatment disposition, and adequate documentation of relevant correspondence 
(e.g., letters, meeting minutes, telephone call reports).  The records should be retained by the investigator 
according to ICH, local regulations, or as specified in the Clinical Trial Agreement, whichever is longer. 
If the investigator is unable for any reason to continue to retain study records for the required period (e.g., 
retirement, relocation), Avanir should be prospectively notified.  The study records must be transferred to 
a designee acceptable by Avanir, such as another investigator, another institution, or to Avanir.  The 
investigator must obtain Avanir’s written permission before disposing of any records, even if retention 
requirements have been met. 
9.7 
Source Data 
The documents that will form the source data for the clinical study (e.g., patient charts, laboratory reports) 
must be defined and documented in the in-house study master file prior to the start of the study.  Data on 
the eCRFs which will be checked against source data during monitoring visits must also be defined and 
documented in the in-house study master file including the percentage of each of the source data to be 
verified and the percentage of patients’ eCRFs to be monitored. 
9.8 
Data Handling 
Data collected on the eCRFs will be entered into EDC system by trained site staff.  Any queries arising 
from data entry will be checked with the investigator and changes approved.  
9.9 
Laboratory Procedures 
Each individual site laboratory will collect hematology and chemistry blood samples and urine samples at 
Screening (Day -28 to Day -1), and Visits 3-6 (Day 22, Day 43, Day 64, and Day 85) for safety analysis.  
Instructions for specimen evaluation and transport to a central laboratory will be provided at the time of 
study initiation.  Blood samples will also be taken 
 for 


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
Page 74 
 
PK analysis on Visits 4 and 6 (Day 43 and Day 85).  Instructions for shipping the laboratory samples for 
evaluation by central facilities will be provided. 
9.10 
Guidelines for Good Clinical Practice 
Standards for GCP must be adhered to for all study-based procedures. 
9.11 
Conditions for Amending the Protocol 
Protocol modification to ongoing studies which could potentially adversely affect the safety of patients or 
which alter the scope of the investigation, the scientific quality of the study, the experimental design, 
dosages, duration of therapy, assessment variables, the number of patients treated, or patient selection 
criteria must be made only after appropriate consultation between an appropriate representative of Avanir 
and the investigator. 
Protocol modifications must be prepared by a representative of Avanir or the investigator, and reviewed 
and approved by Avanir.   
All protocol modifications must be reviewed and approved by the appropriate IRB/EC in accordance with 
local requirements, before the revised edition can be implemented.  Modifications which eliminate an 
apparent immediate hazard to patients do not require pre-approval by the IRB/EC. 
9.12 
Conditions for Terminating the Study 
Both Avanir and the principal investigator reserve the right to terminate the study at the site at any time.  
Should this be necessary, the procedures to effect study termination will be arranged after review and 
consultation by both parties.  In terminating the study, Avanir and the investigator will assure that 
adequate consideration is given to the protection of the patient’s interests. 
9.13 
Confidentiality of Study Documents and Patient Records 
The investigator must assure that the patient’s anonymity will be maintained.  On eCRFs or other 
documents submitted to Avanir, patients should not be identified by their names but by an identification 
code. 
The investigator should keep a separate log of patient’s codes, names, and addresses.  Documents not for 
submission to Avanir, for example, patients’ signed ICFs, should be maintained by the investigator in 
strict confidence. 
9.14 
Reports 
At the completion of the study, the investigator shall provide the sponsor with an adequate report shortly 
after completion of the investigator's participation in the study as described in the Code of Federal 
Regulations (CFR) Title 21, Part 312.64. 


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
Page 75 
 
9.15 
Publications 
It is anticipated that a report of this study will be published in the scientific literature by the sponsor.  The 
investigator will not seek to arrange for publication of any of the information or results from the study in 
any scientific journal, or other publication or by way of lecture without Avanir’s prior review and written 
consent.  
9.16 
Audits/Inspections 
The investigator should understand that source documents for this study should be made available to 
appropriately qualified personnel or designee(s) from Avanir or to health authority inspectors after 
appropriate notification.  The verification of the eCRF data may be by direct inspection of source 
documents (where permitted by law) or through an interview exchange. 
The inspector from the regulatory authority will be especially interested in the following items: 
• 
Visits from the sponsor’s representatives 
• 
IRB/EC approval(s) 
• 
Study medication accountability 
• 
Study protocol and amendments 
• 
ICFs of the patient (if capable of providing ICF, according to the investigator) or patient’s 
authorized representatives and caregivers 
• 
Assent of the patients (if capable of providing assent, according to the investigator) 
• 
Medical records supportive of eCRF data 
• 
Reports to the IRB/EC and the sponsor 
• 
Record retention 
The sponsor will be available to help investigators prepare for an inspection. 


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
Page 76 
 
10 
REFERENCES 
1.  
McKhann GM KD, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s 
disease: recommendations from the National Institute on Aging-Alzheimer’s Association 
workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers & Dementia. 
2011;7(3):263-269. 
2.  
Cummings J, Mintzer J, Brodaty H, et al. Agitation in cognitive disorders: International 
Psychogeriatric Association provisional consensus clinical and research definition. Int 
Psychogeriatr. 2015;27(1):7-17. 
3.  
Brookmeyer R, Evans DA, Hebert L, et al. National estimates of the prevalence of 
Alzheimer’s disease in the United States. Alzheimers Dement. 2011;7(1):61-73. 
4.  
Evans DA, Funkenstein HH, Albert MS, et al. Prevalence of Alzheimer’s disease in a 
community population of older persons. Higher than previously reported. JAMA. 
1989;262(18):2551-6. 
5.  
Losonczy KG, White LR, Brock DB. Prevalence and correlates of dementia: survey of 
the last days of life. Public Health Rep. 1998;113(3):273-80. 
6.  
Kaplan HISB. Synopsis of Psychiatry: Behavioral Sciences-Behavioral Sciences. Clinical 
Psychiatry. 1998. 
7.  
Ballard CG, Gauthier S, Cummings JL, et al. Management of agitation and aggression 
associated with Alzheimer disease. Nat Rev Neurol. 2009;5(5):245-55. 
8.  
Ryu S-H, Katona C, Rive B, Livingston G. Persistence of and changes in 
neuropsychiatric symptoms in Alzheimer disease over 6 months: the LASER-AD study. 
Am J Geriatr Psychiatry. 2005;13(11):976-83. 
9.  
Tractenberg RE, Weiner MF, Patterson MB, Teri L, Thal LJ. Comorbidity of 
psychopathological domains in community-dwelling persons with Alzheimer’s disease. J 
Geriatr Psychiatry Neurol. 2003;16(2):94-9. 
10.  
Rabins PV, Schwartz S, Black BS, et al. Predictors of progression to severe Alzheimer’s 
disease in an incidence sample. Alzheimers Dement. 2013;9(2):204-7. 
11.  
González-Salvador T, Lyketsos CG, Baker A, et al. Quality of life in dementia patients in 
long-term care. Int J Geriatr Psychiatry. 2000;15(2):181-9. 
12.  
Steele C, Rovner B, Chase GA, Folstein M. Psychiatric symptoms and nursing home 
placement of patients with Alzheimer’s disease. Am J Psychiatry. 1990;147(8):1049-51. 



$9$1,53+$50$&(87,&$/6,1&
3URWRFRO$93
9HUVLRQ


3DJH


0XUPDQ'/&KHQ43RZHOO0&.XR6%%UDGOH\&-&ROHQGD&&7KHLQFUHPHQWDO
GLUHFWFRVWVDVVRFLDWHGZLWKEHKDYLRUDOV\PSWRPVLQ$'1HXURORJ\

3HWHUV0(6FKZDUW]6+DQ''5DELQV397VFKDQ]-/\NHWVRV&*1HXURSV\FKLDWULF
V\PSWRPVDVSUHGLFWRUVRISURJUHVVLRQWRVHYHUHDO]KHLPHUkVGHPHQWLDDQGGHDWKWKH
FDFKHFRXQW\VWXG\$P-*HULDWU3V\FKLDWU\66

0DKHU $5 0DJOLRQH 0 %DJOH\ 6 HW DO (IILFDF\ DQG FRPSDUDWLYH HIIHFWLYHQHVV RI
DW\SLFDODQWLSV\FKRWLFPHGLFDWLRQVIRURIIODEHOXVHVLQDGXOWVDV\VWHPDWLFUHYLHZDQG
PHWDDQDO\VLV-$0$

6FKQHLGHU /6 7DULRW 31 'DJHUPDQ .6 HW DO (IIHFWLYHQHVV RI DW\SLFDO DQWLSV\FKRWLF
GUXJVLQSDWLHQWVZLWK$O]KHLPHU¶VGLVHDVH1(QJO-0HG

+X\EUHFKWV.)*HUKDUG7&U\VWDO6HWDO'LIIHUHQWLDOULVNRIGHDWKLQROGHUUHVLGHQWVLQ
QXUVLQJ KRPHV SUHVFULEHG VSHFLILF DQWLSV\FKRWLF GUXJV SRSXODWLRQ EDVHG FRKRUW VWXG\
%0-H

0F.KDQQ * 'UDFKPDQ ' )ROVWHLQ 0 .DW]PDQ 5 3ULFH ' 6WDGODQ (0 &OLQLFDO
GLDJQRVLVRI$O]KHLPHU¶VGLVHDVHUHSRUW RIWKH1,1&'6$'5'$:RUN*URXSXQGHU
WKHDXVSLFHVRI'HSDUWPHQWRI+HDOWKDQG+XPDQ6HUYLFHV7DVN)RUFHRQ$O]KHLPHU
V
'LVHDVH1HXURORJ\

&RKHQ0DQVILHOG - 0DU[ 06 5RVHQWKDO $6 $ GHVFULSWLRQ RI DJLWDWLRQ LQ D QXUVLQJ
KRPH-*HURQWRO0

&RKHQ0DQVILHOG - $JLWDWHG EHKDYLRUV LQ WKH HOGHUO\ ,, 3UHOLPLQDU\ UHVXOWV LQ WKH
FRJQLWLYHO\GHWHULRUDWHG-$P*HULDWU6RF

5DELQRZLW]-'DYLGVRQ0'H'H\Q33.DW],%URGDW\+&RKHQ0DQVILHOG-)DFWRU
DQDO\VLVRIWKH&RKHQ0DQVILHOG$JLWDWLRQ,QYHQWRU\LQWKUHHODUJHVDPSOHVRIQXUVLQJ
KRPHSDWLHQWVZLWKGHPHQWLDDQGEHKDYLRUDOGLVWXUEDQFH$PHULFDQ-RXUQDORI*HULDWULF
3V\FKLDWU\

7DULRW31(UE53RGJRUVNL&$HWDO(IILFDF\DQGWROHUDELOLW\ RIFDUEDPD]HSLQHIRU
DJLWDWLRQDQGDJJUHVVLRQLQGHPHQWLD$P-3V\FKLDWU\

/DNV-(QJHOKDUGW(0DULQKR9HWDO(IILFDF\DQGVDIHW\RIULVSHULGRQHRUDOVROXWLRQLQ
DJLWDWLRQDVVRFLDWHGZLWKGHPHQWLDLQWKHHOGHUO\$UT1HXURSVLTXLDWU

5DYLQD%3XWW06LGHURZI$HWDO'RQHSH]LOIRUGHPHQWLDLQ3DUNLQVRQ¶VGLVHDVHD
UDQGRPLVHG GRXEOH EOLQG SODFHER FRQWUROOHG FURVVRYHU VWXG\ - 1HXURO 1HXURVXUJ
3V\FKLDWU\








 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
 
 


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
 


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
 






 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
 
 
 
 


















































 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
 
 
 
 
 




















 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
 








 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
 
 






 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
 
 




 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
 
 














 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
 
 
































 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
 
 
 
 




 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
 
 


















 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
 
 




 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
 
 








 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
 
 










 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
 
 




 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
 
 




 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
 
 
Appendix 18: 
Investigator Responsibilities 


Guidance for Industry
E6 Good Clinical Practice:
Consolidated Guidance
ICH
April 1996


Guidance for Industry
E6  Good Clinical Practice: 
Consolidated Guidance
Additional copies are available from:
 the Drug Information Branch (HFD-210),
Center for Drug Evaluation and Research (CDER),
5600 Fishers Lane, Rockville, MD 20857 (Tel) 301-827-4573
http://www.fda.gov/cder/guidance/index.htm
or
Office of Communication,
Training, and Manufacturers Assistance (HFM-40)
Center for Biologics Evaluation and Research (CBER)
1401 Rockville Pike, Rockville, MD 20852-1448,
http://www.fda.gov/cber/guidelines.htm
(Fax) 888-CBERFAX or 301-827-3844
(Voice Information) 800-835-4709 or 301-827-1800
U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
Center for Biologics Evaluation and Research (CBER)
April 1996
ICH


13
(b) Changes increasing the risk to subjects and/or affecting significantly the
conduct of the trial (see section 4.10.2). 
(c) All adverse drug reactions (ADRs) that are both serious and
unexpected. 
(d)  New information that may affect adversely the safety of the subjects or
the conduct of the trial.
3.3.9  Ensuring that the IRB/IEC promptly notify in writing the
investigator/institution concerning:
(a) Its trial-related decisions/opinions.
(b) The reasons for its decisions/opinions.
(c) Procedures for appeal of its decisions/opinions.
3.4
Records
The IRB/IEC should retain all relevant records (e.g., written procedures, membership lists,
lists of occupations/affiliations of members, submitted documents, minutes of meetings,
and correspondence) for a period of at least 3 years after completion of the trial and make
them available upon request from the regulatory authority(ies).
The IRB/IEC may be asked by investigators, sponsors, or regulatory authorities to provide
copies of its written procedures and membership lists.
4.
INVESTIGATOR 
4.1
Investigator's Qualifications and Agreements
4.1.1  The investigator(s) should be qualified by education, training, and
experience to assume responsibility for the proper conduct of the trial, should meet
all the qualifications specified by the applicable regulatory requirement(s), and
should provide evidence of such qualifications through up-to-date curriculum vitae
and/or other relevant documentation requested by the sponsor, the IRB/IEC,
and/or the regulatory authority(ies).
4.1.2  The investigator should be thoroughly familiar with the appropriate use of
the investigational product(s), as described in the protocol, in the current
Investigator's Brochure, in the product information, and in other information
sources provided by the sponsor.


14
4.1.3  The investigator should be aware of, and should comply with, GCP and the
applicable regulatory requirements.
4.1.4  The investigator/institution should permit monitoring and auditing by the
sponsor, and inspection by the appropriate regulatory authority(ies).
4.1.5  The investigator should maintain a list of appropriately qualified persons to
whom the investigator has delegated significant trial-related duties.
4.2
Adequate Resources
4.2.1  The investigator should be able to demonstrate (e.g., based on retrospective
data) a potential for recruiting the required number of suitable subjects within the
agreed recruitment period.
4.2.2  The investigator should have sufficient time to properly conduct and
complete the trial within the agreed trial period.
4.2.3  The investigator should have available an adequate number of qualified staff
and adequate facilities for the foreseen duration of the trial to conduct the trial
properly and safely.
4.2.4  The investigator should ensure that all persons assisting with the trial are
adequately informed about the protocol, the investigational product(s), and their
trial-related duties and functions.
4.3
Medical Care of Trial Subjects
4.3.1  A qualified physician (or dentist, when appropriate), who is an investigator
or a subinvestigator for the trial, should be responsible for all trial-related medical
(or dental) decisions. 
4.3.2  During and following a subject's participation in a  trial, the
investigator/institution should ensure that adequate medical care is provided to a
subject for any adverse events, including clinically significant laboratory values,
related to the trial. The investigator/institution should inform a subject when
medical care is needed for intercurrent illness(es) of which the investigator
becomes aware. 
4.3.3  It is recommended that the investigator inform the subject's primary
physician about the subject's participation in the trial if the subject has a primary
physician and if the subject agrees to the primary physician being informed.


15
4.3.4  Although a subject is not obliged to give his/her reason(s) for withdrawing
prematurely from a trial, the investigator should make a reasonable effort to
ascertain the reason(s), while fully respecting the subject's rights.
4.4
Communication with IRB/IEC
4.4.1  Before initiating a trial, the investigator/institution should have written and
dated approval/favorable opinion from the IRB/IEC for the trial protocol, written
informed consent form, consent form updates, subject recruitment procedures
(e.g., advertisements), and any other written information to be provided to
subjects. 
4.4.2  As part of the investigator's/institution’s written application to the IRB/IEC,
the investigator/institution should provide the IRB/IEC with a current copy of the
Investigator's Brochure.  If the Investigator's Brochure is updated during the trial,
the investigator/institution should supply a copy of the updated Investigator’s
Brochure to the IRB/IEC.
4.4.3  During the trial the investigator/institution should provide to the IRB/IEC all
documents subject to its review.  
4.5
Compliance with Protocol
4.5.1  The investigator/institution should conduct the trial in compliance with the
protocol agreed to by the sponsor and, if required, by the regulatory authority(ies),
and which was given approval/favorable opinion by the IRB/IEC.  The
investigator/institution and the sponsor should sign the protocol, or an alternative
contract, to confirm their agreement.
4.5.2  The investigator should not implement any deviation from, or changes of,
the protocol without agreement by the sponsor and prior review and documented
approval/favorable opinion from the IRB/IEC of an amendment, except where
necessary to eliminate an immediate hazard(s) to trial subjects, or when the
change(s)  involves only logistical or administrative aspects of the trial (e.g.,
change of monitor(s), change of telephone number(s)).
4.5.3  The investigator, or person designated by the investigator, should document
and explain any deviation from the approved protocol.
4.5.4  The investigator may implement a deviation from, or a change in, the
protocol to eliminate an immediate hazard(s) to trial subjects without prior
IRB/IEC approval/favorable opinion.  As soon as possible, the implemented


16
 deviation or change, the reasons for it, and, if appropriate, the proposed protocol
amendment(s) should be submitted:
(a)  To the IRB/IEC for review and approval/favorable opinion;
(b)  To the sponsor for agreement and, if required; 
(c)  To the regulatory authority(ies).
4.6
Investigational Product(s)
4.6.1  Responsibility for investigational product(s) accountability at the trial site(s)
rests with the investigator/institution.
4.6.2  Where allowed/required, the investigator/institution may/should assign some
or all of the investigator's/institution’s duties for investigational product(s)
accountability at the trial site(s) to an appropriate pharmacist or another
appropriate individual who is under the supervision of the investigator/institution.
4.6.3  The investigator/institution and/or a pharmacist or other appropriate
individual, who is designated by the investigator/institution, should maintain
records of the product's delivery to the trial site, the inventory at the site, the use
by each subject, and the return to the sponsor or alternative disposition of unused
product(s).  These records should include dates, quantities, batch/serial numbers,
expiration dates (if applicable), and the unique code numbers assigned to the
investigational product(s) and trial subjects. Investigators should maintain records
that document adequately that the subjects were provided the doses specified by
the protocol and reconcile all investigational product(s) received from the sponsor.
4.6.4  The investigational product(s) should be stored as specified by the sponsor
(see sections 5.13.2 and 5.14.3) and in accordance with applicable regulatory
requirement(s).
4.6.5  The investigator should ensure that the investigational product(s) are used
only in accordance with the approved protocol.
4.6.6  The investigator, or a person designated by the investigator/institution,
should explain the correct use of the investigational product(s) to each subject and
should check, at intervals appropriate for the trial, that each subject is following
the instructions properly.
4.7
Randomization Procedures and Unblinding
The investigator should follow the trial's randomization procedures, if any, and should
ensure that the code is broken only in accordance with the protocol.  If the trial is blinded,


17
the investigator should promptly document and explain to the sponsor any premature
unblinding (e.g., accidental unblinding, unblinding due to a serious adverse event) of the
investigational product(s).
4.8
Informed Consent of Trial Subjects
4.8.1  In obtaining and documenting informed consent, the investigator should
comply with the applicable regulatory requirement(s), and should adhere to GCP
and to the ethical principles that have their origin in the Declaration of Helsinki. 
Prior to the beginning of the trial, the investigator should have the IRB/IEC's
written approval/favorable opinion of the written informed consent form and any
other written information to be provided to subjects.
4.8.2  The written informed consent form and any other written information to be
provided to subjects should be revised whenever important new information
becomes available that may be relevant to the subject’s consent.  Any revised
written informed consent form, and written information should receive the
IRB/IEC's approval/favorable opinion in advance of use.  The subject or the
subject’s legally acceptable representative should be informed in a timely manner if
new information becomes available that may be relevant to the subject’s
willingness to continue participation in the trial.  The communication of this
information should be documented.
4.8.3  Neither the investigator, nor the trial staff, should coerce or unduly influence
a subject to participate or to continue to participate in a trial.
4.8.4  None of the oral and written information concerning the trial, including the
written informed consent form, should contain any language that causes the subject
or the subject's legally acceptable representative to waive or to appear to waive
any legal rights, or that releases or appears to release the investigator, the
institution, the sponsor, or their agents from liability for negligence.
4.8.5  The investigator, or a person designated by the investigator, should fully
inform the subject or, if the subject is unable to provide informed consent, the
subject's legally acceptable representative, of all pertinent aspects of the trial
including the written information given approval/favorable opinion by the
IRB/IEC.
4.8.6  The language used in the oral and written information about the trial,
including the written informed consent form, should be as nontechnical as practical
and should be understandable to the subject or the subject's legally acceptable
representative and the impartial witness, where applicable. 


18
4.8.7  Before informed consent may be obtained, the investigator, or a person
designated by the investigator, should provide the subject or the subject's legally
acceptable representative ample time and opportunity to inquire about details of
the trial and to decide whether or not to participate in the trial.  All questions
about the trial should be answered to the satisfaction of the subject or the subject's
legally acceptable representative.
4.8.8  Prior to a subject’s participation in the trial, the written informed consent
form should be signed and personally dated by the subject or by the subject's
legally acceptable representative, and by the person who conducted the informed
consent discussion. 
4.8.9  If a subject is unable to read or if a legally acceptable representative is
unable to read, an impartial witness should be present during the entire informed
consent discussion.  After the written informed consent form and any other written
information to be provided to subjects is read and explained to the subject or the
subject’s legally acceptable representative, and after the subject or the subject’s
legally acceptable representative has orally consented to the subject’s participation
in the trial, and, if capable of doing so, has signed and personally dated the
informed consent form, the witness should sign and personally date the consent
form.  By signing the consent form, the witness attests that the information in the
consent form and any other written information was accurately explained to, and
apparently understood by, the subject or the subject's legally acceptable
representative, and that informed consent was freely given by the subject or the
subject’s legally acceptable representative.
4.8.10  Both the informed consent discussion and the written informed consent
form and any other written information to be provided to subjects should include
explanations of the following:
(a)  That the trial involves research.
(b)  The purpose of the trial.
(c)  The trial treatment(s) and the probability for random assignment to
each treatment.
(d)  The trial procedures to be followed, including all invasive procedures.
(e)  The subject's responsibilities.
(f)  Those aspects of the trial that are experimental.


19
(g)  The reasonably foreseeable risks or inconveniences to the subject and,
when applicable, to an embryo, fetus, or nursing infant.
(h)  The reasonably expected benefits.  When there is no intended clinical
benefit to the subject, the subject should be made aware of this. 
(i)  The alternative procedure(s) or course(s) of treatment that may be
available to the subject, and their important potential benefits and risks. 
(j)  The compensation and/or treatment available to the subject in the event
of trial-related injury. 
(k)  The anticipated prorated payment, if any, to the subject for
participating in the trial.
(l)  The anticipated expenses, if any, to the subject for participating in the
trial.
(m)  That the subject's participation in the trial is voluntary and that the
subject may refuse to participate or withdraw from the trial, at any time,
without penalty or loss of  benefits to which the subject is otherwise
entitled. 
(n)  That the monitor(s), the auditor(s), the IRB/IEC, and the regulatory
authority(ies) will be granted direct access to the subject's original medical
records for verification of clinical trial procedures and/or data, without
violating the confidentiality of the subject, to the extent permitted by the
applicable laws and regulations and that, by signing a written informed
consent form, the subject or the subject's legally acceptable representative
is authorizing such access.
(o)  That records identifying the subject will be kept confidential and, to the
extent permitted by the applicable laws and/or regulations, will not be made
publicly available.  If the results of the trial are published, the subject’s
identity will remain confidential. 
(p)  That the subject or the subject's legally acceptable representative will
be informed in a timely manner if information becomes available that may
be relevant to the subject's willingness to continue participation in the trial. 
(q)  The person(s) to contact for further information regarding the trial and
the rights of trial subjects, and whom to contact in the event of trial-related
injury. 


20
(r)  The foreseeable circumstances and/or reasons under which the subject's
participation in the trial may be terminated. 
(s)  The expected duration of the subject's participation in the trial.
(t)  The approximate number of subjects involved in the trial. 
4.8.11  Prior to participation in the trial, the subject or the subject's legally
acceptable representative should receive a copy of the signed and dated written
informed consent form and any other written information provided to the subjects. 
During a subject’s participation in the trial, the subject or the subject’s legally
acceptable representative should receive a copy of the signed and dated consent
form updates and a copy of any amendments to the written information provided
to subjects.
4.8.12  When a clinical trial (therapeutic or nontherapeutic) includes subjects who
can only be enrolled in the trial with the consent of the subject’s legally acceptable
representative (e.g., minors, or patients with severe dementia), the subject should
be informed about the trial to the extent compatible with the subject’s
understanding and, if capable, the subject should assent, sign and personally date
the written informed consent.
4.8.13  Except as described in 4.8.14, a nontherapeutic trial (i.e., a trial in which
there is no anticipated direct clinical benefit to the subject) should be conducted in
subjects who personally give consent and who sign and date the written informed
consent form.
4.8.14  Nontherapeutic trials may be conducted in subjects with consent of a
legally acceptable representative provided the following conditions are fulfilled:
(a)  The objectives of the trial cannot be met by means of a trial in subjects
who can give informed consent personally.
(b)  The foreseeable risks to the subjects are low.
(c)  The negative impact on the subject’s well-being is minimized and low.
(d)  The trial is not prohibited by law.
(e)  The approval/favorable opinion of the IRB/IEC is expressly sought on
the inclusion of such subjects, and the written approval/favorable opinion
covers this aspect. 


21
Such trials, unless an exception is justified, should be conducted in patients having
a disease or condition for which the investigational product is intended.  Subjects
in these trials should be particularly closely monitored and should be withdrawn if
they appear to be unduly distressed.
4.8.15  In emergency situations, when prior consent of the subject is not possible,
the consent of the subject's legally acceptable representative, if present, should be
requested.  When prior consent of the subject is not possible, and the subject’s
legally acceptable representative is not available, enrollment of the subject should
require measures described in the protocol and/or elsewhere, with documented
approval/favorable opinion by the IRB/IEC, to protect the rights, safety, and well-
being of the subject and to ensure compliance with applicable regulatory
requirements.  The subject or the subject's legally acceptable representative should
be informed about the trial as soon as possible and consent to continue and other
consent as appropriate (see section 4.8.10) should be requested.
4.9
Records and Reports
4.9.1  The investigator should ensure the accuracy, completeness, legibility, and
timeliness of the data reported to the sponsor in the CRFs and in all required
reports.
4.9.2  Data reported on the CRF, which are derived from source documents,
should be consistent with the source documents or the discrepancies should be
explained.
4.9.3  Any change or correction to a CRF should be dated, initialed, and explained
(if necessary) and should not obscure the original entry (i.e., an audit trail should
be maintained); this applies to both written and electronic changes or corrections
(see section 5.18.4(n)).  Sponsors should provide guidance to investigators and/or
the investigators' designated representatives on making such corrections.  Sponsors
should have written procedures to assure that changes or corrections in CRFs
made by sponsor's designated representatives are documented, are necessary, and
are endorsed by the investigator.  The investigator should retain records of the
changes and corrections.
4.9.4  The investigator/institution should maintain the trial documents as specified
in Essential Documents for the Conduct of a Clinical Trial (see section 8.) and as
required by the applicable regulatory requirement(s).  The investigator/institution
should take measures to prevent accidental or premature destruction of these
documents.


22
4.9.5  Essential documents should be retained until at least 2 years after the last
approval of a marketing application in an ICH region and until there are no
pending or contemplated marketing applications in an ICH region or at least 2
years have elapsed since the formal discontinuation of clinical development of the
investigational product.  These documents should be retained for a longer period,
however, if required by the applicable regulatory requirements or by an agreement
with the sponsor.  It is the responsibility of the sponsor to inform the
investigator/institution as to when these documents no longer need to be retained
(see section 5.5.12).
4.9.6  The financial aspects of the trial should be documented in an agreement
between the sponsor and the investigator/institution.
4.9.7  Upon request of the monitor, auditor, IRB/IEC, or regulatory authority, the
investigator/institution should make available for direct access all requested trial-
related records. 
4.10
Progress Reports
4.10.1  Where required by the applicable regulatory requirements, the investigator
should submit written summaries of the trial’s status to the institution.  The
investigator/institution should submit written summaries of the status of the trial to
the IRB/IEC annually, or more frequently, if requested by the IRB/IEC.
4.10.2  The investigator should promptly provide written reports to the sponsor,
the IRB/IEC (see section 3.3.8), and, where required by the applicable regulatory
requirements, the institution on any changes significantly affecting the conduct of
the trial, and/or increasing the risk to subjects.
4.11
Safety Reporting
4.11.1  All serious adverse events (SAEs) should be reported immediately to the
sponsor except for those SAEs that the protocol or other document (e.g.,
Investigator's Brochure) identifies as not needing immediate reporting.  The
immediate reports should be followed promptly by detailed, written reports.  The
immediate and follow-up reports should identify subjects by unique code numbers
assigned to the trial subjects rather than by  the subjects' names, personal
identification numbers, and/or addresses.  The investigator should also comply
with the applicable regulatory requirement(s) related to the reporting of
unexpected serious adverse drug reactions to the regulatory authority(ies) and the
IRB/IEC.


23
4.11.2  Adverse events and/or laboratory abnormalities identified in the protocol as
critical to safety evaluations should be reported to the sponsor according to the
reporting requirements and within the time periods specified by the sponsor in the
protocol.
4.11.3  For reported deaths, the investigator should supply the sponsor and the
IRB/IEC with any additional requested information (e.g., autopsy reports and
terminal medical reports).
4.12
Premature Termination or Suspension of a Trial
If the trial is terminated prematurely or suspended for any reason, the
investigator/institution should promptly inform the trial subjects, should assure appropriate
therapy and follow-up for the subjects, and, where required by the applicable regulatory
requirement(s), should inform the regulatory authority(ies).  In addition:
4.12.1  If the investigator terminates or suspends a trial without prior agreement of
the sponsor, the investigator should inform the institution, where required by the
applicable regulatory requirements, and the investigator/institution should
promptly inform the sponsor and the IRB/IEC, and should provide the sponsor and
the IRB/IEC a detailed written explanation of the termination or suspension.
4.12.2  If the sponsor terminates or suspends a trial (see section 5.21), the
investigator should promptly inform the institution, where required by the
applicable regulatory requirements, and the investigator/institution should
promptly inform the IRB/IEC and provide the IRB/IEC a detailed written
explanation of the termination or suspension.
4.12.3  If the IRB/IEC terminates or suspends its approval/favorable opinion of a
trial (see sections 3.1.2 and 3.3.9), the investigator should inform the institution,
where required by the applicable regulatory requirements, and the
investigator/institution should promptly notify the sponsor and provide the sponsor
with a detailed written explanation of the termination or suspension.
4.13
Final Report(s) by Investigator/Institution
Upon completion of the trial, the investigator should, where required by the applicable
regulatory requirements, inform the institution, and the investigator/institution should
provide the sponsor with all required reports, the IRB/IEC with a summary of the trial’s
outcome, and the regulatory authority(ies) with any report(s) they require of the
investigator/institution.


 
AVANIR PHARMACEUTICALS, INC 
Protocol 15-AVP-786-302 
Version 5.0  
 
 
 
 
 
 
 
 









SAP_001.pdf: 
Official Title: 
NCT Number: 
Document Date: 
A Phase 3, multicenter, randomized, double-blind, placebo-controlled study 
to assess the efficacy, safety, and tolerability of AVP-786 (deuterated [d6]-
dextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the 
treatment of agitation in patients with dementia of the Alzheimer’s type
NCT02442778 
SAP Version 3.0: 26 April 2019 


Sponsor: Avanir Pharmaceuticals, Inc.
Statistical Analysis Plan
Protocol No: 15-AVP-786-302
Effective Date: 26-Apr-2019/Version 3.0
Page 1 of 40
Statistical Analysis Plan
Sponsor:
Avanir Pharmaceuticals, Inc.
Protocol No:
15-AVP-786-302
Protocol Version No./
Date:
Amendment 4
28-Feb-2017
Title
A Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess 
the efficacy, safety, and tolerability of AVP-786 (deuterated [d6]-dextromethorphan 
hydrobromide [d6-DM]/quinidine sulfate [Q]) for the treatment of agitation in patients 
with dementia of the Alzheimer’s type
CRF Version No./
Date:
6.0
18-Apr-2017
PRA Project ID:
AVA78601-786302
SAP Version No./
Date:
3.0
26-Apr-2019
Approvals
Prepared by
PRA
Biostatistician/ Title:
, MS / 
Signature/ Date:
PRA
Project Manager/ Title:
/ 
Signature/ Date:
Sponsor
Sponsor Name:
Avanir Pharmaceuticals, Inc.
Biostatistician / Title:
, MS / 
, Avanir 
Signature/ Date:
CDL / Title:
, MD / 
, Avanir 
Signature/ Date:
CSM / Title:
, Avanir 
Signature/ Date:
Non-Clinical Dev Lead / Title:
, PhD / 
, Avanir 
Signature/ Date:


Sponsor: Avanir Pharmaceuticals, Inc.
Statistical Analysis Plan
Protocol No: 15-AVP-786-302
Effective Date: 26-Apr-2019/Version 3.0
Page 2 of 40
Table of Contents
Approvals ................................................................................................................................................................................. 1
Table of Contents..................................................................................................................................................................... 2
1.0 Introduction ....................................................................................................................................................................... 4
1.1 Changes from Protocol.............................................................................................................................................. 4
2.0 Study Objectives ............................................................................................................................................................... 4
3.0 Study Design....................................................................................................................................................................... 4
3.1 General Description.................................................................................................................................................... 4
3.2 Treatment Assignments ........................................................................................................................................... 8
3.3 Sample Size Considerations.................................................................................................................................... 8
3.4 Randomization............................................................................................................................................................. 8
4.0 Study Endpoints and Covariates................................................................................................................................ 9
4.1 Scales and Questionnaires....................................................................................................................................... 9
4.1.1 Cohen-Mansfield Agitation Inventory (CMAI)........................................................................................ 9
4.1.2 Neuropsychiatric Inventory (NPI).............................................................................................................10
4.1.3 Clinical Global Impression of Severity Illness-Agitation (CGIS-Agitation)................................11
4.1.4 Alzheimer’s Disease Cooperative Study – Clinical Global Impression of Change Rating 
(ADCS-CGIC-Overall)..................................................................................................................................................11
4.1.5 Modified Alzheimer’s Disease Cooperative Study – Clinical Global Impression of Change 
Rating (mADCS-CGIC-Agitation)............................................................................................................................12
4.1.6 Zarit Burden Interview (ZBI).......................................................................................................................12
4.1.7 Patient Global Impression of Change (PGIC).........................................................................................12
4.1.8 Dementia Quality of Life (DEMQOL).........................................................................................................13
4.1.9 Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-cog)...................................13
4.1.10 Cornell Scale for Depression in Dementia (CSDD)...........................................................................14
4.1.11 Resource Utilization Dementia (RUD)...................................................................................................14
4.1.12 General Medical Health Rating (GMHR)...............................................................................................15
4.2 Efficacy Endpoints ....................................................................................................................................................15
4.2.1 Primary Efficacy Endpoint............................................................................................................................15
4.2.2 Secondary Efficacy Endpoints .....................................................................................................................15
4.3 Safety Endpoints........................................................................................................................................................16
4.4 Pharmacokinetic and Genotype Data................................................................................................................16
5.0 Analysis Populations.....................................................................................................................................................16
5.1 mITT Population........................................................................................................................................................16
5.2 ITT Population............................................................................................................................................................16
5.3 Safety Population ......................................................................................................................................................16
6.0 Definitions.........................................................................................................................................................................16
7.0 Interim Analyses.............................................................................................................................................................17
8.0 Data Handling and Review.........................................................................................................................................17
8.1 Visit Windows.............................................................................................................................................................17
8.2 Missing Data Conventions .....................................................................................................................................18
8.3 Treatment Misallocations......................................................................................................................................19
8.4 Data Handling and Transfer..................................................................................................................................19
8.5 Data Screening............................................................................................................................................................19
8.6 Data Safety Monitoring Board (DSMB) ............................................................................................................20
9.0 Overall Statistical Considerations...........................................................................................................................20
9.1 Summary Statistics...................................................................................................................................................20


Sponsor: Avanir Pharmaceuticals, Inc.
Statistical Analysis Plan
Protocol No: 15-AVP-786-302
Effective Date: 26-Apr-2019/Version 3.0
Page 3 of 40
9.2 Hypothesis Testing and Multiplicity of Endpoints ......................................................................................20
10.0 Efficacy Statistical Analysis Methods..................................................................................................................21
10.1 Consideration of Primary Estimands and Sensitivity Analysis............................................................21
10.2 Derivation of Primary Efficacy Endpoints....................................................................................................22
10.3 Primary Efficacy:  Mixed Model Repeated Measures (MMRM)...........................................................22
10.4 Sensitivity Analyses for the Primary Efficacy Endpoint.........................................................................22
10.4.1 Sensitivity Analysis with MNAR Using Multiple Imputation (MI) .............................................22
10.4.2 Analysis of Covariance (ANCOVA) ..........................................................................................................23
10.4.3 Analysis on the ITT Population ................................................................................................................23
10.5 Secondary Efficacy Endpoint Analyses..........................................................................................................24
10.5.1 Secondary Efficacy Endpoint MMRM Analysis...................................................................................24
10.5.2 Response Analysis .........................................................................................................................................24
10.5.3 Resource Utilization in Dementia (RUD) and General Medical Health Rating (GMHR) 
Analysis............................................................................................................................................................................24
 
11.0 Safety Statistical Analysis Methods......................................................................................................................26
11.1 Adverse Events........................................................................................................................................................26
11.2 Clinical Laboratory Assessments.....................................................................................................................28
11.3 ECGs..............................................................................................................................................................................29
11.4 Vital Signs...................................................................................................................................................................30
11.5 Physical and Neurological Examinations......................................................................................................31
11.6 Sheehan Suicidality Tracking Scale (S-STS).................................................................................................31
11.7 Mini Mental State Examination (MMSE).......................................................................................................32
11.8 Timed Up and Go (TUG) Test.............................................................................................................................33
11.9 Epworth Sleepiness Scale (ESS) .......................................................................................................................33
12.0 Additional Summaries...............................................................................................................................................33
12.1 Patient Disposition.................................................................................................................................................33
12.2 Protocol Deviations................................................................................................................................................33
12.3 Demographic and Baseline Characteristics.................................................................................................34
12.4 Medical History........................................................................................................................................................34
12.5 Exposure.....................................................................................................................................................................34
12.6 Compliance................................................................................................................................................................34
12.7 Prior and Concomitant Medications, Non-drug Therapies and Interventions..............................35
12.8 Pharmacokinetics and Pharmacodynamics.................................................................................................35
13.0 Validation........................................................................................................................................................................35
14.0 References......................................................................................................................................................................35
Appendix 1 Glossary of Abbreviations .........................................................................................................................36
Appendix 2 Adverse Event Start/Stop Date Imputation.......................................................................................39
Appendix 3 Prior and Concomitant Medication Start/Stop Date Imputation..............................................40


Sponsor: Avanir Pharmaceuticals, Inc.
Statistical Analysis Plan
Protocol No: 15-AVP-786-302
Effective Date: 26-Apr-2019/Version 3.0
Page 4 of 40
1.0 Introduction
This statistical analysis plan (SAP) describes the statistical methods to be used during the reporting and 
analyses of data collected under Avanir Pharmaceuticals, Inc. Protocol 15-AVP-786-302.
This SAP should be read in conjunction with the study protocol and case report form (CRF). This version 
of the plan has been developed using the Protocol Amendment 4 dated 28-Feb-2017 and CRF dated 18-
Apr-2017. Any further changes to the protocol or CRF may necessitate updates to the SAP.
1.1 Changes from Protocol
Not applicable.
2.0 Study Objectives
The objectives of the study are to evaluate the efficacy, safety, and tolerability of AVP-786 compared to 
placebo for the treatment of agitation in patients with dementia of the Alzheimer’s type.
3.0 Study Design
3.1 General Description
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study with a treatment 
duration of 12 weeks.  Table 1 provides an overview of the study duration:
TABLE 1. OVERVIEW OF STUDY DURATION
Screening
Treatment Period
Follow-up
Duration in Days
Days -28 to -1
Days 1 to 85
30 days after last 
dose
Approximately 470 patients with a diagnosis of probable Alzheimer’s disease (AD) and clinically 
meaningful moderate/severe agitation secondary to AD will be enrolled at approximately 75 centers in 
North America. There will be 8 scheduled clinic visits including a screening visit and 2 safety follow-up 
phone visits in the study.  Clinic visits include Screening, Baseline (Day 1), and Weeks 1, 2, 3, 6, 9, and 
12. Safety follow-up phone calls will occur on Week 4 and Week 10.  An in-clinic Follow-up visit will occur 
30 days after last dose of study medication for subjects who terminate early. Patients who do not roll over 
to the extension study (Study 15-AVP-786-303) will receive a safety follow-up call 30 days after the last 
dose of study medication. The schedule of events is provided in Table 2:












Sponsor: Avanir Pharmaceuticals, Inc.
Statistical Analysis Plan
Protocol No: 15-AVP-786-302
Effective Date: 26-Apr-2019/Version 3.0
Page 10 of 40
4.1.2 Neuropsychiatric Inventory (NPI)
The NPI is a validated clinical instrument for evaluating psychopathology in a variety of disease settings, 
including dementia.  The NPI will be administered to the patient’s caregiver at Baseline, Week 3, Week 6, 
Week 9, and Week 12.  Additionally, the Agitation/Aggression domain of the NPI will be administered to 
the patient’s caregiver at Screening, Week 1, and Week 2.
The NPI is a retrospective caregiver-informant interview covering 12 neuropsychiatric symptom domains:

Delusions

Hallucinations

Agitation/Aggression

Depression/Dysphoria

Anxiety

Elation/Euphoria

Apathy/Indifference

Disinhibition

Irritability/Lability

Aberrant Motor Behavior

Sleep and Nighttime Behavioral Disorders

Appetite/Eating Disorders
The scripted NPI interview includes a compound screening question for each symptom domain, followed 
by a list of interrogatives about domain-specific behaviors that is administered when a positive response 
to a screening question is elicited.  Neuropsychiatric manifestations within a domain are collectively rated 
by the caregiver in terms of frequency and severity, yielding a domain score.  Domain scores range from 
1 to 12 and are calculated using the following formula: 
domain score = frequency x severity
where, frequency and severity are rated according to the following scales:
Frequency
Severity

1 = Rarely – less than once per week

2 = Sometimes – about once per week

3 = Often – several times per week but
less than every day

4 = Very often – once or more per day

1 = Mild – produces little distress in the
patient

2 = Moderate – more disturbing to the
patient but can be redirected by the
caregiver

3 = Severe – very disturbing to the patient
and difficult to redirect
Frequency and severity rating scales have defined anchor points to enhance the reliability of caregiver 
responses.  Caregiver distress is also rated for each positive neuropsychiatric symptom domain using the 
following anchored scores:
Distress

0 = Not at all

1 = Minimally (almost no change in work routine)

2 = Mildly (some change in work routine but little time rebudgeting required)

3 = Moderately (disrupts work routine, requires time rebudgeting)

4 = Severely (disruptive, upsetting to staff and other residents, major time infringement)


Sponsor: Avanir Pharmaceuticals, Inc.
Statistical Analysis Plan
Protocol No: 15-AVP-786-302
Effective Date: 26-Apr-2019/Version 3.0
Page 11 of 40

5 = Very Severely or Extremely (very disruptive, major source of distress for staff and other 
residents, requires time usually devoted to other residents or activities)
The NPI nursing-home (NPI-NH) version will be used for patients from in-patient or assisted living 
facilities.  The questions in the NPI-NH are rephrased for professional caregivers who may not know the 
patient prior to the onset of illness however, the overall instrument domains and scoring is identical to the 
NPI except for the caregiver distress section which is replaced with occupational disruptiveness in the 
NPI-NH version.
A total NPI score is calculated by adding the scores of all 12 domain scores together. The possible total 
scores are from 0 to 144. The NPI Total Score will be unevaluable if less than 10 of the 12 items are 
recorded. If 10 or 11 of the 12 items are available, then the total score is the mean of the available scores 
times 12. All imputed scores are rounded to the first decimal place. The distress score is not included in 
the total NPI score.
The total caregiver distress score is generated by adding together the scores of all 12 domains of the NPI 
distress questions.  Scores range from 0 to 60 with a higher score indicating more distress. Total score 
calculation with missing items follows the same algorithm as the NPI total score.
4.1.3 Clinical Global Impression of Severity Illness-Agitation (CGIS-Agitation)
The CGIS-Agitation is an observer-rated scale that measures illness severity and will be assessed at 
Screening, Baseline, Week 6, and Week 12.
The clinician is asked to rate the patient relative to their past experience with other patients with the same 
diagnosis, with or without collateral information.  The CGIS-Agitation is a 7-point scale and will be 
assessed for severity of agitation.  A value of 0 is given to patients who are not assessed.  The 7-point 
scale for CGIS-Agitation is the following:
Severity of Agitation Scores

0 = Not assessed

1 = Normal, not at all ill

2 = Borderline ill

3 = Mildly ill

4 = Moderately ill

5 = Markedly ill

6 = Severely ill

7 = Among the most extremely ill patient
4.1.4 Alzheimer’s Disease Cooperative Study – Clinical Global Impression of 
Change Rating (ADCS-CGIC-Overall) 
The ADCS version of the Clinical Global CGIC, referred to as ADCS-CGIC-Overall, provides a reliable 
means to assess change from a baseline level of global function within the timeframe of a clinical trial.  
The ADCS-CGIC-Overall focuses on clinicians’ observations of change in the patient’s cognitive, 
functional, and behavioral performance since the beginning of the trial.  Once the baseline level of 
severity is established, the change score at the follow-up visits is based on information gathered from the 
patient and caregiver interviews by an independent evaluator.  The response for the ADCS-CGIC-Overall 
will consist of one of the following:
Overall Clinical Status Responses

1 = Marked Improvement

2 = Moderate Improvement 

3 = Minimal Improvement

4 = No Change

5 = Minimal Worsening


Sponsor: Avanir Pharmaceuticals, Inc.
Statistical Analysis Plan
Protocol No: 15-AVP-786-302
Effective Date: 26-Apr-2019/Version 3.0
Page 12 of 40

6 = Moderate Worsening

7 = Marked Worsening
The baseline ADCS-CGIC-Overall evaluation will be conducted at the Baseline visit.  The 
ADCS-CGIC-Overall will be assessed at Week 6 and Week 12 for change in Overall Clinical Status.  At 
Week 6, change from the Baseline visit will be assessed.  At Week 12, change from Week 6 and change 
from the Baseline visit will be assessed.
4.1.5 Modified Alzheimer’s Disease Cooperative Study – Clinical Global 
Impression of Change Rating (mADCS-CGIC-Agitation) 
The mADCS-CGIC-Agitation is a modified version of the ADCS-CGIC containing additional questions 
related to agitation and an assessment of the Clinician’s Impression of Change focused specifically on 
agitation.  The response for the mADCS-CGIC-Agitation will consist of one of the following:
Responses

1 = Marked Improvement

2 = Moderate Improvement 

3 = Minimal Improvement

4 = No Change

5 = Minimal Worsening

6 = Moderate Worsening

7 = Marked Worsening
The baseline mADCS-CGIC-Agitation evaluation will be conducted at the Baseline visit.  The 
mADCS-CGIC-Agitation will be assessed at Week 6, Week 12, and Follow-up visit (for ET patients) for 
change in agitation.  At Week 6, change from the Baseline visit will be assessed.  At Week 12, change 
from Week 6 and change from the Baseline visit will be assessed. At the Follow-up visit (for ET patients), 
change from Week 12 will be assessed.
4.1.6 Zarit Burden Interview (ZBI) 
The ZBI is a 22-item scale used to assess the impact of patient’s disabilities on the caregiver’s life and will 
be assessed at Baseline, Week 6, and Week 12.  It is designed to reflect the burden experienced by 
caregivers of dementia patients and can either be completed by the caregiver or administered as an 
interview.  Each question is rated on the following 5-point scale:
Zarit Burden Interview Scores for Individual Questions

0 = Never

1 = Rarely

2 = Sometimes

3 = Quite Frequently

4 = Nearly Always
The ZBI is scored by summing the responses of the individual questions and ranges from 0 to 88.  Higher 
scores indicate greater caregiver distress. The ZBI score will be unevaluable if 4 or more of the 22 items
are missing. If 19 to 21 of the 22 items are available, then the total score is the mean of the available 
scores times 22. All imputed scores are rounded to the first decimal place.
4.1.7 Patient Global Impression of Change (PGIC)
The PGIC is a 7-point scale used to assess treatment response and will be assessed and rated by the 
patient’s caregiver at Week 6 and Week 12 and will focus on the patient’s agitation.  The response values 
for the PGIC are provided below:
Patient Global Impression of Change Scale

1 = Very much improved


Sponsor: Avanir Pharmaceuticals, Inc.
Statistical Analysis Plan
Protocol No: 15-AVP-786-302
Effective Date: 26-Apr-2019/Version 3.0
Page 13 of 40

2 = Much improved 

3 = Minimally improved

4 = No change

5 = Minimally worse

6 = Much worse

7 = Very much worse
4.1.8 Dementia Quality of Life (DEMQOL) 
The DEMQOL is a scale used to evaluate health related quality of life in patients with dementia and their 
caregivers.  There are 2 versions of the DEMQOL, a 29-item version (rated by the patient) and a 32-item 
version (DEMQOL-proxy, rated by the caregiver).  The following provides the response categories for the 
individual DEMQOL questions and the overall quality of life question:
DEMQOL Responses for Individual Questions 
Overall Quality of Life Question

1 = A lot

2 = Quite a bit

3 = A little

4 = Not at all

1 = Very good

2 = Good

3 = Fair

4 = Poor
The DEMQOL-proxy (and DEMQOL for patients with a Mini Mental State Examination (MMSE) score ≥10 
at the Baseline visit) will be assessed at Baseline, Week 6, and Week 12.
Scores for DEMQOL Item 1, 3, 5, 6, 10, 29, DEMQOL-proxy item 1, 4, 6, 8, 11, 32, need to be reversed 
for analysis, i.e., 4=A lot, 3=Quite a bit, 2=A little, 1=Not at all. Total score is derived by sum of all item 
scores with item 29 in DEMQOL and item 32 in DEMQOL-proxy being excluded. Missing item handling for 
DEMQOL, 1) count the number of missing items for questions 1 to 28, 2) if the number < 15, set the 
missing item values to the mean of the non-missing item 1 to 28, then add them up; if the number of 
missing >= 15, then the total is missing. Missing item handling for DEMQOL-proxy, 1) count the number 
of missing items for questions 1 to 31, 2) if the number < 16, set the missing item values to the mean of 
the non-missing item 1 to 31, then add them up; if the number of missing >= 16, then the total is missing.
In addition, DEMQOL Item 29 and DEMQOL-proxy Item 32 will be summarized separately.
4.1.9 Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-cog) 
The ADAS was designed to evaluate the cognitive and non-cognitive behavioral dysfunction 
characteristics of patients with AD and will be assessed at Baseline, Week 6, and Week 12 for patients 
with an MMSE score ≥10 at the Baseline visit.  The cognitive subscale (ADAS-cog) consists of 11 
subsets related to memory, praxis, and language.  Scoring of the individual subsets is specific to each 
particular subset.  The ADAS-cog is scored by summing the 11 subset scores and ranges in scale from 0 
to 70. Scoring for each component of the ADAS-cog is as follows:
Component
Measurement
Scoring
Word Recall Task
Mean number of words not 
recalled on 3 trials
Maximum score = 10
Naming Task
Number of objects named 
incorrectly
0 (0 – 2 items) to 5 (15-17 
items)
Commands
Number of correct and incorrect 
commands
0 (all commands correct) to 5 
(all commands incorrect)
Constructional Praxis
Number of drawings correct
0 (all drawings correct) to 5 (no 
figures drawn, no recognizable 
attempt at drawing any 
side/section of any figure)
Ideational Praxis
Number of components 
performed correctly
0 (all components performed 
correctly) to 5 (failure to perform 
5 components)


Sponsor: Avanir Pharmaceuticals, Inc.
Statistical Analysis Plan
Protocol No: 15-AVP-786-302
Effective Date: 26-Apr-2019/Version 3.0
Page 14 of 40
Orientation
One point given for each 
incorrect response
Maximum score = 8
Word Recognition
Mean number of words not 
recognized on 3 trials
Maximum error score = 12
Remembering Test Instructions
Ability to remember the 
requirements of the Word 
Recognition Task
0 (patient never needs extra 
reminders) to 5 (severe – must 
be reminded 7 or more times)
Spoken Language Ability
Quality of speech
0 (no instances of difficulty 
understanding the patient) to 5 
(severe – 1 or 2 word utterance; 
fluent but empty speech; mute)
Word-finding Difficulty
Ability in expressive language
0 (no evidence) to 5 (severe –
nearly total loss of content 
words; speech sound empty; 1 
or 2 word utterances)
Comprehension of Spoken 
Language
Ability to understand what is 
being said to them
0 (patient understands) to 5 
(severe – patient rarely 
responds to questions 
appropriately; not due to poverty 
of speech)
4.1.10 Cornell Scale for Depression in Dementia (CSDD)
The CSDD was developed to assess signs and symptoms of major depression in patients with dementia 
and will be assessed at Screening, Week 6, and Week 12.  Information is elicited through one interview 
with the caregiver and one interview with the patient.  The CSDD has 19 items and each item is rated for 
severity on the following scale:
Severity Scale for CSDD Items

0 = Absent

1 = Mild or intermittent

2 = Severe
The CSDD score is calculated by summing the non-missing scores from each item score.  Items which 
could not be evaluated are assigned value 0 (Psych Congress Network: 
https://www.psychcongress.com/saundras-corner/scales-screeners/depression/cornell-scale-depression-
dementia-csdd). Scores above 10 indicate probable major depression.  Scores above 18 indicate definite 
major depression.  Scores below 6 as a rule are associated with absence of significant depressive 
symptoms.
4.1.11 Resource Utilization Dementia (RUD) 
The RUD is used to calculate healthcare costs associated with dementia and will be assessed at 
Baseline, Week 6, and Week 12.  
The RUD evaluates dementia patients’ utilization of formal and informal healthcare resources, including 
hospitalizations and doctor visits, living assistance, and time spent by nonprofessional caregivers.  The 
RUD is administered as a semi-structured interview with the patient’s primary caregiver.  One section 
focuses on caregiver impact (loss of work and leisure time incurred by the caregiver) and the other 
section focuses on the patient’s use of healthcare resources.  The total healthcare costs associated with 
the patient’s dementia is estimated by multiplying the number of units used (e.g., hours of caregiver time, 
visits to doctors, nights in accommodation) by the corresponding unit price vector.




Sponsor: Avanir Pharmaceuticals, Inc.
Statistical Analysis Plan
Protocol No: 15-AVP-786-302
Effective Date: 26-Apr-2019/Version 3.0
Page 16 of 40
4.3 Safety Endpoints
Safety and tolerability measurements of AVP-786 will include: adverse events (AEs), physical and 
neurological examinations, vital signs, clinical laboratory assessments, resting 12-lead 
electrocardiograms (ECGs), Sheehan Suicidality Tracking Scale (S-STS), MMSE, Time Up and Go (TUG) 
test, and the Epworth Sleepiness Scale (ESS).
4.4 Pharmacokinetic and Genotype Data
Blood samples will be collected between 0 to 3 hours after the morning dose of study medication on 
Week 6 and Week 12 for analysis of plasma levels of d6-dextromethorphan (DM), d6-DM metabolites, 
and quinidine (Q).
5.0 Analysis Populations
Three analysis populations will be used, modified intent-to-treat (mITT), intent-to-treat (ITT), and Safety.
5.1 mITT Population
The mITT population will include all patients randomized in the study who had at least one post-baseline 
efficacy assessment.  The mITT population will be used for all efficacy analyses health outcome 
analyses.  Patients will be included in the treatment group to which they were randomized regardless of 
treatment received.
5.2 ITT Population
The ITT population includes all randomized patients in the study.  The ITT population will be used for 
sensitivity analyses.  Patients will be included in the treatment group to which they were randomized 
regardless of treatment received.  
5.3 Safety Population
The Safety population includes all patients who received at least one dose of study medication.  The 
Safety population will be used for all analyses of safety data.  Patients will be included in the treatment 
group based on the actual treatment received.
6.0 Definitions
Age
The following SAS® code will be used to calculate patient age (years):
Age = floor ([intck{‘month’, birth date, screen date} - {day(informed consent date) < day(birth date)}] / 12),
where intck is a SAS® function counting integer days.
Baseline
Baseline is generally defined as the last assessment prior to the first dose of study drug.
Change from Baseline
Change from baseline (CFB) will be calculated as (post-baseline – baseline).  CFB will be calculated for 
patients with both a baseline and post-baseline value as applicable.
If a baseline value has not been recorded for a parameter, then CFB will not be calculated for that 
parameter.  Patients with missing CFB values will be excluded from analyses in which CFB is the 
endpoint.


Sponsor: Avanir Pharmaceuticals, Inc.
Statistical Analysis Plan
Protocol No: 15-AVP-786-302
Effective Date: 26-Apr-2019/Version 3.0
Page 17 of 40
Percent CFB, when needed, will be calculated by dividing CFB by the baseline value multiplied by 100.  
Patients with a value of 0 at baseline will not have a percent CFB calculated.  
Concomitant medications
Concomitant medications are defined as any medications taken on or after the date of first dose of study 
drug.
Discontinuation of study
A patient will be considered discontinued from the study when a Study Exit CRF page is completed 
indicating primary reason for discontinuation.
End of Treatment (EOT)
EOT is defined as the last value for a given patient, whenever it occurred.  
Enrolled patient
An enrolled patient is one with a record in the database that is not a screen failure.
Prior medication
Prior medications are defined as any medications with start and stop dates prior to the date of first dose 
of study drug. Medications are defined as prior or concomitant, but not both (see also definition of 
concomitant medication in this section).
Protocol deviation
Potential planned or unplanned protocol deviations noted during clinical monitoring will be documented by 
category (i.e., inclusion criteria, exclusion criteria, study drug, safety assessment, efficacy assessment, 
visit window, informed consent, prohibited medication, and other). All deviations will be reviewed, 
categorized, and finalized prior to database lock. 
Relationship to study treatment
AEs related to study treatment will be defined as those entered as possibly related or related.  Unlikely 
related or not related entries will be considered not related to study treatment.  If relationship is missing, 
then it will be considered as related to study treatment.
Study day
Study day is defined relative to the date of the first dose of study drug. For assessments that occur after 
this visit date, study day is calculated as (assessment date – study drug first dose date + 1). For 
assessments that occur prior to study drug first dose date, study day will be calculated as (assessment 
date – study drug first dose date); there is no Study Day 0.
Treatment-emergent adverse event
An AE will be considered a treatment-emergent AE (TEAE) if it begins or worsens on or after the first 
dose date and before the last dose date + 30 days.
7.0 Interim Analyses
There is no Interim analysis planned for this study.
8.0 Data Handling and Review
8.1 Visit Windows
Data at scheduled visits will be assigned to analysis visits as defined in the Visit Window tables below.  
Visit Windows will be used to classify observed data including unscheduled and early termination visits
using study days.  If 2 or more visits occur within the same analysis window, then the values closest to 
the target day will be used.  If the assessment is the same distance from the target day, then the latest 
one will be used.


Sponsor: Avanir Pharmaceuticals, Inc.
Statistical Analysis Plan
Protocol No: 15-AVP-786-302
Effective Date: 26-Apr-2019/Version 3.0
Page 18 of 40
TABLE 3-1. VISIT WINDOWS FOR ASSESSMENTS ON-TREATMENT AT WEEKS 1, 2, 3, 6, 9, AND 12
Week/Visit
Target Day
Study Days                             
Week 1/Visit 2
8
2, 11
Week 2/Visit 2.1
15
12, 18
Week 3/Visit 3
22
19, 32
Week 6/Visit 4
43
33, 53
Week 9/Visit 5
64
54, 74
Week 12/Visit 6 
85
75, 95
Note: for CMAI, NPI AA.
TABLE 3-2. VISIT WINDOWS FOR ASSESSMENTS ON-TREATMENT AT WEEKS 2, 3, 6, 9, AND 12
Week/Visit
Target Day
Study Days                              
Week 2/Visit 2.1
15
2, 18
Week 3/Visit 3
22
19, 32
Week 6/Visit 4
43
33, 53
Week 9/Visit 5
64
54, 74
Week 12/Visit 6 
85
75, 95
Note: for ECG
TABLE 3-3. VISIT WINDOWS FOR ASSESSMENTS ON-TREATMENT AT WEEKS 3, 6, 9, AND 12
Week/Visit
Target Day
Study Days                              
Week 3/Visit 3
22
2, 32
Week 6/Visit 4
43
33, 53
Week 9/Visit 5
64
54, 74
Week 12/Visit 6 
85
75, 95
Note: for NPI other than NPI-AA.
TABLE 3-4. VISIT WINDOWS FOR ASSESSMENTS ON-TREATMENT AT WEEKS 6 AND 12
Week/Visit
Target Day
Study Days                              
Week 6/Visit 4
43
2, 64
Week 12/Visit 6 
85
65, 95
Note: for mADCS-CGIC-Agitation, ZBI, CGIS-Agitation, ADCS-CGIC-Overall, PGIC, DEMQOL, CSDD, 
ADAS-cog, RUD.
TABLE 3-5. VISIT WINDOWS FOR ASSESSMENTS ON-TREATMENT AT WEEK 12 ONLY
Week/Visit
Target Day
Study Days                              
Week 12/Visit 6 
85
2, 95
Note: for GMHR.
8.2 Missing Data Conventions
Missing data will be handled differently depending on the parameter and analysis.  Analyses that are 
done on ‘observed cases’ will not follow any imputation rules below.  Imputation rules are as follows:

Missing baseline values will not be imputed in any situation.

A last observation carried forward (LOCF) and a worst observation carried forward (WOCF) + 
LOCF approach will be used for efficacy analyses, where specified. The table below provides 
imputation rules for LOCF and WOCF.
Missing Imputation for LOCF and WOCF
Missing Value
LOCF
WOCF + LOCF [1]


Sponsor: Avanir Pharmaceuticals, Inc.
Statistical Analysis Plan
Protocol No: 15-AVP-786-302
Effective Date: 26-Apr-2019/Version 3.0
Page 19 of 40
   Missing at scheduled visits
Impute with last non-missing 
value.
Missing due to lack of 
efficacy – Impute with worst 
value after Day 1. If there are 
no values post Day 1, then 
impute with Day 1.
Missing due to other reasons
- Impute with last non-
missing value. 
[1] Only applicable for the primary efficacy endpoints.

Any safety assessments for patients without a Week 12 value will use the last non-missing 
post-baseline observation as EOT.

Missing post-baseline values for by-visit efficacy and safety data will be summarized using the 
Visit Windows from Section 8.1.  If a value is not available within a given window, then no 
imputation will be done.

Missing data for AE relationship will be imputed as “Related”.

Rules for partial dates are provided in Appendices 2 and 3.  These rules will apply to adverse 
events and medications.
8.3 Treatment Misallocations
Efficacy data will be summarized, “as randomized”, according to the treatment the patient was 
randomized to regardless of what treatment was actually received.
Safety data will be summarized, “as treated”, according to the treatment the patient actually received.
8.4 Data Handling and Transfer
Data will be entered by investigational sites into a clinical database built with Bioclinica and exported as 
SAS® version 9.4 or higher datasets (SAS Institute, Inc., Cary, NC). Converted datasets are created using 
SAS® and following Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation 
Model conventions (v3.1.3 implementation guide v1.3). Derived analysis datasets are generated using 
SAS® and following standard CDISC Analysis Dataset Model conventions (implementation guide v1.0). 
Data analyses including summary tables, figures, and listings (TFLs) are produced using SAS®.
Medical history and AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) 
version 18.1 to assign a system organ class (SOC) and preferred term (PT) to each AE. AEs severity will 
be graded on a 3-point scale and reported in detail as indicated on the eCRF. 
Prior and concomitant medications are coded to preferred drug names using the World Health 
Organization Drug Dictionary Enhanced (WHODRUG DDE, 2015SEP01).
8.5 Data Screening
The PRA programming of analysis datasets, tables, figures, and listings (TFL) provides additional data 
screening. Presumed data issues will be output into SAS logs identified by the word “Problem” and 
extracted from the logs by a SAS macro and sent to Data Management.
Review of a pre-freeze TFL run (Dry Run#1) on clean patients and a post-freeze TFL run (Dry Run#2) on 
the frozen database allow for further data screening prior to database lock (DBL). The post-freeze TFLs 
will be discussed with AVANIR in a data review meeting to identify any final data issues and seek 
corrections prior to DBL. The PRA statistician and AVANIR must approve database lock.


Sponsor: Avanir Pharmaceuticals, Inc.
Statistical Analysis Plan
Protocol No: 15-AVP-786-302
Effective Date: 26-Apr-2019/Version 3.0
Page 20 of 40
8.6 Data Safety Monitoring Board (DSMB)
This study is monitored on an ongoing basis by an external data safety monitoring board (DSMB). Safety 
analyses will be provided to the DSMB approximately every 3 months. Select efficacy results may be 
included, although no p-values will be provided. Details of the DSMB can be found in the DSMB charter 
and DSMB SAP.
9.0 Overall Statistical Considerations
9.1 Summary Statistics
All analyses will use SAS® version 9.4 or higher. Summary tables will be organized by treatment group. 
All available data will be used in the analyses, and important data will be included in data listings, sorted 
by treatment group, patient, and by visit within patient.
Unless otherwise noted, categorical data will be presented using counts and percentages, with the 
number of patients in the analysis population by treatment group as the denominator for percentages. 
Percentages are rounded to one decimal place except 100% will be displayed without any decimal places 
and percentages will not be displayed for zero counts. Continuous data, unless otherwise noted, will be
summarized using the number of observations (n), mean, standard deviation (SD), median, minimum, and 
maximum.  The mean will be rounded to 1 decimal place greater than the precision of the original value, 
up to a maximum of 3 decimal places. The SD will be rounded to 2 decimal places greater than the 
precision of the original value, up to a maximum of 3 decimal places.
Supporting figures will be provided for some efficacy or safety analyses in addition to the summary tables.  
Efficacy listings will include analysis flags and/or imputed values to show which values were used in the 
summary tables.  In addition, analysis visits will be displayed in the listing if it is important for the 
corresponding summary.
9.2 Hypothesis Testing and Multiplicity of Endpoints
The primary efficacy endpoint is the change from Baseline to Week 12 in the CMAI total score. For the 
primary efficacy analysis, the null hypothesis is that there is no treatment effect between AVP-786-
42.63/4.9 and placebo, and between AVP-786-28/4.9 and placebo (ܪ଴ଵ ܽ݊݀ ܪ଴ଶሻduring the study versus 
the alternative hypothesis that there is a treatment effect in at least one of the AVP-786 treatment groups 
(ܪ௔ଵ ݋ݎ ܪ௔ଶሻ.
AVP-786-28/4.9 (Low Dose) vs. placebo:
ܪ଴ଵ: ߤ௅െߤ௣௕௢ൌ0
ܪ௔ଵ: ߤ௅െߤ௣௕௢്0
AVP-786-42.63/4.9 (High Dose) vs. placebo:
ܪ଴ଶ: ߤுെߤ௣௕௢ൌ0
ܪ௔ଶ:  ߤுെߤ௣௕௢്0
Average AVP-786-28/4.9 and AVP-786-42.63/4.9 vs. placebo:
ܪ଴: ሺߤ௅൅ ߤுሻ/2 െߤ௣௕௢ൌ0
ܪ௔: ሺߤ௅൅ ߤுሻ/2 െߤ௣௕௢്0
The mITT efficacy family-wise error rate (FWE) for multiple comparisons:
1)
Family 1 - the primary efficacy endpoint (CMAI total score) comparisons: AVP-786-28/4.9 vs. 
Placebo, and AVP-786-42.63/4.9 vs. Placebo














Sponsor: Avanir Pharmaceuticals, Inc.
Statistical Analysis Plan
Protocol No: 15-AVP-786-302
Effective Date: 26-Apr-2019/Version 3.0
Page 27 of 40

Incidence of patients with at least one TEAE, drug-related TEAE, non-serious, serious adverse 
events (SAEs), drug-related serious adverse event, and death

Incidence of patients who discontinued due to TEAE, drug-related TEAE, SAE and drug-related 
SAE

Incidence of deaths and deaths due to drug-related TEAE
TEAEs will be summarized by system organ class (SOC) and preferred term (PT), descending frequency 
of PT, and by maximum severity. Summaries of PTs will also be done for those occurring in at least 5% of 
patients in any treatment group.
AEs leading to discontinuation will be summarized by SOC and PT. Drug-related AEs will be summarized 
by SOC and PT and in descending frequency of PT.
Time to onset for common TEAEs (as defined below) will be summarized descriptively for each of these 
events. In addition, summary stats for the duration and percentage of total study days will be provided for 
each AE. The n (%) of patients with recurrences will also be given.
SAEs will be summarized by SOC and PT and will include a summary of drug-related events.
Below are the rules to follow for AE summaries:

If a patient has multiple AEs within the same SOC or PT, the patient will only be counted once 
within a level of MedDRA. 

A drug-related AE is defined as an AE with an assigned relationship of “possibly related,” 
“related,” or missing.

When assessing severity, if a patient has 2 or more TEAEs, the TEAE with the worst severity will 
be chosen. AEs with missing severity will be excluded from summaries of AE by severity.

A common TEAE is defined as a TEAE with an incidence of ≥3% in either AVP-786 treatment 
group AND ≥2 times the incidence of the placebo treatment group.

Time to onset will be calculated in days as (AE start date – first dose date).

Duration of AE is generally defined as (AE end date – AE start date + 1). Below are some 
additional considerations for AE duration:
o
If the patient has an AE that has not ended when the patient ends the study, AE end date 
is defined as the last dose date of study drug.
o
If the same AE occurs more than once, total duration will be the sum of the individual AE 
durations.

For a given patient, percentage of total study days is defined as total duration (as defined above) 
divided by (last dose date – first dose date + 1) x 100.

Recurrence is defined as a new report of the same TEAE with a new AE start date. 
AEs will be coded using MedDRA version 18.1.


Sponsor: Avanir Pharmaceuticals, Inc.
Statistical Analysis Plan
Protocol No: 15-AVP-786-302
Effective Date: 26-Apr-2019/Version 3.0
Page 28 of 40
11.2 Clinical Laboratory Assessments
Clinical labs will be reported for hematology, chemistry and urinalysis. Labs are collected at Screening, 
Week 3, Week 6, Week 9, and Week 12. The following parameters will be summarized descriptively 
through change from baseline and percent change from baseline by treatment and visit based on the 
Safety Population.

Chemistry: (calcium, magnesium, phosphorus, glucose, sodium, potassium, chloride, carbon 
dioxide, blood urea nitrogen [BUN], serum creatinine, uric acid, albumin, total bilirubin, alkaline
phosphatase, lactate dehydrogenase [LDH], aspartate aminotransferase/serum glutamic 
oxaloacetic transaminase [AST/SGOT], alanine aminotransferase/serum glutamic pyruvic 
transaminase [ALT/SGPT], creatine kinase [CK], gamma-glutamyl transferase [GGT], 
triglycerides, total protein, total cholesterol, and glycosylated hemoglobin [HbA1c])

Hematology: (red blood cell [RBC] count, hemoglobin, hematocrit, white blood cell [WBC] 
count, neutrophils, bands, lymphocytes, monocytes, eosinophils, basophils, platelet count, and 
morphology)

Urinalysis: (pH, specific gravity, protein, glucose, ketones, blood, leucocyte esterase, nitrates, 
and microscopic appearance)

Thyroid function tests: (thyroid stimulating hormone [TSH], and reflex T3 and T4 if TSH is
abnormal).  Thyroid function tests are collected at the Screening visit only and will only be 
provided in a data listing.
Out-of-range values will be assessed through shift tables of baseline to EOT. Each lab value will be 
assessed as low, normal or high based on the normal ranges provided by the central lab. Frequencies of 
each combination of shifts will be provided by treatment group. 
The denominator for the percentages will be the total number of patients in the treatment group with a 
baseline and post-baseline value. Lab tests without normal ranges will be excluded from the shift tables.
Potentially clinically significant (PCS) tables will also be used to summarize out-of-range values. PCS 
values are found in Table 4. The number and percentage of patients meeting the criteria below will be 
summarized by treatment group. Summaries will be given for any time post-baseline. The denominator for 
the percentages will be the number of patients who had a post-baseline assessment for each parameter.
TABLE 4. LAB PCS CRITERIA
Laboratory 
Parameter
Unit
Low 
PCS 
Criteria
High PCS 
Criteria
Laboratory 
Parameter
Unit
Low PCS 
Criteria
High
PCS 
Criteria
Chemistry
Albumin
g/L
≤26
≥60
GGT
U/L
None
> 60
Alkaline 
Phosphatase
U/L
None
≥3X ULN
Glucose
mmol/L
≤2.775
≥11.1
ALT (SGPT)
U/L
None
≥3X ULN
LDH
U/L
None
≥3X 
ULN
AST (SGOT)
U/L
None
≥3X ULN
Magnesium
mmol/L
<0.37
>1.23
Bilirubin
umol/L
None
≥1.5 ULN
Phosphate
mmol/L
≤0.4522
>3.88
BUN
mmol/L
None
≥10.71
Potassium
mmol/L
≤3.0
≥5.5
Calcium
mmol/L
≤1.75
≥3.0
Protein
g/L
≤50
≥100


Sponsor: Avanir Pharmaceuticals, Inc.
Statistical Analysis Plan
Protocol No: 15-AVP-786-302
Effective Date: 26-Apr-2019/Version 3.0
Page 29 of 40
Laboratory 
Parameter
Unit
Low 
PCS 
Criteria
High PCS 
Criteria
Laboratory 
Parameter
Unit
Low PCS 
Criteria
High
PCS 
Criteria
Carbon 
Dioxide
mmol/L
≤ 9
>40
Sodium
mmol/L
≤130
≥155
Chloride
mmol/L
≤85
≥120
Triglycerides
mmol/L
None
>3.39
Cholesterol
mmol/L
None
≥7.77
Urate (Male)
umol/L
None
≥624.54
Creatine 
Kinase 
U/L
None
≥3 ULN
Urate
(Female)
umol/L
None
≥505.58
Creatinine
umol/L
None
>132.6
Hematology
Hemoglobin
g/L
<100
>180
Monocytes
x10^9/L
None
>1
Hematocrit
proportion 
of 1.0
<0.3
>0.5
Monocytes/
Leukocytes
%
None
≥15
Basophils
x10^9/L
None
>0.3
Neutrophils/
Leukocytes
%
≤15
None
Eosinophils/Le
ukocytes
%
None
≥10
Leukocytes
x10^9/L
≤2.8
≥16
Lymphocytes
x10^9/L
≤0.5
>4
Erythrocytes
x10^12/
L
≤2.5
≥7.0
Lymphocytes/
Leukocytes
%
≤10
≥60
Platelet 
Count
x10^9/L
≤100
≥700
Over the course of the study, there may be some lab tests performed that are not mentioned in the 
protocol. These tests will not be summarized but will be included in the listings and flagged as 
non-protocol tests.
11.3 ECGs
ECGs will be assessed by a central reader and will be recorded at the following visits:

Screening

Baseline (pre-dose)

Baseline (2-3 hours post-dose)

Week 2

Week 3

Week 6 (pre-dose)

Week 9

Week 12
The following quantitative parameters will be reported by the central reader: heart rate, PR interval, QRS 
duration, QT interval (uncorrected), and QT interval due to Fridericia’s correction (QTcF). Change from 
baseline and percent change from baseline will be calculated for each parameter and summarized by the 
treatment groups. 
In addition, since ECGs are recorded pre- and post-dose at Baseline, change from pre- to post-dose will 
be summarized at these visits.


Sponsor: Avanir Pharmaceuticals, Inc.
Statistical Analysis Plan
Protocol No: 15-AVP-786-302
Effective Date: 26-Apr-2019/Version 3.0
Page 30 of 40
PR interval and QTcF will be further investigated through PCS tables, for which the criteria are found in
Table 5 below. The number and percentage of patients meeting the criteria below will be summarized by 
treatment group. Summaries will be given for both overall (i.e., any time post-baseline) and by visit. For 
QTcF, males and females will be assessed separately. Patients will be included in all categories for 
which they qualify. For criteria on the “Actual” values, the denominator for the percentages is the number 
of patients who had a post-baseline assessment for each parameter. For criteria on the change, the 
denominator is the number of patients who had a baseline and post-baseline assessment.
TABLE 5. ECG PCS CRITERIA
ECG parameter
Sex
Actual or Change
PCS Criteria
PR Interval (msec)
Both
Actual
>200 to ≤220, >220 to 
≤250, >250
QTcF (msec)
Males
Actual
>450 to ≤480, >480 to 
≤500, >500
Females
Actual
>470 to ≤485, >485 to 
≤500, >500
Both
Change from baseline 
(increase)
>30, >60
ECG overall interpretations will be summarized by the number and percentage that were normal or 
abnormal. The interpretations by the cardiologist (i.e., central ECG) will be used for these summaries. 
The listings will provide all interpretations and corresponding details.
11.4 Vital Signs
Vital signs will be assessed at all visits (except the Follow-up Visit for ET patients). Starting with Protocol 
Amendment #3, orthostatic blood pressure and heart rate measurements will be performed at all clinic 
visits.  Supine blood pressure and heart rate will be measured twice.  The average of the measurements 
will be presented.  Additionally, a single measurement of blood pressure and heart rate while standing will 
be collected.  The following parameters will be summarized: systolic blood pressure (SBP), diastolic blood 
pressure (DBP), heart rate, respiratory rate, and temperature. These parameters will be summarized 
through change from baseline and percent change from baseline in similar fashion as the ECG 
parameters. 
Vital signs will also be assessed through PCS criteria, which are given in Table 6. Patients will be counted 
if they meet the criteria below at any time post-baseline. The definition of baseline is consistent with those 
for ECG parameters. The denominators are the number of patients with both a baseline and
post-baseline assessment. 
TABLE 6. VITAL SIGN PCS CRITERIA
Vital Sign 
Parameter
High values
Low values
SBP (mmHg)
>180 AND ≥20 increase from baseline
≤90 AND ≥20 decrease 
from baseline
DBP (mmHg)
≥105 AND ≥15 increase from baseline
≤50 AND ≥15 decrease
from baseline
Heart rate (bpm)
≥120 AND ≥15 increase from baseline
≤50 AND ≥15 decrease 
from baseline
SBP and heart 
rate
SBP ≥10 increase from baseline AND heart rate
≥5 increase from baseline
DBP and heart 
rate
DBP ≥5 increase from baseline AND heart rate ≥5 
increase from baseline


Sponsor: Avanir Pharmaceuticals, Inc.
Statistical Analysis Plan
Protocol No: 15-AVP-786-302
Effective Date: 26-Apr-2019/Version 3.0
Page 31 of 40
Orthostatic changes in blood pressure and heart rate from supine to standing will also be summarized.  
Additionally, patients meeting orthostatic hypotension or postural tachycardia PCS criteria at any time 
post-baseline will be summarized according to the criteria in Table 7.
TABLE 7. ORTHOSTATIC HYPOTENSION AND POSTURAL TACHYCARDIA PCS CRITERIA
Category
PCS Criterion
Orthostatic hypotension
≥ 20 mmHg decrease in SBP or ≥ 10 mmHg decrease in 
DBP from supine to standing
Postural tachycardia
≥ 30 bpm increase in heart rate from supine to standing or 
a standing heart rate ≥ 120 bpm
11.5 Physical and Neurological Examinations
Physical and neurological examinations will be performed at Screening, Week 6, and Week 12 and 
include assessments of the head, eyes, ears, nose, throat, lymph nodes, skin extremities, respiratory, 
gastrointestinal, musculoskeletal, cardiovascular, and nervous systems.  Physical and neurological 
examination data will be provided in a data listing.
11.6 Sheehan Suicidality Tracking Scale (S-STS)
The S-STS is a prospective scale that assesses treatment-emergent suicidal thoughts and behaviors.  
Each item of the S-STS is scored on a 5-point Likert scale as shown below:
S-STS Item Scale

0 = Not at all

1 = A little

2 = Moderate

3 = Very

4 = Extremely
The S-STS can be analyzed as individual item scores, suicidal ideation subscale score, suicidal behavior 
subscale score, and a total score.  For the screening visit, the timeframe for the items will be ‘in the past 6 
months’ and for all other visits it will be ‘since last visit’.
The S-STS will be assessed at all clinic visits.  Scores, CFB in scores, and percent CFB in scores will be 
summarized descriptively by visit and treatment group for each subscale and total score. S-STS suicidal 
ideation subscale score, suicidal behavior subscale score, and a total score will be calculated as follow:
Parameter
Description of Derivation
Programming Algorithm
Missing Data 
Handling
Suicidal 
Ideation
Sum of:
Questions 2 - 11; Questions are 
on a 0-4 scale
Sum of:
SSTS102, SSTS103, SSTS104, SSTS105, 
SSTS106, SSTS107, SSTS108, SSTS109, 
SSTS110, SSTS111
if any missing 
for Questions 2 -
11, then score 
will be missing
Suicidal 
Behavior
If Question 1b=Yes, then use 
the following algorithm:
Sum of: 
Questions 1a, highest score of 
(Q12 or any row of Q16), highest 
score of (Q14 or any row of 
Q15), 17, and 20
If Question 1a is not present, 
If SSTS101B=Yes (looks like this is only 
present in data if =Yes, then do:
Sum of:
SSTS101A, max(SSTS112 or SSTSQ16C or 
SSTSQ16D), max(SSTS114 or SSTSQ15C 
or SSTSQ15D), SSTS17=Yes add 100, 
SSTS20=Yes add 4
If SSTS101B not present or No, then do:
if Questions 12 
or 14 are 
missing, then 
score will be 
missing


Sponsor: Avanir Pharmaceuticals, Inc.
Statistical Analysis Plan
Protocol No: 15-AVP-786-302
Effective Date: 26-Apr-2019/Version 3.0
Page 32 of 40
then use the following algorithm:
Sum of:
highest score of (Q12 or any row 
of Q16), highest score of (Q14 
or any row of Q15), 17, and 20
Notes: 
Questions 15, 16, 17, and 20 are 
optional and only included in the 
QS datasets if populated with 
data. Scores should still be 
calculated if these Q15, Q16, 
Q17, Q20 are missing.
Sum of:
max(SSTS112 or SSTSQ16C or 
SSTSQ16D), max(SSTS114 or SSTSQ15C 
or SSTSQ15D), SSTS17=Yes add 100, 
SSTS20=Yes add 4
Total Scale 
Score
If Question 1b=Yes, then use 
the following algorithm:
Sum of: 
Questions 2 - 11, Questions 1a, 
highest score of (Q12 or any row 
of Q16), highest score of (Q14 
or any row of Q15), 17, and 20
If Question 1a is not present, 
then use the following algorithm:
Sum of:
Questions 2 - 11, highest score 
of (Q12 or any row of Q16), 
highest score of (Q14 or any row 
of Q15), 17, and 20
Notes: 
Questions 15, 16, 17, and 20 are 
optional and only included in the 
QS datasets if populated with 
data. Scores should still be 
calculated if these Q15, Q16, 
Q17, Q20 are missing.
If SSTS101B=Yes (looks like this is only 
present in data if =Yes, then do:
Sum of:
SSTS102, SSTS103, SSTS104, SSTS105, 
SSTS106, SSTS107, SSTS108, SSTS109, 
SSTS110, SSTS111, SSTS101A, 
max(SSTS112 or SSTSQ16C or 
SSTSQ16D), max(SSTS114 or SSTSQ15C 
or SSTSQ15D), SSTS17=Yes add 100, 
SSTS20=Yes add 4
If SSTS101B not present or No, then do:
Sum of:
SSTS102, SSTS103, SSTS104, SSTS105, 
SSTS106, SSTS107, SSTS108, SSTS109, 
SSTS110, SSTS111, max(SSTS112 or 
SSTSQ16C or SSTSQ16D), max(SSTS114 
or SSTSQ15C or SSTSQ15D), SSTS17=Yes 
add 100, SSTS20=Yes add 4
if any missing 
for Questions 2 -
12, 14, then 
score will be 
missing
11.7 Mini Mental State Examination (MMSE)
The MMSE is a brief 30-point questionnaire test that is used to screen for cognitive impairment and 
severity of cognitive impairment.  The MMSE scale comprises 11 questions or simple tasks concerning
orientation, memory, attention, and language to evaluate a patient’s cognitive state and are scored 
according to the following ranges:  
Item
Score Range

Orientation to Time

Orientation to Place

Registration

Attention and Calculation

Recall

0 to 5

0 to 5

0 to 3

0 to 5

0 to 3


Sponsor: Avanir Pharmaceuticals, Inc.
Statistical Analysis Plan
Protocol No: 15-AVP-786-302
Effective Date: 26-Apr-2019/Version 3.0
Page 33 of 40

Naming

Repetition

Comprehension

Reading

Writing

Drawing

0 to 2

0 to 1

0 to 3

0 to 1

0 to 1

0 to 1
The total score is calculated by summing all of the item scores and ranges from 0 to 30.  Higher scores 
indicate milder cognitive impairment.
The MMSE will be assessed at Screening, Baseline, Week 6, and Week 12.  The MMSE total score, CFB 
in total score, and percent CFB in total score will be summarized descriptively by visit and treatment 
group.
11.8 Timed Up and Go (TUG) Test
The TUG test measures the time (in seconds) taken for an individual to stand up from a standard 
armchair, walk 3 meters, turn, walk back to the chair and sit down.  It is a commonly used scale for 
measuring functional mobility and risk of falls.
The TUG test will be performed at Screening, Week 6, and Week 12.  The TUG time, CFB in TUG time, 
and percent CFB in TUG time will be summarized descriptively by visit and treatment group.
11.9 Epworth Sleepiness Scale (ESS)
The ESS is an 8-item questionnaire that is used to measure sleepiness by rating the probability of falling 
asleep on 8 different situations that most people engage in during the day.  The questions are rated on a 
4-point scale (0 to 3) where 0 = would never doze, 1 = slight chance of dozing, 2 = moderate chance of 
dozing, and 3 = high chance of dozing.  A total score of 0 to 9 is considered to be normal.
The ESS will be assessed at Baseline, Week 6, and Week 12.  The total score, CFB in total score, and 
percent CFB in total will be summarized descriptively by visit and treatment group.
12.0 Additional Summaries
12.1 Patient Disposition
Patient enrollment will provide the number of patients screened along with the reason for screen failures. 
A summary of randomized treatment group will be provided. Patient status will be summarized by the 
following:

Randomized

Took study medication

Discontinued

Completed study
Primary reasons for discontinuation will be provided based on the number of patients in the treatment 
group.  The number of patients in the mITT and Safety populations will be provided.
12.2 Protocol Deviations
Protocol deviations will be reported by category for each treatment group and will be listed and 
summarized.


Sponsor: Avanir Pharmaceuticals, Inc.
Statistical Analysis Plan
Protocol No: 15-AVP-786-302
Effective Date: 26-Apr-2019/Version 3.0
Page 34 of 40
12.3 Demographic and Baseline Characteristics
Demographics will be summarized by randomized treatment group and overall for the mITT and Safety 
populations. The following characteristics will be summarized.

Sex (male/female)

Race (White, Black or African American, Asian, American Indian or Alaska Native, Native 
Hawaiian or Other Pacific Islander, Other)

Ethnicity (Hispanic or Latino, Not Hispanic or Latino)

Age

Age group (<65, ≥65)

Weight
In addition, below information will be summarized by treatment group unless specified otherwise.

Baseline disease characteristics: Safety Population, caregiver relationship to patient, patient living 
arrangement, number of patients enrolled prior to protocol amendment 4 and after.

Randomization Stratification factors: mITT population, Baseline NPI AA domain score (≤ 6 and > 
6), Risk for falls (normal/mild and moderate/severe), Use of concomitant antipsychotic 
medications (yes/no).

Baseline efficacy assessment: mITT population, for CMAI, NPI, CGIS-Agitation 
For categorical parameters, the denominators for the percentages are the number of patients who had 
the parameter assessed.
12.4 Medical History
Medical history will be summarized for the mITT and Safety populations by SOC and PT and will be 
provided in data listings.
12.5 Exposure
Duration of exposure will be summarized quantitatively for the Safety population using the number of 
days on study medication for each patient, displayed by treatment group. Duration will be calculated as 
(last dose date – first dose date + 1). 
An additional summary of exposure will be provided by dose taken for patients who took AVP-786 at any 
time during the study. The number of days at the specified dose level will be summarized. Doses 
summarized will be 18 mg QD, 18 mg BID, 28 mg QD, 28 mg BID, and 42.63 mg BID. 
12.6 Compliance
Overall treatment compliance will be calculated as a percentage using the total number of capsules that 
were taken. Patients will be grouped into categories of <80%, 80% to 120%, >120%. Counts will be 
summed over the visits for each patient to calculate an overall compliance value.
Compliance will be summarized for the Safety population as described above and using descriptive 
statistics by treatment group within each dose regimen: Placebo, 18 mg QD, 18 mg BID, and 28 mg QD, 
28 mg BID, and 42.63 mg BID. The number of doses taken and number of doses should have taken are 
necessary to calculate compliance. In the first 3 weeks the actual number of doses taken by QD or BID 
may not be distinguishable. In which case a combined compliance will be reported. The 3 steps for 
calculating compliance are shown here:
1.
Doses taken = actual amount taken


Sponsor: Avanir Pharmaceuticals, Inc.
Statistical Analysis Plan
Protocol No: 15-AVP-786-302
Effective Date: 26-Apr-2019/Version 3.0
Page 35 of 40
2.
Doses should have taken: 2 * (last dose date – first dose date) + 1
3.
Compliance = (doses taken / doses should have taken) * 100
The formula is based on the assumption that patients take 2 capsules per day except for the last day, in 
which they only take 1.
12.7 Prior and Concomitant Medications, Non-drug Therapies and Interventions
The number and percentage of prior and concomitant medications will be provided by the treatment group
used for the safety analyses. Summaries will be provided by anatomical therapeutic chemical (ATC) and 
preferred term for the Safety population. Non-drug therapies and nonpharmacological interventions will 
be only provided in data listings.
In addition, below information will be summarized; 

At baseline, number and % patients who used medications for AD (donepezil, donamem, 
rivastigmine, galantamine, memantine), medications/medication-classification for agitation 
secondary to AD (atypical antipsychotics, antidepressants, butyrophenones, buspirone). 

Cumulative number and % patients who used short term rescue medication lorazepam by visit.
12.8 Pharmacokinetics and Pharmacodynamics
Plasma concentrations for d6-DM, d6-DM metabolites, and Q will be collected at Week 6 and Week 12.  
Plasma concentration will be summarized by visit and treatment group for the Safety population overall 
.  Additionally, PK/PD correlations 
will be provided.  
13.0 Validation
PRA's goal is to ensure that each TFL delivery is submitted to the highest level of quality. Our quality 
control procedures will be documented separately in the study specific quality control plan.
14.0 References
2.
Lan Kong, et al, Performance of some multiple testing procedures to compare three doses of a test 
drug and placebo. Pharmaceutical Statistics. 2005;4:25-35. 




Sponsor: Avanir Pharmaceuticals, Inc.
Statistical Analysis Plan
Protocol No: 15-AVP-786-302
Effective Date: 26-Apr-2019/Version 3.0
Page 37 of 40
EQ-5D-5L
EuroQol 5-Dimension 5-Level
EOT
End of treatment
ESS
Epworth Sleepiness Scale
GGT
Gamma-glutamyl transferase
GMHR
General Medical Health Rating
ITT
Intent-to-Treat
IWRS
Interactive Web Response System
LDH
Lactate dehydrogenase
LOCF
Last observation carried forward
LS
Least squares
mADCS-CGIC-Agitation
Modified Alzheimer’s Disease Cooperative Study-Clinical Global Impression of 
Change Rating for Agitation
MAR
Missing at random
MCMC
Markov Chain Monte Carlo
MedDRA
Medical Dictionary for Regulatory Activities
MI
Multiple imputation
mITT
Modified Intent-to-Treat
MMRM
Mixed effects model repeated measures
MMSE
Mini Mental State Examination
MNAR
Missing not at random
NPI
Neuropsychiatric Inventory
NPI-NH
Neuropsychiatric Inventory Nursing-Home version
OLS
Ordinary least squares
PCS
Potentially clinically significant
PGIC
Patient Global Impression of Change
pH
Potential hydrogen
PR
The P-R interval from an ECG tracing
PT
Preferred term
Q
Quinidine sulfate
QD
Once daily
QRS
The Q-R-S complex from an ECG tracing
QT
QT interval from an ECG tracing
QTc
QT interval corrected for heart rate
QTcB
QT interval corrected for heart rate using the Bazett’s formula


Sponsor: Avanir Pharmaceuticals, Inc.
Statistical Analysis Plan
Protocol No: 15-AVP-786-302
Effective Date: 26-Apr-2019/Version 3.0
Page 38 of 40
QTcF
QT interval corrected for heart rate using the Fridericia’s formula
RBC
Red blood cell
RUD
Resource Utilization in Dementia
SAE
Serious adverse event
SAP
Statistical analysis plan
SBP
Systolic blood pressure
SD
Standard deviation
SNRI
Serotonin-norepinephrine reuptake inhibitor
SSRI
Selective serotonin reuptake inhibitor
SOC
System organ class
SPCD
Sequential parallel comparison design
S-STS
Sheehan Suicidality Tracking Scale
T3
Triiodothyronine
T4
Thyroxine
TEAE
Treatment-emergent adverse event
TFLs
Tables, figures, and listings
TSH
Thyroid stimulating hormone
TUG
Timed Up and Go
VAS
Visual analog scale
WBC
White blood cells
WHODRUG DDE
World Health Organization Drug Dictionary Enhanced
WOCF
Worst observation carried forward
ZBI
Zarit Burden Interview


Sponsor: Avanir Pharmaceuticals, Inc.
Statistical Analysis Plan
Protocol No: 15-AVP-786-302
Effective Date: 26-Apr-2019/Version 3.0
Page 39 of 40
Appendix 2 Adverse Event Start/Stop Date Imputation
Imputation Rules for Partial Dates (D = day, M = month, Y = year)
Parameter
Missing
Additional Conditions
Imputation
Start date for 
AEs
D
M and Y same as M and Y of first dose 
of study drug
Date of first dose of study drug
M and/or Y not same as date of first 
dose of study drug
First day of month
D and M
Y same as Y of first dose of study 
drug
Date of first dose of study drug
Y prior to Y of first dose of study drug 
but same as Y of screening date
Date of screening date
D, M, Y
None - date completely missing
Date of first dose of study drug
Stop date for 
AEs
D
M and Y same as M and Y of last dose 
of study drug
Date of last dose of study drug
M and/or Y not same as date of last 
dose of study drug
Use last day of month
D and M
Y same as Y of last dose of study drug
Date of last dose of study drug
Y not same as Y of last dose of study 
drug
Use Dec 31
D, M, Y
None - date completely missing
No imputation, but assume 
ongoing
Note:  In all cases, if an estimated start date is after a complete stop date, use the first day of the stop date 
month.
Similarly, if the estimated stop date is before a complete or imputed start date, use the last day of the start day 
month.


Sponsor: Avanir Pharmaceuticals, Inc.
Statistical Analysis Plan
Protocol No: 15-AVP-786-302
Effective Date: 26-Apr-2019/Version 3.0
Page 40 of 40
Appendix 3 Prior and Concomitant Medication Start/Stop Date 
Imputation
Imputation Rules for Partial Dates (D = day, M = month, Y = year)
Parameter
Missing
Additional Conditions
Imputation
Start date for 
con meds 
D only
M and Y same as M and Y of first dose 
of study drug
Date of first dose of study 
drug
M and/or Y not same as date of first 
dose of study drug
First day of month
M and D
Y same as Y of first dose of study 
drug
Date of first dose of study 
drug
Y not same as Y of first dose of study 
drug
Use Jan 01 of Y
M, D, and Y
None - date completely missing
Day prior to date of first dose 
of study drug
Stop date for 
con meds 
D only
M and Y same as M and Y of last dose 
of study drug
Date of last dose of study 
drug
M and/or Y not same as date of last 
dose of study drug
Last day of month
M and D
Y same as Y of last dose of study drug
Date of last dose of study 
drug
Y not same as Y of last dose of study 
drug
Use Dec 31 of Y
M, D, and Y
None - date completely missing and 
NOT ongoing
Date of last dose of study 
drug
Note:  In all cases, if an estimated start date is after a complete stop date, use the first day of the stop date 
month.
Similarly, if the estimated stop date is before a complete or imputed start date, use the last day of the start day 
month.